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Opioid use globally is increasing resulting in rising numbers of pregnant women 
exposing their unborn babies to opioid drugs, with an estimated 30,000 children each 
year in Europe born to mothers who have used opioids during pregnancy. Methadone 
is the recommended opioid substitute during pregnancy. Although maternal and 
perinatal outcomes for pregnant opioid users can be improved by maintenance 
methadone, there are increasing uncertainties about the safety of methadone on the 
developing brain and subsequent neurodevelopmental outcomes of children who are 
exposed prenatally to methadone. Advanced MRI techniques, such as diffusion MRI 
(dMRI), allow detailed non-invasive investigation of brain microstructure. Imaging 
biomarkers such as fractional anisotropy (FA), mean diffusivity (MD), axial 
diffusivity (AD) and radial diffusivity (RD) derived from dMRI, are robust markers of 
white matter development, with FA associated with later neurodevelopmental 
outcome. Tract-based spatial statistics (TBSS) enables group-wise comparison of 
dMRI data and has been optimised for the neonatal brain.  
 
The aim of this thesis was to test the hypotheses that: (i) systematic review of existing 
published literature shows that prenatal methadone exposure is associated with altered 
neurodevelopment, visual development and / or brain tissue injury apparent on 
imaging; (ii) infants with prenatal methadone exposure have altered brain white matter 
microstructure when compared with term born unexposed control infants, which is 
manifest by a reduced FA and increased MD and increased RD; (iii) infants with 
prenatal methadone exposure have reduced total brain volumes and regional brain 
volumes when compared with term born unexposed infants. 
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A systematic review of the literature was performed and where amenable data were 
pooled in random effects meta-analysis. 43 studies were included, 29 reported 
neurodevelopmental outcomes, 12 reported visual, and 2 reported neuroimaging data. 
8 studies were meta-analysed and effect size was expressed as weighted mean 
difference (WMD) in developmental quotient scores. Childhood neurodevelopment, 
visual development and behaviour were altered in association with prenatal methadone 
exposure. Meta-analysis point estimates of cognitive indices (WMD of -4.43, 95% CI 
-7.24 to -1.63) and motor indices (PDI scores: WMD of -5.42, 95% CI -10.55 to -0.28) 
in 2 year old children exposed to prenatal methadone were lower than in age matched 
children with no prenatal drug exposure. 
 
Term born methadone-exposed infants were recruited and underwent an MRI scan 
shortly after birth. These were compared with 20 non-exposed term controls. An 
optimised Tract-based Spatial Statistics (TBSS) pipeline was used to perform voxel-
wise statistical comparison of FA data.  Prenatal methadone exposure was associated 
with microstructural alteration in major white matter tracts which were present at birth 
and when head circumference was adjusted for; these changes persisted in the anterior 
and posterior limbs of the internal capsule and the inferior longitudinal fasciculus 
(p<0.05). In a subgroup of prenatal methadone exposed infants, lower white matter 
volumes (p = 0.049) and higher cerebrospinal fluid volumes (p = 0.001) were 





This thesis has shown that through systematic review of the literature, there is an 
association between prenatal methadone exposure and both lower neurodevelopmental 
scores and visual dysfunction. TBSS showed that prenatal methadone exposure is 
associated with atypical white matter development compared with unexposed controls. 
Reduced FA in the white matter skeleton is apparent soon after birth, indicating an 
association between methadone exposure and brain development in utero; polydrug 
use among maternal cases limits causal inference. The data do not confirm the safety 





Opioid drugs such as heroin are extremely addictive. Methadone is a medication which 
is prescribed to help addicts not take illicit opioid drugs and is recommended during 
pregnancy, as it results in less pregnancy-related complications, such as being born 
early. However, methadone crosses the placenta, resulting in unborn babies being 
exposed to methadone whilst they are still developing in the womb. There are concerns 
that methadone might affect the way brain connections develop and that children 
exposed to methadone whilst in the womb might not develop normally through 
childhood as a result. Special MRI scans, known as diffusion MRI, assess the 
movement of water in the brain, and provide an indication of how well formed the 
brain white matter tracts (connections) are. White matter tracts that are well developed 
(mature) and healthy are linked to normal childhood development and less mature 
tracts are linked to more developmental problems.  
 
This thesis was undertaken to answer the following questions: (i) Is there evidence 
from studies already published, that exposing unborn babies to methadone causes 
problems with childhood development? (ii) Are the white matter tracts of the brain 
different in otherwise healthy babies who were exposed to methadone in the womb, 
when compared with healthy babies not exposed to any drugs? (iii) Are the whole 
brains, or specific parts of the brain of babies exposed to methadone in the womb 
smaller than healthy babies not exposed to any drugs? 
 
A thorough review of the medical literature using specific search words was 
performed, and where possible, results from studies were combined and statistically 
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analysed (meta-analysis). 43 studies in total were included, 29 reported development, 
12 reported vision and 2 reported brain imaging studies. 8 studies were combined in 
meta-analysis. Altered childhood development, and problems with vision and 
behaviour, are more common in children who were exposed to methadone in the 
womb. Combining the studies (meta-analysis) confirmed this, with developmental 
scores being on average 4 or 5 points lower if children had been exposed to methadone 
before birth.   
 
Methadone-exposed babies born around their due date (term) were recruited and 
underwent an MRI scan shortly after birth. These were compared with 20 term healthy 
babies not exposed to any drugs. Specialised MRI scans showed that major white 
matter tracts were less well developed in the babies who were exposed to methadone 
in the womb, and in a smaller group of babies, the amount of white matter in the brain 
was less than in healthy babies. Many of the mothers taking methadone also took other 
prescribed medications such as sedatives or illicit drugs such as heroin, therefore this 
study was not able to definitively conclude that methadone itself is responsible for the 
differences described. 
 
The long-term implications of differences in brain connections and worse childhood 
development in children exposed to methadone in the womb are worthy of further 
study. In particular, whether alternative strategies or medications to treat drug 
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CHAPTER 1: INTRODUCTION 
1.1 Opioid use disorder 
1.1.1 Drug use disorders and Opioids  
Five per cent of the global adult population used drugs at least once in 2015, equating 
to approximately a quarter of a billion people worldwide, and almost 30 million adults 
suffer harmful effects from their drug use, either resulting in drug dependence, or 
necessitating treatment, or both(World Drug Report, 2017). Opioid use accounts for 
the heaviest burden of disease attributable to drug use disorders, and there are an 
estimated 35 million past-year users of opioids worldwide.  
 
The term ‘opioid’ includes drugs such as heroin and morphine, but also encompasses 
a range of synthetic medications such as fentanyl, oxycodone, codeine, methadone and 
buprenorphine. Opioid drugs act via the opioid receptor and are involved in pain 
modulation, but they also produce euphoria, a state of intense happiness or excitement, 
which makes them prone to misuse and dependence. Opioids remain the most harmful 
drug type in terms of health effects because their use is associated with fatal overdose, 
addiction, blood borne virus acquisition and medical and psychiatric co-morbidities.  
 
Although heroin is the commonest opioid on the European market, mostly originating 
from Afghanistan, Iran or Pakistan, other commonly seized opioids include 
buprenorphine, methadone and tramadol, all of which have are subject to misuse and 
illicit sales(European Drug Report, 2017). This is consistent with the observation that 
heroin use has been increasing since 2007 against the backdrop of a prescription 
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opioids epidemic and whilst 1.3 million opioid users in Europe are deemed ‘high risk’, 
synthetic opioids such as methadone and oxycodone are increasingly seen in high risk 
opioid use(European Drug Report, 2017) not just heroin. 
 
1.1.2 Opioid use disorder in pregnancy 
Although opioid use is more common in men, once women have initiated substance 
misuse, they progress more rapidly to drug use disorders. There are estimated to be 
between 250,000 and 350,000 children with a problem drug-using parent in the UK. 
In Scotland, there are between 41,000 and 59,000 children with a problem drug using 
parent, which represents 4 – 6% of all children under 16 years in Scotland and is double 
the rate in England and Wales(Hidden Harm, 2003). Whilst parental problem drug use 
can cause serious harm to children of all ages, the effects of maternal drug use during 
pregnancy poses a unique threat by exposing the unborn child to exogenous drugs at a 
critical point in their formation and early development. 
 
Rates of heroin use have more than doubled between 2002–4 and 2013–5, from 0.8 to 
2.0 per 1000 women(World Drug Report, 2017) and this has resulted in a rise in the 
number of pregnant women with opioid use disorder (OUD). A study from the United 
States (US) reports an annual average of 21 000 pregnant women using opioids during 
their pregnancy(Smith and Lipari, 2013), but exact prevalence is difficult to ascertain 
due to under-reporting during pregnancy(McGlone et al., 2012). It is estimated that 
across Europe, over 30,000 children each year are born to mothers who have used 
opioid drugs during pregnancy(Gyarmathy et al., 2009). US figures pertaining to 
neonatal abstinence syndrome (NAS), a drug withdrawal syndrome most commonly 
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used as a proxy measure of prenatal drug exposure, suggest a 5-fold increase in the 
number of babies prenatally exposed to opioid medications with 5.8 per 1000 births 
affected by NAS in 2012(Patrick et al., 2015a). This cost the state approximately $1.5 
billion in 2012, as the majority of cases were billed through Medicaid. Furthermore, 
NAS incidence is likely to be an under-estimate of true prenatal opioid exposure rates, 
as not all babies with a prenatal drug exposure will experience NAS. 
 
In Scotland, the Information Services Division (ISD), a branch of NHS National 
Services Scotland, state that 1.3% of all maternities (a pregnancy which results in a 
live birth or a still birth) reported drug misuse (13.2 per 1000 maternities)in 
2014/2015(ISD Scotland, 2014). Of these, 42% were opioids, estimated at 299 
pregnant women admitting to prenatal opioid exposure. Similar to the reports from the 
US, considerable geographic variation in the rates of drug misuse in Scotland have 
also been observed, with the highest rates correlating to the most deprived areas of 
Scotland – as high as 22 per 1000 in the most deprived areas.  
 
The risks of opioid use during pregnancy relate to both the health and wellbeing of the 
mother and the potential adverse effects on their unborn child. Drug and alcohol 
addiction are important risk factors for maternal death through suicide, accidental 






1.1.3 Treatment of OUD in pregnancy 
Pregnant women who use heroin, or who have problem opioid use, are recommended 
medically assisted treatment (MAT) with a long acting opioid substitute, such as 
methadone(ACOG, 2012). Methadone is a synthetic mu-receptor opioid agonist with 
a long half-life, making it suitable for once daily dosing. It was introduced as an opioid 
substitute in the 1960s for treatment of heroin addiction. Methadone maintenance 
treatment was extended to pregnant heroin addicts in an attempt to reduce the high 
perinatal morbidity and mortality for infants born to addicted mothers. As part of a 
comprehensive antenatal care plan, methadone is associated with improved use of 
antenatal services, reduced use of heroin during pregnancy, and reduced risk of 
preterm delivery when compared with no treatment (Burns et al., 2007, Mattick et al., 
2009, Zelson et al., 1973). Fetal benefits of methadone use include improved 
growth(Hulse et al., 1997, Kandall et al., 1976) and less risk of intrauterine 
death(Kandall et al., 1977). 
 
However, the introduction of methadone into clinical practice during pregnancy was 
not accompanied by any randomised trials assessing infant outcome. Thus, the long-
term effects of prenatal methadone on the infant through childhood remain unknown. 
Methadone freely crosses the placenta, exposing the fetus to methadone at a critical 
time during brain development. Given the role of endogenous opioids in normal brain 
development, fetal exposure to exogenous opioids raises concerns about the potential 
detrimental effects this may have on brain development. Such effects will be explored 




1.1.4 Polydrug use and alcohol use in OUD 
Polydrug use is acknowledged as one of the major challenges when undertaking 
research involving drug misusing populations (Konijnenberg, 2015) because it 
prevents assessment of causation. In addition, pregnant women often underreport 
substance misuse(Kelly et al., 2001, McGlone et al., 2012). Studies attempting to 
quantify polydrug rates in methadone maintained pregnant women report rates of 
between 50%(Delano et al., 2013) and 80%(McGlone et al., 2012, McGlone et al., 
2013b) and importantly, maintenance methadone therapy does not appear to decrease 
polydrug use(Delano et al., 2013).  
 
A retrospective case review of 444 infants whose mothers were prescribed methadone 
found that 80% used illicit drugs(Dryden et al., 2009), with benzodiazepines and 
heroin being the most commonly used, followed by cannabis. Another study reported 
similar rates, with 74% of infants exposed to opiates other than methadone, followed 
by 66% benzodiazepines and 62% cannabis exposure(McGlone et al., 2013a). In this 
cohort of 100 methadone exposed infants, only 9 infants were exposed to methadone 
alone. In another study from the same region in Scotland, the rate of excess alcohol 
exposure was 47%, calculated by detectable alcohol metabolites in meconium samples 
of 21/47 infants born to mothers prescribed methadone(McGlone et al., 2012). 
Therefore, assessing potential consequences of a single drug, such as methadone, 




The possibility that prenatal alcohol and opioid exposure in combination may have a 
synergistically deleterious effect should be considered. Aside from one small study 
which reported more severe NAS in an infant with FAS (Kreitinger et al., 2013) this 
remains speculative, but further research in this area is warranted. 
 
1.1.4.1 Meconium for exposure profiling in OUD 
Meconium analysis for prenatal substance exposure profiling is a recognised and 
sensitive method of ascertaining prenatal drug and alcohol exposure. It is superior to 
maternal interview, and more sensitive than urine analysis(McGlone et al., 2012). 
Meconium formation begins at approximately 12 weeks’ gestation and continues 
throughout pregnancy. It is a stable matrix and has the benefit of allowing longer drug 
and alcohol detection windows representing the second and third trimester 
exposures(Lozano et al., 2007), although meconium likely is most representative of 
the last trimester exposures(Gray et al., 2010). 
 
Fatty acid ethyl esters (FAEE) and Ethyl-glucuronide (EtG) are products of non-
oxidative ethanol metabolism and have been established as biomarkers of fetal ethanol 
exposure (Vaiano et al., 2016). FAEE and EtG do not cross the placenta, therefore 
their presence in meconium is due to fetal synthesis, largely from transplacental 
movement of ethanol ingested by the mother, and hence they can quantify prenatal 
alcohol exposure. Small amounts of FAEEs are derived endogenously and so validated 
cut-off values to discriminate between endogenous FAEEs and those derived from 
maternal alcohol intake are used. As meconium is a stable matrix and has high 
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sensitivity, it lends itself to be the gold standard for prenatal drug and alcohol exposure 
profiling. 
 
1.1.5 Challenges of research in pregnant women with OUD  
Women with OUD are a vulnerable population. There is a high rate of abuse, in 
particular early sexual abuse, amongst women with OUD, reported to range between 
30 and 50% among women with OUD (Hans, 1999), which may result in a distrust of 
people in authority, or those with perceived ‘power’.  
 
In addition, women with OUD are more likely to have co-existing mental health 
problems, particularly anxiety and/or depression, experience domestic violence and 
poor physical health, have low education, and be socially isolated (Konijnenberg, 
2015) than women without OUD. It is widely acknowledged that children with 
prenatal drug exposure are at increased risk of experiencing instability in their home 
lives(Konijnenberg, 2015) and studies have tried to disentangle the ‘nature vs nurture’ 
aspect, which is explored later in this Chapter. These factors are extremely important 
to acknowledge because they have implications when recruiting such women to enrol 
their infants in research trials and may provide, in part, an explanation as to why the 
studying this population of women and their children so challenging and also why the 
literature is so sparse in this area.  
 
The thesis will explore the inherent challenges posed when undertaking research in 
pregnant women with OUD in more detail in Chapter Five, based on the experience 
gained during the MRI study. 
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1.2 Consequences of prenatal opioid exposure 
1.2.1 Fetal neurobehaviour 
Opioids ingested by pregnant women cross the placenta and enter the fetal circulation. 
Thus, effects of maternal drugs, and possible withdrawal from these drugs, can be 
observed in the fetus. Fetal neurobehaviour describes patterns in fetal movements and 
fetal heart rate patterns, including baseline heart rate, beat to beat variability and 
accelerations or decelerations. Fetal neurobehaviour provides integral information 
about fetal wellbeing and health(Nijhuis, 2003), and also provides a window into the 
developing nervous system. Any disruption to fetal neurobehaviour warrants particular 
consideration, as it may represent a threat to normal fetal development.  
 
Maternal methadone ingestion results in altered neurobehaviour in the fetus. Reduced 
quality and quantity of movement, assessed by ultrasound visualised behaviours, is 
described after methadone ingestion (Wouldes et al., 2004). Other studies have also 
reported slower, less variable fetal heart rate, with fewer accelerations and less motor 
activity after maternal methadone(Jansson et al., 2005). Less fetal neurobehavioural 
suppression occurs with divided daily dosing of methadone compared with single daily 
dose of methadone (Jansson et al., 2009, Wittmann and Segal, 1991) suggesting that 
dosing frequency and peak levels in maternal blood are important factors to consider. 
However, single daily dosing of methadone continues to form the mainstay of 
treatment. 
 
Different neurobehavioural effects are seen with different opioids. Buprenorphine, a 
parital mu and kappa opioid agonist also used for OUD in pregnancy, appears to induce 
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less fetal effects compared with methadone(Jansson et al., 2011, Salisbury et al., 
2012). This may in part reflect the partial mu agonist and kappa antagonist action that 
buprenorphine has compared to the pure mu actions of methadone(Belcheva et al., 
1998). Buprenorphine is also associated with reduced rates of drug withdrawal after 
birth(Jones et al., 2010), and the same reasons may underlie this observation. 
 
Finally, polydrug use in addition to methadone use appears to potentiate effects of 
methadone on baseline heart rate and heart rate variability(Jansson et al., 2012). 
 
1.2.3 Neonatal Abstinence Syndrome  
A well described consequence of prenatal opioid exposure is NAS, a newborn drug 
withdrawal syndrome. NAS is a manifestation of abrupt drug cessation in the newborn, 
characterised by sympathetic and autonomic nervous system overdrive(Kocherlakota, 
2014). Affected infants often show signs of drug withdrawal within the first few days 
of life, but this is variable and is dependent on the drug the mother has been taking, 
timing of her last dose in relation to the birth of the baby and also on genetic factors 
that influence infant metabolism of  drugs(Wachman et al., 2014, Wachman et al., 
2017). Characteristic features of NAS include a high-pitched cry, jitters and tremors, 
diarrhoea, irritability, incoordinate sucking leading to poor feeding and excessive 
weight loss. At its most severe, NAS can cause seizures.  
 
NAS is believed to be a self-limiting condition, which can be treated with 
pharmacological measures to ameliorate the withdrawal symptoms. First line 
pharmacological agents commonly used to treat NAS include opioid drugs such as oral 
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morphine, methadone, buprenorphine. The use of phenobarbitone to treat NAS has 
reduced significantly, although many centres still use it as a second line agent if the 
infant continues to show signs of withdrawal despite an opiate medication. Although 
NAS has been extensively studied over many decades, critical knowledge gaps remain 
in terms of optimal management of infants exposed prenatally to opioid drugs. Of 
particular importance, and yet frequently overlooked, is the key question of whether 
treating NAS, and by doing so further exposing the developing brain to exogenous 
opioids, is better and/or safer than adopting a more conservative approach to managing 
the withdrawal syndrome.  
 
There is a lack of long term data on the effects of prenatal methadone exposure on 
children, perhaps because it was introduced into clinical practice five decades ago 
during an era when trial methodology was less well-developed and less emphasis was 
given to fetal effects of maternal medical treatments. Whilst NAS could be considered 
an inevitable consequence of prenatal drug exposure, it has acted as somewhat of a 
distraction in the research field, as it is not an outcome, rather a symptom of an 
underlying exposure. Most trials assessing prenatal drug exposure report only short-
term outcomes such as length of hospital stay, rates of NAS, or are non-inferiority 
trials to assess pharmacological agents or different dosing regimens of various drug 
therapies (Jones et al., 2010, Mattick et al., 2014). There is a need for studies to assess 
the long term outcomes of infants treated for NAS (Kocherlakota, 2014) to help bridge 





1.2.4 Sudden infant death syndrome  
Sudden infant death syndrome (SIDS), more recently re-named sudden unexplained 
death in infancy (SUDI) refers to the sudden death of an infant younger than one year, 
which remains unexplained after formal examination. It is the leading cause of death 
in the post-neonatal period(Blair et al., 2006). An association with maternal substance 
misuse and SIDS was first described in 1972 by Pierson and colleagues, with a case 
series of three infants who had sudden unexplained deaths in infancy(Pierson et al., 
1972). They noted that although maternal health and lifestyle factors may have 
contributed in part to the deaths, the association between SIDS and maternal heroin 
use had not been described, and this raised the suspicion that methadone may be in 
some way implicated.  
 
Several other studies went on to report higher rates of SIDS in prenatal drug exposure: 
Rajegowda and colleagues in a retrospective cohort study reported that of 383 infants 
who died of SIDS, 8 were prenatally exposed to drugs, resulting in a SIDS rate of 5.5 
per 1000(Rajegowda et al., 1978). They postulated that the underlying mechanism may 
be the effect of narcotics on the respiratory centre. Chavez in 1979 reported 17 deaths 
out of 688 infants born to addicted mothers (2.5%), compared to 2 deaths out of 388 
matched unexposed infants(0.5%) with a mean age of death in the drug exposed group 
of 9.2 months (Chavez et al., 1979). Of the 17 infants who died in the addicted mother 
group, 14 mothers were enrolled in the methadone programme during their pregnancy. 
At post-mortem, there was no evidence of physical abuse or trauma in any of the 





Further data supporting an association between prenatal drug exposure and SIDS came 
in 1990 from Ward and colleagues (Davidson Ward et al., 1990) who reported a SIDS 
rate of 8.87 per 1000 cases in the prenatal drug group (19/2143) compared with a rate 
of 1.22 per 1000 amongst control infants (396 / 325,372). They commented on the 
difficulty of separating the effects of the prenatal substance use from the other 
confounders associated with SIDS, such as preterm birth, intrauterine growth 
restriction, maternal smoking and deprivation. 
 
A large retrospective cohort study from New York City attempted to address the issues 
of confounders common in prenatal drug users. They studied more than 1.2 million 
infants and identified 1760 cases of SIDS over a ten-year period (Kandall et al., 1993). 
There were 33 cases of SIDS out of 3416 births with prenatal methadone exposure. 
When adjusting for high risk variables, the adjusted SIDS rate was 5.83 per 1000 births 
in prenatal drug exposed compared with 1.39 per 1000 births for unexposed infants.  
 
In 2010, another large retrospective cohort study reported infant mortality in prenatal 
methadone exposure in Australia, and the single main cause of death was SIDS (Burns 
et al., 2010). They reported unadjusted infant mortality rates of 24.3 per 1000 
compared to infant mortality rates of 4 per 1000 in unexposed infants. They also 
reported a higher rate of smoking in the methadone-maintained mothers, which may 




UK data also confirmed an unexpectedly high proportion of infants with prenatal drug 
exposure, most commonly methadone, dying of SIDS(Cohen et al., 2015) when post-
mortem findings were investigated. There were 138 neonatal deaths over an 8 year 
period, and 32 were cases of SIDS. Of the 32, 12 (37.5%) were exposed prenatally to 
drugs, and 10 (31%) were exposed to prenatally to methadone. All cases had other risk 
factors for SIDS, including heavy smoking, sharing a sleeping surface with mother 
and low birth weight. This data did not capture deaths in the post-neonatal period, 
which may have underestimated the incidence, as the mean age of death in previous 
reports was 9 months(Chavez et al., 1979). 
 
Interestingly, when ‘drug-exposed’ cohorts were broken down into drug class, 272 out 
of the 2143 were exposed to opiates, and there were 5 SIDS deaths in the opiate-
exposed group, giving a SIDS rate of 18.38 per 1000(Davidson Ward et al., 1990). 
This finding was replicated by Kandall, who also reported the higher risk associated 
with opiates, even higher than cocaine, with a risk ratio for SIDS after prenatal 
methadone exposure of 3.6(Kandall et al., 1993). 
 
The pathophysiological process underlying the observation of increased risk of SIDS 
and prenatal opiate exposure has been partially explored. Olsen and colleagues in 1980 
describe a depressed ventilatory response to hypercarbia in infants prenatally exposed 
to methadone(Olsen and Lees, 1980). More recently Ali and colleagues describe an 
impaired response to a hypoxic challenge in a prospective study of infants prenatally 
exposed to drugs and of infants of smoking mothers compared to control unexposed 
infants(Ali et al., 2016, Ali et al., 2017).  There is also a suggestion that myelination 
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is delayed in infants with SIDS(Kinney et al., 1991) when compared to infants who 





1.2.5 Pre-clinical studies  
The endogenous opioid system is a central mediator of pain modulation, reward and 
stress responsivity(Byrnes and Vassoler, 2017). It consists of three families of opioid 
peptides: beta-endorphin, encephalins and dynorphins and three receptor types: mu, 
kappa and delta. These are distributed throughout the central and peripheral nervous 
system, allowing for regulation of a wide range of behavioural and physiological 
effects. The neural effects of opioids will be explored later in this chapter in section 
1.3.3. Many pre-clinical studies have attempted to describe the effects of opioid drugs 
on growth, behaviour, memory and on neural cells. Most studies use the rodent model 
because it is the most similar in terms of human brain development to replicate, 
although mice, chick and lambs have also been used. Different opioid drugs have been 
studied; most commonly morphine, but methadone and buprenorphine, and more 
recently oxycodone have all been studied. 
 
Opiate exposure, either prenatally or in early postnatal life, has several potential 
consequences including adverse development(Enters et al., 1990, Steingart et al., 
2000), impaired spatial learning(Davis et al., 2010), impaired memory (Wang and 
Han, 2009, Che et al., 2005) and abnormal social function(Niesink et al., 1999) and 
increased vulnerability to developing neuropsychiatric conditions in later life(Tan et 
al., 2015). Prenatal opioid exposure alters reward-related behaviours, which has been 
postulated to enhance susceptibility to later addiction(Wong et al., 2014).  
 
Opioids appear to have a noticeable influence on the activity of hippocampal neurons: 
synaptic plasticity in the hippocampus is modulated by endogenous opioids (Simmons 
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and Chavkin, 1996); prenatal morphine exposure in rats results in lowered levels of 
post-synaptic density protein-95, an important component of the cytoskeleton of 
neurons (Yang et al., 2006) and affect hippocampal neurogenesis causing loss of 
neural progenitor cells in the subgranular zone of dentate gyrus, either through 
modulating proliferation or interfering with differentiation and maturation(Zhang et 
al., 2016). This is important, because the hippocampus has an important role in spatial 
learning, and several animal studies have noted disruption to spatial learning in the 
context of prenatal opioid exposure(Davis et al., 2010, Eisch et al., 2000, Wang and 
Han, 2009). Validated tests, such as the Morris water maze testing (MWM), designed 
to test spatial memory with particular sensitivity to hippocampal lesions have shown 
that mice exposed prenatally to heroin had neuro-behavioural deficit in memory and 
learning and authors attributed this to alterations in the apoptotic pathway in the 
developing hippocampus(Wang and Han, 2009). Another study confirmed these 
findings when mice exposed prenatally to heroin performed significantly worse on a 
test indicative of spatial memory and discrimination, related specifically to the septo-
hippocampal cholinergic projection(Steingart et al., 2000). They also showed that 
these changes were reversible if fetal cholinergic cells were injected into the 
hippocampus after prenatal exposure. 
 
Animal studies have shown alterations in pain perception in later life, with prenatal 
morphine exposed rats displaying enhanced nociceptive response in the adult 
life(Rozisky et al., 2011). Endocrine effects relating to prenatal opioid exposure have 
also been reported in rat models. These include increased levels of serotonin after 
prenatal morphine exposure(Laborie et al., 2005), increased circulating levels of 
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adrenaline but reduced adrenal levels of  adrenaline and noradrenaline (Dutriez-
Casteloot et al., 1999). These findings can be partially explained by the role of 
endogenous opioids in the stress response, mediated by the Hypothalamic-Pituitary-
Adrenal (HPA) axis.  
 
Pre-clinical studies provide a useful window, as they can control for confounders such 
as polydrug use that human studies cannot. However, the limitations of pre-clinical 
systems for making inference about possible human effects include difference in the 
timing of neurodevelopment, with rodents having a much shorter gestation than 
humans, meaning that exposing a dam to opioid throughout pregnancy only equates to 
first and second trimester exposure in humans; differences in the timing of drugs; the 
route of administration; stress caused by injections; the dosage of drug; and species-
specific differences in drug metabolism. 
 
1.2.5 Developmental effects of prenatal opioid exposure in 
childhood and beyond 
Literature reporting neurodevelopmental outcome after prenatal opioid exposure is 
conflicting(Konijnenberg and Melinder, 2011). Many studies report ‘normal 
outcomes’ where scores fall within the normal range, when in fact the opioid-exposed 
group performed consistently worse than control groups across a number of 
developmental domains(Doberczak et al., 1988, Wilson et al., 1979, Hans and Jeremy, 
2001). A systematic review into the developmental effects of prenatal opioid exposure 
reported a tendency towards poorer neurodevelopmental outcome (Baldacchino et al., 
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2015), and more recent studies were more likely to report worse neurodevelopmental 
outcomes(Hunt et al., 2008, McGlone and Mactier, 2015). 
 
Long term childhood data relating to outcomes after prenatal opioid exposure is sparse. 
One longitudinal study followed 72 opioid-exposed children up to the age of 8 years 
and compared them with 58 children with no prenatal exposures and found that 
developmental trajectory worsens rather than improves  in the opioid exposed group, 
and that this difference is more marked in girls(Nygaard et al., 2016). Another 
longitudinal study from the same Norwegian group examined a cohort of 45 prenatally 
exposed 17-22 year old young adults and compared them to 48 young adults without 
prenatal opioid exposure. This study found that although cognitive scores were within 
the normal range, the cognitive problems were more evident in the drug exposed group 
compared with controls, and this did not disappear with time(Nygaard et al., 2017).  
 
A further preliminary study using functional MRI to assess working memory examined 
11 children with prenatal opioid exposure and compared them to 12 children without 
prenatal opioid exposure. They describe memory impairments in those with prenatal 
opioid exposure(Sirnes et al., 2018) adding weight to the argument that developmental 
deficits do occur in association with prenatal opioid exposure and that these are evident 
in later childhood. Childhood neurodevelopmental deficits commonly become more 





Increased addictive behaviour is also reported in children of addicts, highlighting a 
particular vulnerability and possible intergenerational transmission of drug abuse. 
(Glantz and Chambers, 2006). The direct mechanism is unknown, but it is concerning 
nonetheless. It could represent either a genetic predisposition, modulation of the areas 
of the brain involved in addiction pathways which are activated in utero (DiNieri et 
al., 2011)  or environmental factors resulting in poor coping mechanisms and learned 
behaviour.  
 
A study of adolescents has shown that increased risk-taking behaviour, executive 
dysfunction and early sexualised behaviour are all associated with prenatal drug 
exposure, although this study was from those predominantly exposed to cocaine in 
utero(Miguel-Hidalgo, 2009, Conradt et al., 2014). Children of alcoholics have been 
more extensively studied, and are at increased risk of behavioural, psychological and 
cognitive deficits(Johnson and Leff, 1999), independent of fetal alcohol spectrum 
disorder (FASD).  
 
Although there is limited data about the outcome of adults who were prenatally 
exposed to drugs, one study reports increased rates of substance misuse, crime and 
unemployment in a cohort of adults with known prenatal opiate exposure (Skinner et 
al., 2009). Whilst the current evidence is by no means robust, studies are using 
increasingly reliable methodology, and building up a picture suggestive of harm. 
Taken together, the findings of pre-clinical studies and human studies raise significant 
concerns about the long-term effects of prenatal opioid exposure on the developing 
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brain and subsequent behaviour, learning and memory. Further longitudinal studies 
are needed.  
 
1.2.6 Nature versus Nurture  
One of the widely acknowledged challenges when performing research with substance 
misuse is the myriad of environmental, social and health confounders that can 
accompany drug misuse to some degree. These include social deprivation, 
unemployment, crime, poor health and nutrition, co-existence of mental health 
disorders and inadequate access to health services including prenatal care. Studies 
have attempted to disentangle the complicated interactions between biological (nature) 
and environmental factors (nurture) influencing child development and these are 
summarised below. 
 
Mental health disorders are commonly associated with substance misuse(Jane-Llopis 
and Matytsina, 2006). Depression in women with OUD can result in less accessing of 
prenatal care, longer postnatal stay and increased likelihood of NAS(Hensley et al., 
2018). Depression during pregnancy predicts postnatal depression, which is known to 
impact on childhood neurodevelopment, in particular behaviour and IQ(Nulman et al., 
2012). In addition, drugs commonly used to treat depression, such as selective 
serotonin reuptake inhibitors (SSRIs) are recognised as a cause of neonatal abstinence 
syndrome(Klinger and Merlob, 2008), with neonatal symptoms in between 10 – 30% 
of all pregnant women treated with SSRIs(Jefferies, 2011). This may make the baby 
more challenging to look after in the early weeks and months and have an additive 
effect with the withdrawal related to methadone. Prevalence of substance use disorders 
21 
 
and comorbid mental health problems are highest for women abusing opiates(Conway 
et al., 2006), again identifying women as a particularly vulnerable group. 
 
Children at high risk of developmental problems have been shown to benefit from 
stable home environments (Ornoy, 2003) and it has been hypothesised that a stable 
home environment may mitigate some of the adverse effects associated with prenatal 
opioid exposure. However, drug dependent parents are also more likely to physically 
and/or sexually abuse their children(Smith et al., 2007, Walsh et al., 2003). Children 
who suffer abuse have delayed cognitive development which is likely to result from 
under stimulating environment, poor learning environment, or less commonly as a 
direct result of brain trauma (Carrey et al., 1995).  
 
Ornoy and colleagues believed that the home environment was much more important 
than the specific role of prenatal heroin exposure in determining long term 
developmental outcome. They report that children prenatally exposed to heroin raised 
in adopted families had normal development compared with those also exposed 
prenatally but raised at home (Ornoy et al., 1996). They also compared development 
with a control group who had matched social deprivation and found that these children 
had worse developmental scores than those prenatally exposed to heroin, implying that 
environmental and social factors are more important than prenatal drug exposure per 
se for cognitive development. In a later study, they reported a high rate of attention 
deficit hyperactivity disorder (ADHD) amongst all children with prenatal heroin 
exposure, the ADHD rate being twice as high in children raised at home compared 
with those raised in foster care (Ornoy et al., 2001). This finding of increased ADHD 
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and impulsivity in 42 children in foster care with prenatal drug exposure compared to 
50  non-exposed children was corroborated by a Norwegian study (Slinning, 2004). 
 
The concept that being raised at home by biological parents leading to worse outcomes 
was reinforced by an Italian study who assessed spatial, mnemonic, visuo-perceptive, 
linguistic and learning abilities in twenty-nine children with prenatal heroin exposure. 
They compared the abilities of 19 children who were raised by biological parents at 
home with 10 children raised in foster care and reported a significantly worse 
performance in the group raised at home, especially with visuo-spatial and mnemonic 
abilities(Fundaro et al., 2002). They hypothesised that the prenatal drug may itself 
have a direct effect on functions such as visuo-spatial processing, but that this could 
be counteracted by a stable home environment, which allows the child to develop 
compensatory strategies. 
 
Reports that outcomes were worse in drug exposed children if fostered(Soepatmi, 
1994) were supported by another study which assessed  children prenatally exposed to 
drugs during adolescence, which showed that adoption did not appear to mitigate the 
negative effects of prenatal drug exposure(Ornoy et al., 2010). Interestingly, in this 
study the ‘control’ children were matched for social and environmental deprivation 
but were not drug exposed, and they performed similarly to the drug exposed children, 
suggesting that environment might be more important than the drug exposure(Ornoy 
et al., 2010). However, this may reflect the fact that children going into foster care are 
likely to be from more chaotic and unstable backgrounds and therefore their inherent 




More recently, Nygaard and colleagues investigated the effect on cognitive function 
of 45 adolescents with prenatal drug exposure, in the context of early placement with 
stable foster or adoptive parents and compared this to the same assessment in 48 
control adolescents who had no prenatal opioid exposure. They report a positive effect 
of undergoing fewer changes in caregiver but were unable to assess the role of maternal 
upbringing versus foster care as their sample only included one child who was reared 
by the biological mother(Nygaard et al., 2017).  
 
Many of these studies have compared outcomes of children with prenatal drug 
exposure raised either by their biological parents or by foster/ adopted parents, in an 
attempt to isolate the prenatal drug exposure by comparing only the postnatal 
environmental. One problem with this approach, is that foster care or adoption success 
can be affected by many confounding variables, such as the age at which the child 
enters the care system-with younger ages generally being associated with more 
favourable outcomes- the number of placements that a child is exposed to, and how 
the child becomes involved in the care system in the first instance.  
 
Most studies assume that foster care and or adoption is providing a more stable home 
environment than remaining with their biological parents, and this may not be the case. 
One study acknowledging this compared the outcomes of a cohort of children in foster 
care, where only some had been drug exposed prenatally(Brooks and Barth, 1998), 
although the authors unfortunately provided minimal details regarding the prenatal 
drug exposure. However, this study also investigated the effect of being placed either 
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with strangers, or with family (kinship care) in a questionnaire-based study, to try to 
discern whether an outcome was related to drug exposure, kinship status or both. 
Although educational performance was similar between groups, drug exposed children 
were more likely to have special educational needs, irrespective of whether in kinship 
care or non-relative foster care. Emotional development was generally worse in drug 
exposed children, and more so for those in non-relative foster care. Behavioural 
problems were three times more likely in the drug exposed group, but more so when 
placed with family. Authors acknowledge that placing some drug-exposed children 
with family may involve placing them in environments that do not adequately meet 
their emotional needs and conclude that further research is needed. 
 
It is extremely difficult to separate and control for the social and environmental 
confounders frequently observed in association with drug misuse. Removing children 
from their unstable home environment and placing them in foster care may improve 
their outcomes if the situation they were removed from was particularly detrimental, 
or if they were placed within a nurturing loving family, or both. However, removing a 
child from their mother and potentially their siblings, especially at a slightly older age, 
could be extremely traumatic, and may not be beneficial for the child in the long term.  
 
A recent study has illustrated the complex interaction between adverse life events of 
the mother and subsequent effects on her children, by demonstrating intergenerational 
effects of maternal childhood maltreatment which manifest in reduced intracranial 
volumes on MRI imaging in offspring(Moog et al., 2018). These reductions were 
primarily due to reduced cortical gray matter and occurred independently of potential 
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confounders such as maternal socioeconomic status, recent violence, obstetric risk 
factors, and age at MRI. This study suggests that effects which occur in a child’s 
intrauterine life may have important downstream consequences for later life and 
illustrate a common and gross over-simplification that exists when attempting to 
attribute cause and effect or elucidate associations.   
 
It is likely that biological risk factors of prenatal drug exposure determine vulnerability 
to later neurodevelopmental effects, but that postnatal environmental factors modulate 
the severity of the effects(Moe, 2002). As there is no consensus in the published 
literature, reflecting the numerous factors contributing to each complex case, it would 
seem that an individualised approach is required to ensure the basic needs of the child 
are met in a suitable environment, whilst remaining aware of the unknown effect of 




1.3 Cerebral white matter and opioids 
White matter is comprised of myelinated axons, comprising more than half of the 
volume of the cerebral hemispheres(Feldman et al., 2010). Axons are encased in a 
lipid-rich sheath called myelin, which appears white, hence the term white matter. 
Axons are the long thin segments of nerves that conduct electrical impulses from 
neuron to neuron and are responsible for propagating an electrical signal either to 
another are of the central nervous system, or to the peripheral nervous system, and 




1.3.1 The oligodendrocyte 
The oligodendrocyte is a neural cell responsible for production of myelin. Myelin is a 
lipid-rich structure which provides axonal insulation and increases the speed of 
conduction down nerves. Oligodendrocytes have to undergo a complex and precisely 
timed cell lineage involving proliferation, migration and differentiation before 
becoming mature oligodendrocytes capable of producing myelin. Premyelinating 
oligodendrocytes are particularly vulnerable to damage or disruption during early 
brain development, see Figure 1. 
 
Oligodendrocytes express mu and kappa opioid receptors, implicating endogenous 
opioids in their regulation. Mu-opioid receptors are expressed by both immature and 
mature oligodendrocytes, whereas kappa-opioid receptors are only expressed in 
differentiated oligodendrocytes(Knapp and Hauser, 1996). This could have important 
clinical implications, as methadone is a mu-agonist whereas buprenorphine is a partial 




Figure 1 : Oligodendrocyte maturation and methadone  
 
Historically it was believed that oligodendrocytes had only one function - to produce 
myelin - and that myelin in turn had only one function: to insulate axons, resulting in 
improved speed of axonal transmission, essentially improving the information transfer 
efficiency of the brain. However, there is increasing evidence that oligodendrocytes 
have a much more important and varied role than initially thought. 
 
Oligodendrocytes provide trophic support to axons and promote their activity(Mitew 
et al., 2014). Myelin also appears to have important regulatory roles. Pre-clinical 
models have implicated myelin in the maturation and viability of axons. Yin et al 
showed that mice deficient in myelin associated glycoprotein(Yin et al., 1998), had 
reduced axonal calibers and decreased neurofilament spacing. Yamazaki and 
colleagues describe myelin having a dynamic role regulating impulse transmissions 
through axons in a rat model; the depolarisation of oligodendrocytes increased the 
conduction velocity of an action potential along the axon, indicating that white matter 
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can have functional as well as structural plasticity(Yamazaki et al., 2014). They go on 
to propose that myelination may be regulated according to functional activity in axons. 
Fields et al describe neural synchrony among the multiple axons under the domain of 
an individual oligodendrocyte promoted by myelin(Fields, 2008). In addition, there is 
a sub category of oligodendrocyte precursor cells (OPCs) that can generate action 
potentials, receive synaptic input and are preferentially damaged by 
ischaemia(Ragnhildur et al., 2008).  
 
1.3.2 Myelination 
1.3.2.1 Normal pattern of myelination 
Developmentally, myelination is considered the last stage of white matter 
development. Myelination is an exquisitely complex process, which starts in utero 
from the mid-trimester, and continues for several decades(Dubois et al., 2014). It 
follows a predictable pattern, termed regional asynchrony. This refers to the earlier 
myelination of areas more centrally and inferiorly, and earlier maturation of sensory 
pipelines rather than motor. Asynchrony of the maturational process reflects the 
hierarchy of connections between cortical areas. The early maturation of sensory areas 
responsible for low level processing, enables stabilisation of the information used for 
integrative areas, used for high level processing, which develop later on.  
 
Myelinated axons form white matter fibre tracts, or bundles. White matter tracts 
connect the cerebral cortex to other areas of the brain and carry both sensory and motor 
fibres. The majority of myelination occurs within the first 2 years of life, with some 
areas of the brain such as parts of the prefrontal cortex remaining unmyelinated until 
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late adolescence. This is related to the function of the frontal lobe, which is involved 
in higher cognitive functions, such as executive function, emotions and behaviour and 
therefore on the basis of regional asynchrony, it is logical that these areas myelinate 
much later in life. 
 
1.3.2.2 Disruption of ‘normal’ myelination  
The complex sequence of oligodendrocyte differentiation and maturation and 
subsequent axonal myelination makes the oligodendrocyte an extremely vulnerable 
cell. Whilst it is clear that endogenous opioids play a role in myelination, the exact 
mechanism remains unclear. Studies investigating oligodendrocytes and precursor 
cells show that they are affected by exogenous opiates perhaps because both mu-opioid 
receptors and kappa-opioid receptors are expressed by oligodendrocytes(Knapp et al., 
1998, Knapp and Hauser, 1996). Methadone affects early lineage of the 
oligodendrocyte by stimulating the proliferation of progenitor cells and accelerating 
the maturation of immature pre-oligodendrocytes (Vestal-Laborde et al., 2014), which 
may in turn disrupt the complex sequence of myelination and brain maturation. 
Prenatal buprenorphine exposure has also been shown to adversely affect the number 
and calibre of myelinated axons in the developing brain (Sanchez et al., 2008). 
 
Historically, myelination was only ascertained post mortem, by histological staining 
for myelin. However, nowadays, magnetic resonance imaging is able to demonstrate 




1.3.3 Neural effects of opioid drugs 
Opioid drugs affect the developing central nervous system. As opioid receptors are 
expressed by the neural progenitor cells that are common precursors of all central 
nervous system (CNS) neurons and microglia, prenatal opioid exposure might directly 
influence very early lineage and fate decisions via paracrine or autocrine feedback 
loops(Hauser and Knapp, 2018). Studies suggest that prenatal opioid exposure may 
modify developing dopaminergic, cholinergic and serotonergic systems, alter 
myelination and exert damaging neurotoxic effects and these studies are discussed 
below. 
 
Morphine induces a general neurotoxic effect on chick embryonic brain 
cultures(Sakellaridis et al., 1986) and reduces neuronal cell packing density and total 
number of neurons, implying that morphine might affect cortical cell proliferation and 
maturation(Seatriz and Hammer, 1993). Prenatal morphine exposure suppresses 
neuronal proliferation(Sadraie et al., 2008), inhibits purkinje cell survival and 
dendritic differentiation in the mouse cerebellum(Hauser et al., 1994) and reduces total 
dendritic length in the rat brain(Ricalde and Hammer, 1990), an effect which can be 
reversed by opiate receptor blockade. It also disrupts neuronal migration and adversely 
affects neuronal survival, with increasing evidence of this in areas on the brain 
containing higher numbers of mu-opiate receptors(Harlan and Song, 1994).  
 
Methadone can affect levels of neurotransmitters variably depending on brain region, 
gender and whether exposed prenatally or postnatally(Robinson et al., 1997), with 
reduced levels of norepinephrine and increased levels of serotonin in the rat 
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hippocampus. Methadone also reduces striatal acetyl choline (ACh) levels(Robinson 
et al., 1996, Guo et al., 1990) which could impact on later motor development. Direct 
neurotoxicity has also been demonstrated(Droblenkov et al., 2010) including neuronal 
apoptosis in human fetal brain neurons induced by morphine(Hu et al., 2002).  
 
A recent review of the effects of opioid drugs on the endogenous opioid system 
summarised the neural effects of opioids largely derived from pre-clinical studies, and 
commented that whilst many animal studies show the response to acute administration 
of opioids, chronic opioid exposure leads to compensatory mechanisms(Hauser and 
Knapp, 2018), which is likely mediated by up or down-regulation of opioid 
receptors(Belcheva et al., 1998, De Vries et al., 1991) and it is these consequences that 
could be responsible for differences seen in prenatal opioid exposure. 
 
Finally, a review summarising the pre-clinical literature around prenatal opioid 
exposure highlights the current knowledge gaps, specifically with regards to the effects 
of methadone and buprenorphine, which are commonly used for medically assisted 






1.4.1 Conventional MRI 
The first human MRI scan was performed in 1977. Initially described as nuclear 
magnetic resonance imaging, over time the ‘nuclear’ has been dropped due to negative 
public connotations and MRI has now become a powerful diagnostic and prognostic 
tool. MRI requires a magnetic field that is strong and uniform, with increasing strength 
being represented by increasing Tesla (T) value. Most clinical MRI scanners are 1.5T, 
although 3T scanners are increasingly being used. 
 
MRI is safe, has no ionising radiation exposure and can acquire detailed images in 
multiple planes, with better soft tissue contrast than other imaging modalities such as 
computed tomography (CT). Furthermore, advanced techniques such as diffusion and 
MR spectroscopy allow for tissue characterisation, whilst functional MRI allows 
visualisation of active parts of the brain during activities. These characteristics explain 
why MRI has become the imaging modality of choice for many medical specialities, 
particularly neonates. Some disadvantages include the inability to perform an MRI on 
a patient with metal artefacts and devices in their body and the longer scanning time 
and increased cost incurred by MRI when compared with other imaging modalities.
  
 
1.4.1.1 Neonatal MRI  
Neonatal MRI was introduced into clinical practice in the 1980s, shortly after first 
being used in adults, although it was not widely available until the 1990’s. Of 
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particular importance for the developing brain, MRI is the only imaging modality that 
can distinguish the presence or absence of myelin within the brain.  
 
Neonatal MRI is now an integral part of modern neonatology, with a clear framework 
for the indications for neonatal MRI and standards for reporting(British Association 
of  Perinatal Medicine, 2016). There are many factors that affect neonatal MR image 
acquisition, quality and interpretation, including scan time, signal to noise ratio (SNR), 
increased water content of the neonatal brain, movement artefact and the dynamic 
nature of myelination in the first years of life.  
 
SNR refers to the difference between the signal intensity of the area of interest and the 
background noise and determines how grainy the image is. SNR is proportional to the 
volume of the voxel and is closely related to acquisition time and field strength. Spatial 
resolution is defined by the size of the imaging voxel, a voxel representing a small 
arbitrary unit of volume in a magnetic resonance scan, and it determines how sharp the 
image looks. Higher resolution images result in crisper images, therefore images 
obtained at 3T have higher SNR and higher resolution when compared to images 
obtained at 1.5T. Alternatively, the images are of similar quality in terms of spatial 
resolution, but are obtained over a shorter acquisition time(Rutherford et al., 2004).  
 
Because the neonatal brain is much smaller than the adult brain but of similar 
complexity (e.g. cortical configuration at birth resembles that of the adult human), 
higher-resolution scans are needed to depict anatomic features in detail, and therefore 
a high SNR is a prerequisite for the increased resolution needed for MR imaging of 
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newborn infants(Hillenbrand and Reykowski, 2011). Bespoke neonatal phased array 
head coils are available which dramatically improve SNR, resulting in better quality 
images and / or shorter acquisition times. 
 
The immature brain has a much higher water content than the adult brain(Huppi and 
Dubois, 2006). This increased water content results in a marked increase in T1 and T2 
relaxation times, occurring most noticeably from term until age 1, in association with 
myelination.  
 
Imaging of the newborn brain typically takes between 30 and 60 minutes, depending 
on the specific MRI protocol. MRI makes characteristic noises which are sequence 
dependent and although ear protection is routinely used (Minimuffs, Natus), the noise 
and vibration risk waking the infants. Previously, neonates undergoing MRI scan 
would have been routinely sedated using a rapidly absorbed oral sedation such as 
chloral hydrate (Ibrahim et al., 2015, Finnemore et al., 2014, Delgado et al., 2015). 
There has been a move away from routine sedation of healthy babies involved in 
research, and most infants less than 3 months, are scanned during natural sleep, after 
a feed. This technique is commonly referred to as a ‘feed and swaddle’ and is used 
with varying levels of success, although successful acquisition of longer MRI 
sequences can be challenging in neonates without sedation (Ibrahim et al., 2015, Vasu 
et al., 2014). 
 
Because brain maturation occurs in an organized and predictable fashion, neonatal-
specific brain atlases exist (Blesa et al., 2016) to provide a context to allow 
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interpretation. Furthermore, with the increasing diagnostic and prognostic capabilities 
of MRI scans and the complexities specifically relating to neonatal MRI interpretation 
described above, neonatal neuroradiology is an evolving radiological sub-specialty. 
 
1.4.2 Quantitative MRI 
1.4.2.1 Diffusion MRI 
Diffusion MRI (dMRI), also referred to as diffusion tensor imaging (DTI), is an 
advanced MRI technique that measures the movement of water in tissues. At body 
temperature, water molecules within the brain are in a constant state of random 
Brownian motion, see Figure 2. dMRI uses this directional dependence of water to 
allow inference about underlying brain microstructure to be made. 
 
Figure 2 :The movement of water within the brain   
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1.4.2.1.1 The diffusion tensor 
A tensor is a 3D version of a vector, and so it provides both magnitude and 
directional information in 3 orthogonal directions. The magnitude data is provided by 
the eigenvalues of the tensor, which are used to generate FA/MD, while the 
directional information is given by the three eigenvectors.  
 
The diffusion tensor model is best visualised as an ellipsoid, see figure 3. The tensor 
assumes there is one fibre population in a voxel and that water diffuses mostly down 
the fibre direction. Thus, the eigenvector which corresponds to the largest 
eigenvalue, referred to as AD is taken to be the principal fibre direction. The two 
other eigenvectors are orthogonal to this with the magnitude of water diffusion in 
these directions given by the two remaining eigenvalues, which are averaged to give 
the RD.  
 
Isotropic diffusion is represented by unrestricted random water molecule movement 
in cerebrospinal fluid (CSF). In cerebral grey matter internal cellular structures slow 
the rate of water diffusion, but it is still isotropic in nature. In cerebral white matter, 
the axonal structure impedes free diffusion and directs water molecules preferentially 
to diffuse in the direction parallel to the axon, known as anisotropic diffusion. FA is 
frequently used in neonatal dMRI and indicates the degree of directional coherence of 
water molecule diffusion. Other measures include mean (MD), axial (AD) and radial 
(RD) diffusivity which indicate the overall magnitude of water molecule diffusion, and 




Figure 3 : The diffusion tensor model 
 
 
The main parameters from the diffusion tensor model are the three eigenvalues, l1, 
l2, l3 representing diffusion along the three axes (eigenvectors) of an ellipsoid in each 
voxel. The first eigenvalue represents axial diffusivity (AD) along the first eigenvector 
which is assumed to be orientated along the fibre direction. The rate of water diffusion 
perpendicular to l1 is an average of the second and third eigenvalues and is referred 
to as radial diffusivity (RD). 
 
1.4.2.1.1 Fractional anisotropy  
FA takes scalar values between 0 and 1, where 0 represents isotropic and 1 completely 
anisotropic water diffusion. Higher FA values indicate more mature and well 
myelinated white matter tracts, whereas lower FA values often indicate structurally 
compromised white matter. Normal neonatal FA values range between 0.13 to 0.61, 
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the higher values representing FA in areas such as the PLIC and corpus callosum(Kunz 
et al., 2014). In regions of complex fibre structure, FA can also take low values as it is 
unable to resolve crossing fibres, for example. FA is the most commonly used 
biomarker of diffusion anisotropy, and has found use in describing white matter 
structure in the developing brain(Hasan et al., 2004).  
 
1.4.2.1.2 Axial diffusivity  
The eigenvector which corresponds to the largest eigenvalue is the AD and represents 
the principal fibre direction. 
 
1.4.2.1.3 Radial diffusivity 
RD is calculated as an average of the 2 eigenvectors orthogonal to the principal 
diffusion direction, see Figure 3. It provides useful information when used in 
conjunction with FA. RD typically is low in densely packed, well myelinated tracts 
and conversely it is high in less well packed or poorly myelinated tracts. 
 
1.4.2.1.4 Mean diffusivity  
MD is an inverse measure of membrane density and characterises the net degree of 
displacement of water molecules. MD is measured in micrometres2 per second. MD is 
sensitive to cellularity, oedema and necrosis and it decreases with age in childhood, so 
MD values are higher for neonatal brains than for paediatric and young adult brains. 
This may in part represent increasing complexity of white matter structures with 








1.4.3 Analysis using dMRI metrics 
There are several ways of analysing dMRI data, broadly categorised into regional or 
whole brain analyses. Regional analyses are where water diffusion measures are 
obtained in one or more pre-defined area of the brain. There are two main approaches; 
region of interest analysis (ROI) and tractography. Whole brain analyses can also 






1.4.3.1 Region of Interest  
ROI  obtains water diffusion measures from a specific brain area, which can be defined 
manually or automatically. It has the advantage of assessing specific regions of the 
brain, but it requires a hypothesis about which regions might be affected. It also 
introduces bias if manual delineation of the ROI is used, as these are inherently 
subjective. If multiple ROIs are used, this increases the number of statistical tests and 
it is important to correct for multiple comparisons. 
 
1.4.3.2 Tractography 
Tractography is a method of identifying and visualising a white matter tract by 
connecting estimates of fibre orientation derived from the principal eigenvector of the 
diffusion tensor. Once the tract has been identified, the measures of diffusion 
previously described can be averaged over the entire tract or calculated for individual 
segments of the same tract.  
 
















Image reproduced with thanks to 
Dr Mark Bastin. 
41 
 
1.4.3.3 Tract-based spatial statistics  
TBSS is an unbiased observer-independent mechanism of analysing dMRI data. First 
described in 2006 by Smith et al and developed in Oxford, UK, TBSS aims to improve 
the sensitivity, objectivity and interpretability of multi-subject dMRI data(Smith et al., 
2006).  It does this by projecting FA values onto a subject-mean FA tract skeleton 
(centre of the white matter tracts) prior to statistical voxel-wise analysis. The FA 
skeleton data is then analyses in the same way as VBM. See Table 1 for benefits of 
using TBSS to analyse neonatal dMRI data. 
 
Table 1 : Advantages of using TBSS to analyse dMRI data in neonates 
 
Unbiased and automated Optimised processing pipeline 
Whole brain analysis technique negates 
need for pre-defined areas of interest 
Reduced group sizes needed to show a 
difference 




TBSS removes the potential bias of having to delineate areas by hand, which is 
required for some regional analyses, and is still sensitive and robust in the estimates 
of FA being taken from the relevant voxels. A slight limitation is that it might miss 






1.4.4 TBSS in neonatal imaging 
Neonatal dMRI data sets are frequently of lower resolution compared with adult data 
and have relatively poor signal to noise. In addition, the neonatal brain undergoes 
significant changes in the period after birth, with large increases in brain volume and 
complexity during the neonatal period and these can present further technical 
challenges when analysing dMRI data(Ball et al., 2010).  
 
With respect to TBSS in particular, the main difference between neonatal and adult 
TBSS is that they use different target images to register all the FA volumes to. In 
adult TBSS, all the FA volumes are registered to a standard template. A key pre-
requisite for TBSS is the need for accurate spatial alignment of individual data, and 
if an adult template is used to analyse neonatal data it results in poorly aligned data 
sets that prevents meaningful statistical analysis and may result in individual data 
sets being removed from studies(Bassi et al., 2008). To overcome this, in neonatal 
TBSS analysis, the most representative subject of the cohort is used as the target. In 
this option every FA volume is registered to every other one to identify the "most 
representative" subject (one with the minimum mean displacement score from all 
other subjects in the group), and this is used as the target image. 
 
A further minor difference between adult and neonatal TBSS is that the mean FA 
skeleton image has a threshold of 0.2 in adults and 0.15 in neonates. This is to 
remove voxels with lower anisotropy at the edges of the skeleton which may be 




Neonatal imaging studies using TBSS have assessed; structural alterations in white 
matter microstructure in preterm infants; factors which may be associated with or 
predispose to these alterations; whether dMRI can predict neurodevelopmental 
outcome; the use of TBSS as a biomarker for treatment effects of neuroprotective 
agents.  
 
TBSS has significantly improved understanding of preterm brain injury. Studies have 
investigated the effect of factors such as lower gestation(Anjari et al., 2007), 
bronchopulmonary dysplasia(Ball et al., 2010), punctate white matter lesions(Bassi et 
al., 2011) and chorioamnionitis(Anblagan et al., 2016) on white matter microstructure 
and have found that all of these factors negatively impact white matter development.  
 
The first study to identify the link between genetic effects and preterm brain injury 
used TBSS in combination with DNA analysis and described significant alterations in 
white matter FA with genetic variants in 2 single nucleotide polymorphisms within 
candidate genes(Boardman et al., 2014).  One was found in the Armadillo Repeat gene 
deleted in Velo-Cardio-Facial syndrome (ARVCF) gene which has been linked to 
neuronal migration and schizophrenia, and one in the fatty acid desaturase 2 (FADS2) 
gene, which has been linked to intelligence.  
 
TBSS can also map to later developmental outcome both in preterm infants and in term 
asphyxiated infants. Van Kooij and colleagues showed increased FA in the corpus 
callosum in preterm infants undergoing MRI at term-equivalent age (TEA) was 
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associated with improved cognitive performance and increased FA in the posterior 
limb of the internal capsule (PLIC); FA values in the fornix and thalamus were 
associated with improved gross motor performance at 2 years (van Kooij et al., 2012). 
These findings were corroborated by Duerden and colleagues who reported increased 
cognitive scores at 18 months were associated with higher FA at TEA (Duerden et al., 
2015). They also reported that early MRI, around 32 weeks postmenstrual age can 
predict motor outcomes but not cognitive outcomes. 
 
Even with only 10 infants per group, Porter and colleagues were able to demonstrate 
that widespread microstructural abnormalities in white matter tracts in full term infants 
after asphyxia were reduced after treatment with therapeutic hypothermia (Porter et 
al., 2010). Comparing the cooled group with healthy controls, the only abnormality 
was that FA was significantly reduced in the internal capsule.  
 
Tusor and colleagues reported significantly lower FA values in asphyxiated infants 
treated with therapeutic hypothermia who went on to have an unfavourable outcome, 
defined as death or significant neurodisability (Tusor et al., 2012). They report a 
significant linear correlation between developmental scores and FA; a correlation 
between locomotor function and FA in the corpus callosum and corticospinal tracts; a 
correlation between developmental scores and FA values in the fornix, cingulum and 
uncinate fasciculus, the structures associated with cognition and memory.  
 
Finally, TBSS has been used to assess neuroprotective agents. One study investigated 
the effect of erythropoietin (EPO) in preterm infants in a randomised double-blind 
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placebo controlled prospective multicentre trial(O'Gorman et al., 2014).  This trial 
reported that preterm infants treated with EPO had significantly higher FA than those 
in the placebo group. The second trial was a proof-of-concept, open-label, randomised 
controlled trial using FA in the PLIC, assessed by TBSS, as one of its primary outcome 
measures to investigate whether adjuvant therapy with inhaled xenon has synergistic 
benefits when combined with hypothermia for the treatment of perinatal asphyxial 
encephalopathy(Azzopardi et al.). There was no difference in FA between groups and 
this trial concluded that it had not proven a beneficial effect of using xenon in 
combination with therapeutic hypothermia. Interestingly, although this was reported 
as a negative trial, authors also report a higher FA in the PLIC in the group who had a 
normal/mildly abnormal neurological examination when compared to the group with 
very abnormal neurology (mean FA difference 0.03, p = 0.02).  
 
1.4.4.1 Power calculations for neonatal imaging studies using 
TBSS 
Traditional power analysis techniques are not directly applicable to TBSS analyses but 
sensitivity analyses have been performed by modelling a treatment effect as a global 
increase in FA(Ball et al., 2013). This was compared to a real effect of increasing age 
at scan since myelination increases as gestation at scan increases and FA is inherently 
linked to myelination. They demonstrated that a mean increase in FA of 5% is 
sufficient to detect a widespread ‘treatment’ effect when comparing equal group sizes 
of 20 or more. This has provided a guide for future studies with regards to sample size 




1.4.5 Brain volume  
Head circumference (HC), also known as occipitofrontal circumference (OFC), is a 
surrogate for intracranial brain volume, as calculated by MRI scans, in both 
infants(Cheong et al., 2008) and adults(Hshieh et al., 2016). Brain volume also 
correlates with neurodevelopmental outcome in preterm infants(Setanen et al., 2016, 
Loh et al., 2017, Keunen et al., 2016). Changes evident in infancy persist throughout 
childhood, with another study of 7 year olds who were born very preterm showing 
smaller brain volumes were associated with long term poorer functional 
outcomes(Monson et al., 2016).  
 
Neuroimaging analysis pipelines rely on atlases generated from healthy individuals to 
provide an anatomical context in which it is possible to interpret structural or diffusion 
MRI data(Blesa et al., 2016). Until recently, the atlases used were derived from adult 
data, introducing bias. In addition, volumes were derived from manual delineation of 
structures by hand, which was time consuming and susceptible to inter and intra-rater 
variability. Neonatal atlases now exist, an example of one being the Edinburgh 
Neonatal Atlas (ENA33), which was derived using data from 33 healthy term born 
infants(Blesa et al., 2016), and automated segmentation processes have been 
developed (Serag et al., 2016, Serag et al., 2017). 
 
Challenges for segmentation of the neonatal brain include the large changes that occur 
in brain shape and appearance associated with normal postnatal development, the 
reduced SNR and movement artefact(Makropoulos et al., 2014). Quantitative volumes 
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from brain MRI are useful for investigating brain development and understand early 
life determinants(Serag et al., 2017). 
 
1.4.6 Neuroimaging in opioid exposure 
1.4.6.1 Infants and children 
There are a limited number of published MRI studies in infants and children with 
prenatal opioid exposure(Kristine et al., 2009), and one of the crucial difficulties is 
that studies after the immediate neonatal period have not been able to exclude the 
effects of postnatal factors, such as socio-economic status, pharmacological treatment 
of NAS, environmental factors, on brain structure. Therefore, it remains unknown 
whether the brains of children with prenatal methadone exposure are different to 
children without such an exposure at birth. 
 
Studies assessing brain volumes in prenatal opioid exposure report reduced volumes 
in the basal ganglia(Walhovd et al., 2007, Yuan et al., 2014, Sirnes et al., 2017), the 
thalamus(Sirnes et al., 2017), the cerebellum(Sirnes et al., 2017) and increased volume 
of the lateral ventricles(Yuan et al., 2014), which is commonly seen in preterm infants 
as a consequence of white matter loss, although cerebral white matter loss was not 
reported in any of the studies. Cerebellar growth has been shown to be negatively 
impacted by postnatal morphine in preterm infants(Zwicker et al., 2016), and this also 




The observation of reduced volumes in the basal ganglia, thalamus and cerebellum is 
interesting, as mu opiate receptors are distributed mainly in the frontal cortex, the 
hippocampus, cerebellum and basal ganglia, illustrated by human autopsy studies 
showing distribution of methadone within the brain(Pertschuk and Sher, 1975, Wehner 
et al., 2000). Methadone also exerts specific effects in the basal ganglia of rat 
brains(Martin et al., 2007). All drugs of abuse promote dopamine release, and the basal 
ganglia is known for its dopamine-rich structure, so its vulnerability as a region that 
prenatal exposure may adversely affect is plausible. However the underlying 
mechanism remains unknown. 
 
Several of the published MRI studies are from a Norwegian group undertaking a 
longitudinal project on the development of children born to mothers who abused drugs 
during pregnancy, primarily but not exclusively opiates. In 2007  this group reported 
reduced regional brain volumes in 14 children with prenatal ‘substance-exposure’ 
(mean age at MRI 11 years), of which 10 were exposed to opioids, and compared them 
to 14 control children (mean age at MRI 9 years) (Walhovd et al., 2007). They reported 
reduced volumes in the pallidum and putamen specifically in the opioid-exposed 
group, all of whom were placed in foster care from a young age, so minimising the 
effects of postnatal environmental factors.  
 
Subsequently, a pilot study of 16 infants with prenatal opioid exposure reported 
reduced whole brain volume and specifically reduced basal ganglia volumes and 
increased lateral ventricle volume(Yuan et al., 2014). This study lacked a comparison 
group, circumventing this issue by using population means. It also used manual 
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segmentation, which is prone to bias. More recently, a study in 16 children with 
prenatal opioid exposure aged 10 – 14 years at imaging reported reduced basal ganglia 
volumes when compared to sixteen unexposed children (Sirnes et al., 2017). These 
changes occurred independent of reduced birthweight and the basal ganglia volumes 
were normalised to intracranial volume. The opioid exposures were variable; seven 
were exposed to opioids as part of a treatment programme, nine were exposed to illicit 
heroin use. Polydrug use was high, with benzodiazepines being frequently used (69%) 
as well as cannabis and amphetamines. All children in the exposed group were in foster 
care or adopted. Interestingly 11 out of 16 opioid exposed children had a diagnosis of 
ADHD compared with only 1 out of the control group, and there are previous reports 
of reduced basal ganglia volumes associated with ADHD(Frodl and Skokauskas, 2012, 
Greven et al., 2015). Again, direction of causation is not known. A neonatal MRI study 
which quantified brain volumes before onset of symptoms of ADHD would provide 
useful information, as neonatal imaging offsets environmental or later postnatal 
events. 
 
Data from a study investigating the effects of postnatal morphine exposure in the 
neonatal period in very preterm infants also provided useful insight into the effects of 
opiates on the developing brain, albeit prematurity is a different clinical context to 
prenatal exposure, however both encapsulate times of critical brain 
development(Zwicker et al., 2016). Zwicker and colleagues performed a sophisticated 
prospective cohort study of very preterm infants (24 weeks to 32 weeks gestational 
age at birth) who underwent serial MRI scans, had their total morphine exposure 
calculated and underwent developmental assessment at 18 months corrected gestation. 
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They reported that morphine exposure is independently associated with impaired 
cerebellar growth in the neonatal period and poorer neurodevelopmental outcomes in 
early childhood. These changes were evident even when correcting for multiple 
clinical confounders, such as the need for surgery, hypotension and other factors 
known to impact brain growth. 
 
There are two TBSS studies in prenatal drug exposure: the first was published in 2010, 
and used TBSS in childhood to assess the white matter microstructure, and involved 
the same cohort of children as detailed in the 2007 volume study by Walhovd and 
colleagues(Walhovd et al., 2007). The ‘substance exposed’ group included 14 
children, imaged at a mean age of 11 years, and of whom 10 were exposed to heroin, 
compared to 14 unexposed children imaged at a mean age of 9 years (Walhovd et al., 
2010). Authors reported reduced FA in the substance-exposed group in the superior 
longitudinal fasciculus (SLF) and inferior longitudinal fasciculus (ILF), but this study 
was limited by small sample size, postnatal confounders and an increase in ADHD 
symptoms in the exposed group.  In 2012, the same Norwegian group published the 
first neonatal TBSS study of 13 methadone-exposed infants and 7 control 
infants(Walhovd et al., 2012). They used the previous study as a basis for their pre-
defined areas of interest (ILF and SLF) and used mean diffusivity (MD) rather than 
FA. They reported that MD was increased in the superior longitudinal fasciculus. This 
study was limited by small sample size, polydrug use and the use of MD rather than 
FA, which makes comparison with other studies more difficult. Nonetheless this study 
reported preliminary findings supporting the hypothesis of white matter damage 
potentially mediated by prenatal opioid exposure.  
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Although there is emerging evidence that prenatal opioid exposure leads to regional 
brain volume deficits, the childhood studies are confounded by postnatal diagnoses 
such as ADHD which can have accompanying brain volume changes associated with 
it(Frodl and Skokauskas, 2012, Greven et al., 2015). Postnatal morphine exposure 
negatively impacts cerebellar growth, and this is linked to poorer neurodevelopmental 
outcome in childhood. The two TBSS studies are both small numbers and report 
preliminary findings. All the studies acknowledge the need for further MRI studies to 
further investigate brain volume and white matter microstructure in prenatal substance 
abuse. 
 
1.4.6.2 Adult MRI studies 
There are several MRI studies in the adult literature assessing the impact of opioid 
drug abuse, and all which use dMRI report extensive disruption to the organisation of 
white matter tracts(Qiu et al., 2015, Li et al., 2016b, Qiu et al., 2013, Ma et al., 2015, 
Wang et al., 2011), likely as a manifestation of loss of myelin and axonal integrity 
indicated by increased RD and reduced FA(Bora et al., 2012). Several studies report 
an association between duration of drug misuse and severity of white matter disruption 
(Ma et al., 2015, Bora et al., 2012, Qiu et al., 2013, Qiu et al., 2015, Shen et al., 2012, 
Liu et al., 2008), although one study found no correlation between FA and duration of 
heroin use(Li et al., 2013). A study in abstinent heroin addicts reported higher FA in 
participants with longer periods of abstinence compared to those with shorter 
periods(Shen et al., 2012), and this suggests an element of reversibility or 
improvement over time. Lower FA in the PLIC has also been shown to correlate with 
higher risk of relapse in heroin dependent patients(Li et al., 2016b). Furthermore, a 
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recent systematic review investigating the white matter changes associated with 
substance misuse showed studies consistently reported that white matter is impacted 
early, and that a dose-dependent relationship exists(Baker et al., 2013), although this 
was mainly related to cannabis or alcohol use. 
 
The studies that have used TBSS to assess the white matter microstructure have all 
investigated different opioids, including heroin, codeine and methadone. One study 
included 33 adults who were chronic users of codeine containing cough syrup and 
compared their MRI scans with 30 matched controls(Qiu et al., 2015). Authors 
reported reduced FA in the corona radiata, an area previously linked to risk taking and 
impulsive behaviour (Berns et al., 2009).  
 
Another study investigated the effects of methadone in a longitudinal self-controlled 
design, whereby 33 adults prescribed methadone were imaged at the start of the study 
and 1 year later, and the differences in their diffusion metrics (FA, RD) were 
calculated(Li et al., 2016a). The authors reported significant reductions in FA and 
increased RD in the second MRI scan in several overlapping areas; the corticospinal 
tract, the main motor tract of the central nervous system, the corona radiata and the 
right superior longitudinal fasciculus. They also report a correlation between higher 
methadone dose and more severe white matter impairment. This study specifically 
reports the damaging effects of methadone on the white matter integrity, although this 
study was also limited by polydrug use, with many relapsing with heroin use in the 




Adult MRI studies have reported other changes in association with opioid use, 
including reduced frontal grey matter volume in fifteen heroin addicts compared to 
fifteen healthy control adults(Liu et al., 2009). In addition, the clinical syndrome of 
heroin-associated encephalopathy has characteristic MRI findings that correlate with 
histological findings, including low signal on T1 weighted images, and high signal on 
T2 weighted images, the abnormal signal being largely attributed to demyelination and 
vacuole formation, with extensive involvement of both cerebral hemispheres, 
brainstem and cerebellum(Zhang et al., 2007).  
 
1.5 Summary 
This chapter has outlined the escalating problem of OUD during pregnancy and 
described the myriad of challenges and confounders when studying this population 
and their children and when interpreting the existing literature. The theoretical harm 
associated with prenatal opioid exposure has been summarised in both pre-clinical and 
human studies, building a picture suggesting that prenatal opioid exposure could be 
harmful. The role of the oligodendrocyte in brain white matter development and its 
potential role in the underlying mechanism of opioid-related harm has been explored. 
The ability to investigate underlying brain microstructure in the neonatal population 
and correlate these findings with later developmental outcome with advanced MRI 
techniques has been described.  
 
The paucity of data relating to the long-term effects of prenatal opioid exposure, and 
more specifically of prenatal methadone exposure has been highlighted. The widely 
held belief that methadone is safe during pregnancy needs to be further investigated 
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and possibly challenged, and this thesis aims to either fill or expose knowledge gaps 
through systematic review and meta-analysis of the existing literature relating 
specifically to childhood outcomes after prenatal methadone exposure. Following this, 
the thesis will describe the use of advanced MR imaging to investigate brain 
microstructure shortly after birth in a group of infants with prenatal methadone 
exposure exploring the timing of the microstructural changes, which is crucial: if 
alterations in brain structure are already evident around the time of birth, before 
environmental factors such as home environment or postnatal opioid exposure can 
confound the results, this means the later outcomes of children with prenatal 
methadone exposure cannot solely be attributable to postnatal events and should focus 






CHAPTER 2: AIMS AND HYPOTHESES 
2.1 Aims: 
1. To perform a systematic review of the published literature investigating the 
effects of prenatal methadone exposure on childhood development 
2. Where study design allows, to meta-analyse quantitative developmental scores 
and produce forest plots  
3. To design, set up and recruit pregnant women prescribed methadone into an 
MRI based research study investigating brain development after prenatal 
methadone exposure 
a. To obtain dMRI data from infants with prenatal methadone exposure 
shortly after birth 
b. To analyse the dMRI data using TBSS and to compare prenatal 
methadone exposed infants with unexposed control infants 
c. To perform volumetric segmentation of the brain and to compare 
prenatal methadone exposed infants brain volumes with unexposed 
control infants brain volumes. 
 
2.2 Hypotheses: 
I. Adverse childhood neurodevelopmental outcomes are associated with 
prenatal methadone exposure 
II. White matter development is altered in infants with prenatal methadone 
exposure; manifest by dMRI data showing 
a. Reduced FA across the white matter skeleton 
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b. Increased RD across the white matter skeleton 
c. Increased MD across the white matter skeleton 
when compared with healthy neonates not exposed to opioids during 
pregnancy. 
III. Brain volumes from structural MRI data will be smaller in prenatal 







CHAPTER 3 : PRENATAL METHADONE AND CHILDHOOD 
OUTCOMES 
3.1 General introduction 
The increasing incidence of pregnant women using opioid drugs during pregnancy has 
been outlined in Chapter 1, as have the potential detrimental effects on animals and 
humans. The literature commonly refers to ‘substance misuse’ or ‘opioid exposure’ as 
a homogenous group, often without specific information about the exposure profiles 
of children who are exposed to potentially harmful drugs in utero. This, along with the 
issue of polydrug use, makes assessing causation extremely difficult.  
 
In this chapter of the thesis, the childhood developmental outcomes associated 
specifically with maternal methadone therapy during pregnancy will be investigated, 
through systematic review of the literature and meta-analysis where appropriate to test 
the hypotheses that (1) adverse childhood neurodevelopmental outcomes are 
associated with prenatal methadone exposure and (2) adverse visual outcomes are 
associated with prenatal methadone exposure. It has been appropriately formatted for 
this thesis.  
 
3.1.1 The Bayley Scale of Infant Development 
The Bayley Scale of Infant Development (BSID) original edition is an individually 
administered developmental assessment which could be performed on infants aged 
from 1 month to 36 months(Bayley, 1969). It was first described in 1969 by a 
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psychologist, Nancy Bayley and involves a series of developmental play tasks from 
which a developmental quotient is derived, and tests two developmental domains; 
mental and motor development. Raw scores awarded to the child during the assessment 
for successfully completing tasks are converted to composite scores, referred to as 
mental developmental index (MDI) which is the childhood equivalent to intelligence 
quotient (IQ), and a psychomotor developmental index (PDI) assessing motor 
function. These indices are compared with norms taken from typically developing 
children of their age in months. As is the case with IQ, both MDI and PDI have a mean 
score of 100, with one standard deviation below the mean being a score of 85.  
 
The original Bayley Scales of infant development (BSID) was described and used from 
1969 until 1993 but has now been now been superseded. The second edition (Bayley-
II) came into use in 1993(BSID-II) and described three developmental domains; 
cognitive, motor and behavioural(Bayley, 1993). The third edition (Bayley-III) has 
been in use since 2006, and describes five developmental domains; cognitive, 
language, motor, social-emotional, and adaptive behaviour scales(Bayley, 2006).  
 
3.2 Background 
Globally, heroin use has been increasing since 2007 against the backdrop of a 
prescription opioids epidemic(World Drug Report, 2017). Pregnant women who use 
heroin are recommended medically assisted treatment (MAT) with an opioid 
substitute, such as methadone, as part of a comprehensive antenatal care plan because 
it is associated with improved use of antenatal services, reduced use of heroin during 
pregnancy, and reduced risk of preterm delivery when compared with no 
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treatment(Burns et al., 2007, Mattick et al., 2009, Zelson et al., 1973). Fetal benefits 
of methadone use include improved growth(Hulse et al., 1997, Kandall et al., 1976) 
and less risk of intrauterine death(Kandall et al., 1977). 
 
Methadone is a synthetic long acting µ-opioid agonist that crosses the placenta freely, 
which exposes the developing fetal brain to exogenous opioid at a critical period. Pre-
clinical studies suggest that exogenous opioids exert pleiotropic harmful effects on the 
central nervous system(Vestal-Laborde et al., 2014, Thompson et al., 2009, 
Hutchinson et al., 2011) and studies reporting childhood outcomes suggest that 
prenatal opioid exposure might impair neurodevelopment(Hunt et al., 2008, 
Baldacchino et al., 2015), but definitive conclusions are hampered by polydrug 
exposure and difficulties with adequately controlling for socioeconomic status, quality 
of care and environmental risk factors(Brogly et al., 2014).  
 
Methadone substitution therapy for pregnant women with opioid use disorder was 
introduced into clinical practice in the 1960s without evaluation of childhood 
outcomes in randomized trials. Improved understanding of the long-term outcome of 
children exposed to prenatal methadone is essential for women and their physicians as 
alternative management strategies may be more suitable, including buprenorphine 
substitution therapy or medically supervised opioid withdrawal with psychosocial 






The goals of this study were: to perform a systematic review of published literature on 
childhood neurodevelopment, neuroimaging, and visual outcomes following prenatal 
methadone exposure; and to meta-analyse results of studies that used a common 
assessment instrument.  
 
3.4 Materials and methods 
3.4.1 Systematic review search information 
The study protocol was registered with the international prospective register of 
systematic reviews (PROSPERO), registration number CRD42017063987 
(https://www.crd.york.ac.uk/prospero/). Methodology is reported according to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement (Liberati et al., 2009). 
 
We included randomized trials, cohort studies, cross-sectional studies and case series 
that reported neurodevelopmental outcome, visual development / function, and / or 
neuroimaging of children whose mothers had taken methadone during pregnancy. 
There was no language restriction. Exclusion criteria were: studies of children whose 
mothers were prescribed alternative opioid substitutes during pregnancy and studies 




Two reviewers independently searched MEDLINE, EMBASE and PsycINFO for 
studies published between 1975 and 2017. MeSH terms used were “methadone” and 
“prenatal” or “prenatal exposure” or “prenatal drug exposure” or “prenatal exposure 
delayed effects” or “in utero”. Bibliographies of primary studies and review articles 
meeting the inclusion criteria were hand searched to identify further eligible studies. 
 
Three reviewers independently screened titles and abstracts to identify potentially 
eligible studies. Where necessary, full text was retrieved and reviewed to confirm 
eligibility. Duplication was avoided if it was clear that the same cohort was reported 
in two publications; where more than one publication for a study was retrieved, the 
report that contained the maximum data points was reviewed in full to ensure inclusion 
of all relevant data.  
 
Four reviewers independently extracted data from included studies using a 
standardized template. Extracted information included study setting, design, 
population and participant demographics, details of methadone exposure if available, 
control conditions, recruitment and completion rates, age at outcome measurement, 
assessment instrument and outcome of assessment. No authors were contacted to 
request missing information. Each study had data extracted by two reviewers 
independently, and templates were combined to ensure complete data collection. 





3.4.2 Quality assessment of included studies 
A quality assessment instrument was modified from the Grading of Recommendations 
Assessment Development and Evaluation (GRADE) Guidelines (Guyatt et al., 2011a, 
Guyatt et al., 2011b, Balshem et al., 2011). It incorporated objective criteria about 
study design, sample size and characteristics, use of validated outcome measures, risk 
of bias (blinding, confounding, attrition) and data analysis. Each study was assessed 
independently by two reviewers and scored as good (A, 6.5–8), intermediate (B, 3.5–




Where studies used the same assessment tool for any outcome domain, quantitative 
data were pooled in statistical meta-analysis using R 3.2.2 (https://cran.r-project.org/). 
Effect sizes were expressed as weighted mean differences (WMD) and their 95% 
confidence intervals. For longitudinal studies, data for assessments at 6 months and at 
2 years were analysed. Heterogeneity was assessed using the standard I-squared and 
tau statistics and graphically using forest plots. Where statistical pooling was not 
possible, data were collated in tables for outcomes across the three domains 
(neurodevelopmental, visual development and neuroimaging) and statements were 




3.5.1 Characteristics of included studies 
Forty- three eligible studies were identified with a total of 1476 methadone-exposed 
children compared to 864 unexposed children (Figure 5). 29 studies reported 
neurodevelopmental outcome (1247 methadone-exposed vs 740 unexposed subjects), 
12 reported visual outcome (275 methadone-exposed vs 128 unexposed), and two 
reported neuroimaging findings (35 methadone-exposed vs 22 unexposed). No 
randomized trials were found.  
 
Figure 5 : PRISMA flowchart showing process of inclusion and 




Fourteen studies (32.6%) were classified as poor quality, 28 (65.1%) as intermediate 
and one (2.3%) as good quality(McGlone et al., 2014), see Figure 6. Of those classified 
as poor quality, the main reasons were lack of blinding, small sample size, high 
attrition rates, and lack of comparison group validity (Beschner et al., 1977, Ramer 
and Lodge, 1975, Suffet and Brotman, Davis and Templer, 1988, Doberczak et al., 
1988, Bunikowski et al., Paul et al., 2014, Nelson et al., 1987, Gaillard and Borruat, 
2002, Hamilton et al., 2010, Gupta et al., 2012, Tinelli et al., 2013, Yoo et al., 2017, 
Kaltenbach and Finnegan) 
 
Figure 6 :Quality rating of all included studies. ND, neurodevelopmental 
outcome studies 
 
Twenty of 43 studies provided information about methadone exposure. 24 of 43 
studies (597 methadone-exposed children) provided information about maternal 
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polydrug use during pregnancy: where polydrug use was assessed, most studies 
reported a majority of subjects to be polydrug exposed. For this reason, when we use 
the term “methadone exposed” hereafter, it should be taken that a probable majority 
of those described will have been polydrug exposed. 
 
33 of 43 studies reported infants receiving pharmacological treatment of NAS; in 19 
of these the treatment regimen was described, with the most frequently used drugs 
being morphine, phenobarbital, benzodiazepines, or a combination. Sixteen studies 
(615 methadone-exposed children) stated that preterm infants were included, while 
only seven explicitly excluded infants born before 36 weeks’ gestation. In 20 studies, 
it could not be determined whether preterm infants were included. 
 
3.5.2 Neurodevelopmental outcome 
3.5.2.1 Meta-analysis 
Of the 29 studies reporting neurodevelopmental outcome, 15 used the original Bayley 
Scales of Infant Development(Bayley, 1969). Five of these fifteen were uncontrolled 
and not amenable to meta-analysis(Ramer and Lodge, 1975, Suffet and Brotman, 
Doberczak et al., 1988, Beschner et al., 1977, Kaltenbach and Finnegan) one study did 
not report any measure of variance(Kaltenbach and Finnegan, 1987) and one assessed 
children only at 9 months(Wilson et al., 1981) so these were excluded from meta-
analysis. A total of eight studies reported BSID data were therefore eligible for meta-
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6 m *: MDI 115.7 
(16.8) vs 114.3 (20.9), 
PDI 109.4 (12.2) vs 
111.7 (14.5)  
 
Original cohort 60 methadone-exposed 
infants vs 53 unexposed infants (no 
information on matching); Data 
reported only for infants who 
underwent Bayley at all 3 time points. 
Attrition rate at 6 months was 58.4% 
vs 51%. 
One case of SIDS in the methadone-
exposed group. 
GA at birth not stated. Assessor 
blinding not stated. 
No information about NAS or 
treatment. 
Kaltenba
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Original cohort 43 methadone-exposed 
infants vs 51 unexposed (matched for 
maternal SES, ethnicity and medical 
conditions). 
Attrition rate at 2 years 60.5% vs 53%. 
Assessors blinded to group. 62% 1 
year olds and 67% 2 year olds had 
been treated for NAS in the neonatal 
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4/31 used drugs in 
addition to heroin 
during pregnancy 
BSID (MDI, 
PDI) at all 
ages 
 
6 m*: MDI 105.9 
(12.4) vs 111.0 (12.3); 
PDI 103.9 (9.0) vs 
107.6 (15.1) 
2 yr‡: MDI 97.5 (16.1) 
vs 96.2 (15.9); PDI 
99.3 (16.9) vs 98.2 
(8.9)  
No p values stated 
Original cohort 39 methadone exposed 
vs 34 unexposed (matched for 
maternal age, education, gravidity and 
smoking). Attrition rate at 6 months 
was 66.7% vs 14.7%; at 2 years 
attrition rate was 84.6% vs 58.8%. All 
infants were term. Assessor blinding 
not stated. No information about NAS 
or treatment. 
Rosen 
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M-P at 3yr 
6 m*: MDI 95 (2.5) vs 
100.7 (4.2), ns, PDI 
101 (2.8) vs 105.1 
(2.9), ns 
2 yr‡:  MDI 90.4 (2.6) 
vs 96.9 (3.1) ns    PDI 
99.1 (2.7) vs 108 (2.7), 
p=0.05 
All scores are mean 
(SE)f 
Original cohort 61 methadone-exposed 
infants vs 32 unexposed infants 
(matched for maternal ethnicity, SES, 
infant gender, BW and GA). Attrition 
rate at 6 months was 32.8% vs 28.1%; 
at 2 years was 44.3% vs 31.3%. Both 
groups included preterm infants. 
Assessor blinding not stated, 75% 
methadone-exposed had NAS; number 
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(12.23) vs 105.6 (7.31), 
no p value 
2 yr ‡: MDI 100.9 
(18.04) vs 103.9 
(11.49) no p value;  
 
No information about original cohort, 
therefore attrition rates unknown. 
Unexposed group matched for 
maternal ethnicity and SES. Mean GA 
infants not stated. Blinding of 
assessors not stated.92% treated for 
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Original cohort 39 methadone-exposed 
vs 57 unexposed infants (matched for 
maternal age, ethnicity, SES and 
marital status). Attrition rate at 2 years 
was 18% vs 16%. Mean GA not stated 
for either group. Assessor blinding not 
stated. 87% original cohort treated for 
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Original cohort; 6 
IV drug users;  
94% used multiple 
drugs; 60% use 
cocaine 
BSID (MDI, 
PDI, NDI) at 
all ages  
 
WWPAf at  
18 m (n=14),  
2 yr (n=16) 
and 2.5 yr 
(n=15) 
6 m * MDI 103 (12) vs 
107 (13), PDI 116 (18) 
vs 114 (21), NDI 105 
(13) vs 109 (14) 
2 yr ‡: MDI 86 (15) vs 
98 (16) p<0.05  PDI 
102 (16) vs 100 (18) 
ns, NDI 93 (16) vs 102 
(22)    
Original cohort 35 methadone-exposed 
vs 37 unexposed infants (not matched).  
Attrition rate at 6 months was 19.2% 
vs 0% and at 2 years was 19.3% vs 
8.1%. 
Assessor blinding not stated. 
28/35 (80%) were treated for NAS, 
pharmacological agent not stated. 
Hans 
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 2 yr ‡: MDI 92 (12.7) 
vs 96 (12.3); PDI 100 
(14.2) vs 108 (14.9). 
 
Original cohort 47 methadone-exposed 
vs 45 unexposed infants (matched for 
maternal age, SES and IQ).  
Attrition rate 29.8% vs 0%.  
Assessors blinded to group. No 



















Notes relating to table 2 
 
*indicates studies included in meta-analysis at 6 months,  ‡ indicates studies included in meta-analysis at 2 years.   
 
a Quality rating: A = good, B = intermediate, C = poor, based on modified GRADE criteria; b Age expressed in days (d), months (m) or years (yr).c Drug information 
includes mean daily methadone dose (in milligrams), maternal urine screening (MUS) and/or infant urine screening (IUS) for drug exposure and information on maternal 
polydrug (PD) use, where these are reported. Unless otherwise stated, all information in this column refers to methadone-exposed group only; d. Scores are presented as 
mean values (standard deviation) unless otherwise stated; e Comments include information on attrition, matching, gestation, blinding, proportion of infants treated for 
NAS and pharmacological treatment for NAS, where provided in the original study. f Standard errors were converted to standard deviation for the meta-analysis.  
 
BDZ = benzodiazepine, BSID = Bayley Scales of Infant Development (1969), BW = birth weight, GA = gestational age, GCI = General Cognitive Index, IQ = intelligence 
quotient, MDI = Mental Developmental Index, mg = Milligrams, MSCA = McCarthy Scales of Childhood Abilities, NAS = neonatal abstinence syndrome, NDI = non-
verbal developmental index, PD = polydrug (defined as methadone plus any other drug use during pregnancy, excluding tobacco), PDI = Psychomotor developmental 




3.5.2.1 Meta-analysis of neurodevelopmental scores at 6 
months 
At 6 months of age, five studies reported Mental Development Index (MDI)(Strauss 
et al., 1976, Chasnoff et al., Rosen and Johnson, 1985, Kaltenbach and Finnegan, 1989, 
van Baar, 1990) and four reported Psychomotor Development Index (PDI)(Strauss et 
al., 1976, Chasnoff et al., Rosen and Johnson, 1985, van Baar, 1990), (Figure 7). 
 
Methadone-exposed infants had poorer cognitive outcomes (MDI scores) than control 
infants (WMD of -1.56 (95% CI -4.98 to 1.87) between 127 methadone-exposed 
infants and 132 unexposed infants (Figure 7, Panel A), and also poorer motor outcomes 
(PDI scores: WMD of -2.46 (95% CI -6.75 to 1.82) between 100 methadone-exposed 
infants and 115 unexposed infants, (Figure 7, Panel B), but confidence intervals were 
wide and included zero.  
 
Studies included in the 6 month meta-analysis were all of intermediate quality: attrition 
ranged from 31%(Rosen and Johnson, 1985) to 70%(Chasnoff et al.); two of the five 
studies gave no information about methadone dose and three described variable mean 
doses (range 15–42 mg per day)(Chasnoff et al., Kaltenbach and Finnegan, 1989, 
Rosen and Johnson, 1985). Two of the five studies excluded preterm infants(Chasnoff 
et al., van Baar, 1990); one included preterm infants(Rosen and Johnson, 1985); and 
two did not report gestational age of participants(Strauss et al., 1976, Kaltenbach and 




Figure 7 : WMD in MDI (panel A) and PDI (panel B) at age 6 months between infants exposed to prenatal methadone 





3.5.2.2 Meta-analysis of neurodevelopmental scores at 2 
years 
At 2 years of age, seven studies reported MDI(Kaltenbach et al., 1979, Chasnoff et al., 
Rosen and Johnson, 1985, Kaltenbach and Finnegan, 1989, van Baar, 1990, Hans and 
Jeremy, 2001, Wilson, 1989) and four reported PDI(Chasnoff et al., Rosen and 
Johnson, 1985, van Baar, 1990, Hans and Jeremy, 2001). Methadone-exposed children 
had poorer cognitive outcomes (MDI scores) than control children (WMD of -4.43 
(95% CI -7.24 to -1.63) between 170 methadone-exposed children and 204 unexposed 
children, (Figure 8 Panel A), and also poorer motor outcomes (PDI scores: WMD of -
5.42 (95% CI -10.55 to -0.28) between 94 methadone-exposed children and 115 
unexposed children, (Figure 8, Panel B).  
 
Studies included in the 2 year meta-analysis were also all of intermediate quality. 
Attrition rates ranged from 18%(Wilson, 1989) to 84%(Chasnoff et al.). Mean 
methadone dose was reported in five of seven studies and ranged from 15–42 mg per 
day(Chasnoff et al., Kaltenbach and Finnegan, 1987, Hans and Jeremy, 2001, Rosen 
and Johnson, 1985, Kaltenbach and Finnegan, 1989). Polydrug use was reported in 
five of seven studies and ranged from 56%(Rosen and Johnson, 1985) to >90% of 
mothers(Wilson, 1989, van Baar, 1990).  
 
Two studies, describing 27 methadone-exposed children, included only term born 
infants(Chasnoff et al., van Baar, 1990); one included preterm infants(Rosen and 
Johnson, 1985) and the gestational age of participants was not stated in four 
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studies(Kaltenbach et al., 1979, Kaltenbach and Finnegan, 1989, Wilson, 1989, Hans 
and Jeremy, 2001). Five studies reported rates of treated NAS which ranged from 
67%(Kaltenbach et al., 1979) to 92%(Kaltenbach and Finnegan, 1989); two studies 
provided no information about NAS(Chasnoff et al., Hans and Jeremy, 2001), and no 
study described the treatment received. For the MDI assessment, mean attrition from 
the original cohort escribed to the 2 year cohort assessed was 43% for the methadone 
group vs 27.7% for control; and for PDI assessment it was 45% versus 22.5%.
 
 






3.5.2.3 Qualitative analysis 
Two studies reported outcomes using the Infant Behavior Record (IBR). Marcus et al 
reported poorer motor performance at 4 months in 15 methadone-exposed African-
American infants compared with 23 matched unexposed infants(Marcus et al., 1982). 
Wilson et al compared 33 methadone-exposed infants with 55 unexposed infants, 
matched for maternal age, race, socioeconomic status and marital status, at 9 months 
of age and reported poorer fine motor co-ordination and less attentiveness and lower 
motor scores on the BSID, but no difference in cognitive scores was observed at this 
age(Wilson et al., 1981). 
 
Five case series of methadone-exposed children used the BSID at varying ages. Suffet 
et al(Suffet and Brotman) found significant associations with gender at 1 year, with 
girls performing better than boys for both MDI (mean 108.8 versus 102.7, p<0.05) and 
PDI (mean 102.3 versus 95.7, p<0.05). This association persisted for cognition up to 
2 years of age, when girls had higher mean MDI scores than boys (99.2 versus 82.0, p 
<0.01). Bier et al(Bier et al., 2015) assessed cognition at 4 months of age using the 
BSID third edition(Bayley, 2006) in a large cohort of infants exposed prenatally to 
either low dose methadone (<100mg per day) or high dose methadone (≥100mg per 
day) and reported MDI scores in the normal range. 
 
Two studies used the Griffiths Scales of Mental Development; one at 6 months in 81 




exposed versus 42 unexposed(Bunikowski et al.). McGlone et al reported reduced 
median scores across all domains, which persisted after adjustment for alcohol and 
maternal smoking, and noted that scores were lower for infants treated for NAS (n=39) 
compared with infants not requiring treatment (median General Quotient 95 vs 99, 
p<0.008). Bunikowski et al reported reductions in quotients for two subscales (hearing 
and speech and intellectual performance) at 1 year of age in a case series of prenatally 
exposed infants(Bunikowski et al.).  
 
A cohort study reported no difference in ‘focus ratio’ (a measure of attention) between 
2 year old methadone-exposed and unexposed children when observed during free 
play(Schneider and Hans, 1996). A case series of methadone-exposed children 
reported no difference in P2 amplitudes of auditory event-related potentials (ERP) in 
infants aged 4–15 days, but a difference was evident in older groups (16–32 days and 
33–120 days)(Paul et al., 2014). 
 
3.5.2.4 Children beyond 2 years of age 
 
Twelve of the 29 neurodevelopmental studies evaluated children older than 2 years 
(323 methadone-exposed children compared to 321 unexposed children), using a wide 
range of assessment tools, see Table 3. 
 
Of the 10 studies measuring cognitive outcomes, six reported no difference between 




Rosen and Johnson, 1985, Kaltenbach and Finnegan, 1989, de Cubas and Field, 1993, 
Wilson, 1989). The remaining four studies reported poorer cognition in methadone-
exposed children at 2.5 years(van Baar, 1990), 3 years(Hunt et al., 2008), 3.5 
years(Van Baar and De Graaff, 1994), 4.5 years(Van Baar and De Graaff, 1994), 5.5 
years(Van Baar and De Graaff, 1994) and 8.5 years(Davis and Templer, 1988). Two 
studies assessed language development using the Reynell Developmental Language 
Scales, and both report poorer performance in expressive and comprehensive language 
at 3 years (Hunt et al., 2008) and 4 years (Van Baar and De Graaff, 1994) in a total of 
93 methadone-exposed children versus 76 unexposed children.  
 
Of the seven studies assessing behavior, six reported more behavioral problems 
including more anxiety, more aggressive and withdrawn behavior and a higher rate of 
psychiatric referrals (16% vs 5%) in methadone-exposed children than in unexposed 
children(Wilson, 1989, Sandberg et al., 1990, de Cubas and Field, 1993, Van Baar and 
De Graaff, 1994, Hunt et al., 2008, Konijnenberg et al., 2015) (see Table 3).  
 
Two cohort studies used care-giver questionnaires(Konijnenberg et al., 2015, 
Sandberg et al., 1990). Sandberg et al (Sandberg et al., 1990)observed ‘more feminine 
game play’ among methadone-exposed boys at 5–8 years and Konijnenberg and 
colleagues(Konijnenberg et al., 2015) report increased tendencies towards aggressive 
and withdrawn behavior at 4 years. The only study that reported no differences in 
childhood behavior evaluated hyperactivity in 19 methadone exposed and 34 




studies reporting neurodevelopmental outcomes after prenatal methadone exposure are 




Table 3 : Summary of the twelve studies reporting neurodevelopmental outcomes in children beyond age 2 years 




Age b Drug Info c Assessment tool Main findings d 
Results appear as methadone vs unexposed 
Strauss 1979  B 31 27 5yr No information  MSCA 86.8 (13.3) vs 86.2 (16.2), ns 
Lifschitz 
1985  
B 26 41 3yr 
5m 
95% taking heroin or 
psychoactive drugs 
MSCA 90.4 (13) vs 89.4 (10.8), ns 
Rosen 1985  B 39 21 3yr 42 (mean of original 
cohort) 
M-P 44.6 (2.1) vs 46.3 (2.3) ns    
Davis 1988  C 12 28 8.5 
yr 
No information  WISC-R 89.58 (10.32) vs 96.32 (8.72) no p-value  











No information  
 
MSCA (GCI) 
Survey + school 
reports,  
IQ testing 
GCI: 90.4 (13.0) vs 89.4 (10.8) ns 
IQ 1- 2 sd below norm 8% vs 5%, Language disability 
8% vs 5%, Special education needs 16% vs 19%, 
Behavioural problems 75% vs 48%, Psychiatric referral 
16% vs 5% 
Kaltenbach 
1989  
B 27 17 3.5 – 
4.5 
yr 
Mean dose 38.42 MSCA (GCI) GCI: 106.5 (12.96) vs 106.05 (13.10), t=0.11 
Sandberg 
1990  
B 30 16 5 – 8 
yr 
39.5 (boys), 38.7 
(girls) 
Original cohort, 68% 
PD use; 15% moderate 
to heavy alcohol 
intake. 
CGPQe, 
CBAQe (boys only) 
Methadone-exposed boys showed more feminine game 
play than control boys (p<0.04).  
Van Baar 
1990  
B  19 34 2.5 
yr 
No information  
 
 




MDI 86 (15) vs 98 (16) p<0.05     
PDI 102 (16) vs 100 (18) ns  
NDI 93 (16) vs 102 (22)  








Age b Drug Info c Assessment tool Main findings d 
Results appear as methadone vs unexposed 
De Cubas 
1993 
B 20 20 8.5 
yr 







SBIS: 97.6 vs 98.1, ns 
KABC-A: 98.8 vs 102.4, no p value 
RATC: Methadone-exposed scored higher on anxiety, 
aggression, rejection, maladaptive outcome, p<0.01 for 















PD use; 16/35 heroin 
and cocaine, only 2/35 
solely methadone 
SON IQ at 3.5 yr;  
RC and RE at 4 yr;   
RAKIT at 4.5 and 
5.5 yr; IBR at  
3.5 yr (n=22),  
4.5 yr (n=23)   
5.5 yr (n=22)  
 
 
SON IQ: 99 (9) vs 109 (11), p<0.01 
RC: 46 (6) vs 52 (6), p<0.01   
RE: 46 (9) vs 50 (6), p<0.05 
RAKIT 4.5 yr: 85 (11) vs 103 (15), p<0.01 
RAKIT 5.5 yr: 90 (12) vs 102 (17), p<0.05 
IBR: Results median(range) 
3.5 yr:  Free of fear: 9 (4-9) vs 6.5 (2-9), p<0.05; Activity 
level: 6 (3-9) vs 5 (2-9), p<0.05; Attention: 5 (1-7) vs 5.5 
(1-9) p<0.05; Fine motor: 3 (1-5) vs 3 (1-5), p<0.05  
4.5 yr:  Co-operation: 6 (2-9) vs 7 (3-9), p<0.01; 
Endurance: 4 (2-9) vs 6 (1-9), p<0.01; Attention: 8 (2-9) 
vs 5 (2-8), ns 
5.5 yr: Co-operation: 6 (1-9) vs 8 (4-9), p<0.01; Free of 
fear: 8 (2-9) vs 9 (5-9), ns; Attention: 5 (2-8) vs 5 (3-9), 
ns. 
Hunt 2008  B 67 44 3yr No information SBIS;  
VL; 
MSCA;  
RC and RE 
SBIS: 99.9 (15.1) vs 107.5 (13.4), p<0.01 
VL: 38.4 (8.1) vs 46.1 (7.7), p<0.05 
MSCA: 49.5 (8.7) vs 53.9 (8.3), p<0.05 
RC: 42.4 (11.6) vs 49.2 (11.4), p<0.05  
RE: 35.5 (7.9) vs 42.8 (12.8), p<0.05   
Konijnenberg 
2015  
B 24 0 4 yr Mean 85.96*; 
PD use in 40% (illegal 
drug use), 25% alcohol 
CBCLe Scores >55 on aggressive behaviour and withdrawn 
behaviour  
























Explanatory notes relating to table 3: 
 
a Quality rating: A = good, B = intermediate, C = poor, based on modified GRADE criteria; b Age expressed in days (d), months (m) or years (yr);  c Drug information 
includes mean daily methadone dose (in milligrams) and information on maternal polydrug (PD) use, where these are reported. Unless otherwise stated, all information 
in this column refers to methadone-exposed group only; d Scores are presented as mean values (standard deviation) unless otherwise stated; e Questionnaire completed 
by parent or care-giver 
 
BSID = Bayley Scale of Infant Development (original version 1969), BW = birth weight, CBAQ = Child Behavior Attitude Questionnaire CBCL = Child Behavior 
Checklist, CGPQ = Child Game Participation Questionnaire, IBR = Infant behavior record, GCI = general cognitive index (used in the MSCA), MDI = mean 
developmental index (cognitive score), KABC-A = Kaufman Assessment Battery for Children, achievement component (tests the acquired knowledge of fact), M-P = 
Merril-Palmer Scale, MSCA = McCarthy Scales of Childhood abilities, PD = polydrug (defined as methadone plus any other drug use during pregnancy, excluding 
tobacco), PDI = psychomotor developmental index (motor score), RA = Robert’s Apperception RAKIT = Revision of the Amsterdam Children’s Intelligence Test, 
RATC = Robert’s Apperception Test for Children (tests the child’s perception of common interpersonal situations), RC = Reynell Developmental Language Scales 
(Comprehensive), RE = Reynell Developmental Language Scales (Expressive), SBIS = Stanford-Binet Intellectual scale, SON-IQ = Snijders-Oomen Nonverbal 






3.5.3 Visual development and function 
 
Twelve studies reported visual outcomes (Table 4). Five of the twelve studies measured 
visual evoked potentials (VEPs; 143 methadone exposed and 103 unexposed), and four 
of these five reported more VEP abnormalities (absent; smaller, slower) in methadone-
exposed children. 
 
Two studies reported flash VEPs at 1–4 days after birth(McGlone et al., 2008, McGlone 
et al., 2013a)to be more frequently absent or immature, and to be smaller on average, in 
methadone-exposed infants than in comparison unexposed infants. Two studies reported 
pattern VEPs in infancy: at 4 months(Whitham et al., 2010) and at 6 months(McGlone et 
al., 2014), pattern-reversal and pattern-onset VEP peak times respectively were 
significantly slower (>10 milliseconds on average) in methadone-exposed infants than in 
the unexposed group. A follow up study of ten 3-year old children previously tested at 4 
months found no group difference in pattern-reversal VEP peak times(Whitham et al., 
2015).  
 
A further six visual studies were case series detailing abnormal visual outcomes in a total 
of 108 methadone-exposed children(Nelson et al., 1987, Gaillard and Borruat, 2002, 
Hamilton et al., 2010, Gupta et al., 2012, Tinelli et al., 2013, Yoo et al., 2017) . The most 
common abnormalities reported were nystagmus (50/108) and strabismus (51/108): 
22/108 cases had both. The nystagmus direction in all described cases was horizontal and 
either jerk or pendular in waveform.  
 
83 
Abnormal visual outcomes at six months, reported as part of a cohort study(McGlone et 
al., 2014), were present in 40% (32/81) of methadone-exposed children (nystagmus 9/81 
cases, strabismus 20/81 cases; both 5/81). One “negative priming” study estimated 4 year 
old methadone-exposed children’s ability to suppress attention to a non-relevant 




















Age b Drug info c 
Visual 
assessment  
Main findings d  




C 29 0 6 – 








7/29 had strabismus. 4 esotropia 
diagnosed at a mean age of 10.5 
months, 3 exotropia diagnosed at a 
mean age of 15 months.  
Paper compared the strabismus group 
with the non-strabismus group to look 
for associations. 
Original cohort of 40 infants 
examined in neonatal period. No 
unexposed comparison group.  
2/29 preterm. 21/29 treated for NAS, 





















Case 5: BDZ 
Nystagmus Case 1, Female. Nystagmus until 3 yr. 
Development normal. 
Case 2: Male. Nystagmus presented at 
30 m, still present at 38 m. Noted to 
have psychomotor retardation. 
Case 3: Male. Nystagmus still present 
at 8 m. Rest of examination normal.  
Case 4: Female. Nystagmus at 4 m, 
resolved by 10 m. 
Case 5: Male. Nystagmus noted at 2 m, 
resolved by 9 m. 
Case series. 
1.NAS, treatment not stated 
2. No clarification regarding the 
developmental delay 
3. Preterm (34 w). NAS but 
treatment not stated 
4. NAS but treatment not stated 

















b Drug info c 
Visual 
assessment  
Main findings d  
















Peak latency P2 
and N3 
Day 1 -4, methadone-exposed infants 
had fewer typical VEPs, more 
immature waveforms and non-
detectable VEPs in 5/21 cases, p<0.01 
Median amplitude 10.6mV vs 
24.4mV, p<0.001.  
After 1 week, 14/21 methadone-
exposed infants had repeat VEPs: 
remained low amplitude, median 
11.3mV 
Peak latencies for P1 and N3 did not 
differ significantly between groups.  
24% methadone-exposed had no 
detectable VEP but all unexposed 
infants had a detectable VEP. 
Unmatched unexposed 
comparison group. 
All infants ³37 weeks GA. 
VEP assessors blinded to group.  
VEP measured at 7 days if 
methadone-exposed infant still 
in hospital.  























95% had reduced visual acuity 
70% nystagmus (horizontal, mostly 
pendular or jerk) 
50% had delayed visual maturation 
35% had strabismus 
30% had refractive errors.  
25% (n=5) had significant 
neurodevelopmental problems (4 = 
developmental delay, 1 = Cerebral 
palsy). Incidence of CVI was 25% 
2 preterm infants included  
12 treated for NAS, drug not 
stated. 3 children with 
neurodevelopmental problems 
had CVI 
4/20 had MRI scans, 1 reported 





















Main findings d  
Results appear as methadone vs 
















(opioids = 3, 
cannabis = 







P1 latencies (ms) to 48’ 136.25 
(18.02) vs 124.34 (12.35) – 12ms 
(95%CI 4-20ms, p=0.0052)  
P1 latencies (ms) to 69’ 134.99 
(33.46) vs 119.92 (11.74) – 15ms 
(95%CI 2.4-28ms, p=0.021)  
Multiple regression analysis revealed 
that prenatal methadone exposure is a 
significant predictor of prolonged P1 
latency in response to checks of 48’ 
retinal arc (Regression coefficient -
0.30, p<0.05) after correcting for 
confounders. 
Part of a buprenorphine vs 
methadone vs unexposed study. 
Original cohort 72 opioid mothers 
and 35 mothers not taking opioids 
(unexposed group matched for 
maternal age, parity, gravida, self-
reported alcohol use and smoking). 
Mean GA at birth 38.09 vs 38.85, 
no range GA. 
VEP assessors were blinded. 11/22 




C 22 n/a Mean 
18.5 

























All children had horizontal 
nystagmus: 9/22 jerk nystagmus, 8/22 
pendular, 5/22 type nystagmus not 
stated. 
16/22 strabismus, 15/16 esotropia, 
1/16 exotropia, 6 no strabismus. 
Median VA 0.5 logMAR (range 0.2 – 
1) in 18 children where VA testing 
possible. 1 child not fixing and 2 
fixing and following when tested at 
4m and 6m. 
2/22 bilateral optic nerve hypoplasia, 
8/22 delayed visual maturation 
Case series 25 children, 2 exposed 
to opiates other than methadone and 
1 exposed only to BDZ 
GA at birth not stated. 12/25 
demonstrated signs of NAS, 
information about treatment for 



















Main findings d  
Results appear as methadone vs 
unexposed Comments e 
McGlone 
2013  



















of peaks and 
troughs 
measured (P1, 
P2, N3, P3) 
 
Methadone-exposed were less likely 
to demonstrate P1 components of 
VEP (21% vs 48%, p=0.001) and N2 
components of the VEP (38% vs 60%, 
p = 0.011)  
Methadone-exposed infants had 
smaller amplitude VEPs median 27µV 
vs 39µV, p<0.001 and had more 
immature or atypical VEPS, p=0.001.  
All differences persisted after 
correcting for confounders (HC, 
cigarette smoking, excess alcohol)  
No association between maternal 
methadone dose and VEP 
abnormalities. NAS did not impact on 
VEP amplitude, morphology or 
implicit times. 
Unexposed group matched for GA 
(completed weeks), BW (±250g), 
Carstairs deprivation index (±1) 
Excluded infants <36 weeks GA. 2 
VEP assessors, 1 blinded to group. 
All VEPs recorded prior to any NAS 
treatment. 48/100 treated for NAS 
with morphine, 22/48 required 2 











m – 8 
m 
Case 1: 30 
 





Case 1: Preterm (33 w). Nystagmus 
noted at 2 m, still present at 1yr 
Reduced VA (1.3 logMAR) at 3 m, 
gradually improved (0.47 logMAR). 
Case 2: Term (40 w). Nystagmus at 5 
m with associated reduced VA (0.87 
logMAR). 8 m nystagmus still present 
but able to follow target. VA 
improving (0.47logMAR) 
Case 1: No NAS. Normal CrUSS 
and fundi at 2 m. At 1 yr 
development normal  
 
Case 2: NAS treated with 
phenobarbital for 15 days. Flash 
VEP prolonged latency and reduced 
amplitude right eye. Neurological 
examination at 8 m normal 
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Results appear as methadone vs 










































32/81 vs 2/26 infants failed the visual 
assessmenti.  
Abnormalities in methadone-exposed 
infants: 
Strabismus (25%) - 12 exotropia, 8 
esotropia, reduced VA >0.9 logMar 
(22%), horizontal nystagmus (11%) 
Methadone-exposed infants had a 
five-fold higher chance of failing their 
visual assessment after correcting for 
alcohol exposurei (p=0.007) 
Relative risk of abnormal visual 
assessment in methadone-exposed 
infants was 5.1 (95%CI 1.3 – 20), 
p=0.02. C2 latency (ms) at 120’ 115 
vs 99, p=0.019, at 60’ 115 vs 106, 
p=0.036, at 15’ 128 vs 108, p=0.0002 
C2 amplitude (µV) at 120’ 24 vs 26 , 
p=0.091, at 60’ 24  vs 34, p=0.003, at 
15’ 10  vs 17, p=0.003 
Methadone-exposed infants 
significantly less likely to have a VEP 
in response to the smallest check size 
of 15’ (51/70 vs 24/24, p=0.006). 
Overall, 70% methadone-exposed 
infants had one or more abnormal 
VEP parameter. 
Initial cohort 100 methadone 
exposed vs 50 unexposed.. 
Infants <36 weeks GA excluded. 1 
pediatrician and 1 optometrist 
assessed vision. Optometrist blinded 
to group. Corrected for confounding 
effect of excess prenatal alcohol 
exposure 
55/81 treated NAS with morphine. 
No infant had a clinical diagnosis of 
fetal alcohol syndrome. 
 
g Same cohort as McGlone 2013, examined at 6 months; h Atkinson Battery is a full visual assessment and includes pupil response to light, observation for nystagmus, 
convergence of eyes to approaching object, defensive blink, visual following of falling toy, batting and reaching, near retinoscopy, dynamic retinoscopy, Cardiff acuity 
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Quality 













Main findings d  
Results appear as methadone vs 



























Mean saccade latency(ms) 376.3 
(74.6) vs 331.2 (45.50)k. SNP 
difference score -12 (85.93) vs 23.5 
(45.50)l. 
Less random distractor trials (121 vs 
315) and unexposed trials (115 vs 
336) included in the analysism.  
 
Part of a study comparing 
buprenorphine exposed and 
methadone exposed infants with 
an unexposed group, which was 
not matched for maternal or infant 
characteristics. 
Mean GA at birth 38.7 vs 39.8 
weeks, range not stated. Assessor 
blinding not stated. 13/22 treated 


















P100 latencies: 48’ retinal arc:  
103.7 vs 104.7, p=0.47, 69’ retinal 
arc:  101.1 vs 102.7, p=0.65 
 
Multiple regression analysis showed 
that HC at time of testing was a 
significant predictor of P100 latency 
for checks of 69’, p=0.04. 
Follow up study of Whitham 2010. 
Inclusion of preterm infants not 
known as GA not stated. 
11 methadone-exposed infants 
tested; one had significantly 
prolonged P100 latencies, and was 
excluded from the analysis as an 
‘outlier’. 
Blinding of assessor not stated. 
6/10 treated for NAS. 
j Mean methadone dose excludes outlier daily dose of 660mg methadone; k Proportion of infants affected per group is not stated; l no p-value stated;  mTrials excluded if 
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Yoo 
2017  











dose <100 n = 




























21/32 with strabismus (16 
exodeviations, 5 esodeviations), 
median age of onset 12 months. 5/21 
with strabismus had additional 
nystagmus. Presence of strabismus 
not associated with methadone dose, 
exposure by trimester, polydrug 
exposure, history of NAS, 
prematurity or small for gestational 
age. 
9 preterm and 5 small for 
gestational age infants included 
27 NAS, 25/27treated, drug not 
stated. 3 with perinatal intracranial 
disease. 
Blinding of assessor not stated. 
Likely underestimate as sample 





























Explanatory notes relating to table 4: 
 
a Quality rating: A = good, B = intermediate, C = poor, based on modified GRADE criteria;  
b Age expressed in days (d), months (m) or years (yr);   
c Drug information includes mean daily methadone dose (in milligrams), maternal urine screening (MUS) and/or infant urine screening (IUS) for drug exposure and 
information on maternal polydrug (PD) use, where these are reported. Unless otherwise stated, all information in this column refers to methadone-exposed group only; 
d Scores are presented as mean values (standard deviation) unless otherwise stated;  
e Comments include information on attrition, matching, gestation, blinding, proportion of infants treated for NAS and pharmacological treatment for NAS, where 





3.5.4 Neuroimaging  
 
There were two small cohort studies reported neuroimaging using different modalities 
so synthesis was not possible in 35 methadone-exposed and 22 unexposed infants 
(Table 5). Pasto et al observed ‘slit-like ventricles’ in the newborn period using cranial 
ultrasound(Pasto et al., 1985), and Walhovd et al observed a regional difference in a 
measure of white matter microstructure (MD from dMRI) at around 3 weeks of 
age(Walhovd et al., 2012). Neither study was blinded and the majority of infants in 
























Results appear as 
































Significantly more of the 
methadone-exposed infants 
had slit-like ventricular 
configurations during the 
24-73 hours following birth, 
and at 1 month after birth 
compared with control 
infants, p<0.05c.  
Methadone-exposed infants 
had smaller ICHD at 1 
monthe,f. 
Initial cohort 52 
methadone exposed and 
38 unexposed infants 
(matched for maternal 
age and SES). All infants 
born at term. Blinding 
was not stated. 17/22 
were treated for NAS 
with morphine (n=7), 
phenobarbital (n=4) or a 














at MRI = 
21 d (13 – 
44 d) in 
meth 
infants vs  
23 d (14 -












3T MRI  
Tract-based spatial 
statistics (MD) 
Whole tract analysis 
(probabilistic) 
 
MD of left SLF was 
0.00138326 (S.D., 
0.00003818) for methadone-
exposed and 0.00133076 
(S.D., 0.00002958) for 
comparison infants, after co-
varying for age at scan, 
p=0.046 
Initial cohort 15 
methadone exposed and 
9 unexposed infants 
(matching not stated). 
Mean GA at birth 38.1 
(range 36-42) vs 40.0 (38 
– 41) weeks. Blinding 
not stated. 11/13 treated 
NAS with morphine. 
 
2D = 2 dimensional, 3T = 3 Tesla, ICHD = intracerebral hemi-diameter, MD = Mean diffusivity, MRI = magnetic resonance imaging, NAS = Neonatal 























Explanatory notes relating to Table 5: 
a Quality rating: A=good quality, B= intermediate quality, C= poor quality, based on modified GRADE criteria;  
b Age at time of imaging assessment expressed in hours (hr) or days (d);   
cDrug information includes mean daily methadone dose (in milligrams), maternal urine screening (MUS) for drugs and infant urine screening (IUS) for 
drugs, and information on maternal polydrug use (PD) where reported. Unless otherwise stated, all information in this column refers to methadone-
exposed group only;  
dComments include information on attrition, matching, gestation, blinding, proportion of infants treated for NAS and pharmacological treatment for 
NAS, is stated where provided in the original study;  
eProportion of infants affected per group is not stated;  






This systematic review of long-term neurodevelopmental, visual and neuroimaging 
outcomes of children with prenatal methadone exposure has collated detailed 
outcomes from 43 studies describing a total of 1476 methadone-exposed children and 
864 unexposed comparison children. The data describe poorer neurodevelopment and 
visual development in children with prenatal methadone exposure compared with 
unexposed comparison children. Eight studies reported BSID data at 6 months and/or 
at 2 years of age and were amenable for meta-analysis: meta-analyses point estimates 
of cognitive and motor indices in children exposed to prenatal methadone are reduced 
at 6 months of age, and by 2 years the WMD in both indices are increased with 95% 
confidence intervals that make the possibility of no difference unlikely. The 
emergence of difficulties as children grow older is well-recognized after complications 
in the perinatal period and reflects the ontogeny of higher-order function through 
childhood. The finding of behavioural problems in six out of seven studies that 
measured this domain, and lower cognitive performance in four out of 10 studies that 
reported outcome after 2 years, suggests that exposed children may be at increased risk 
of long term problems.  
 
The association between prenatal methadone exposure and atypical visual 
development is striking, with four of out five studies reporting significant differences 
in VEPs in infancy and childhood, reflecting altered visual pathways(McGlone et al., 
2008, Whitham et al., 2010). McGlone et al(McGlone et al., 2014) in their cohort of 
81 methadone-exposed and 29 unexposed infants at 6 months of age, describe a 
methadone-attributable risk of abnormal visual assessment of 80%, after correcting for 
 
96 
excess prenatal alcohol exposure. The prevalence of childhood strabismus and 
nystagmus in the methadone-exposed population is considerably higher than expected, 
which suggests that disorders of childhood visual function, as well as altered 
electrophysiological measures, are associated with prenatal methadone exposure. 
 
3.7 Study strengths  
A strength of this work is its pragmatic and systematic approach to summarizing 
childhood outcome following prenatal methadone exposure across three important 
domains chosen to reflect a broad perspective of the developing brain: 
neurodevelopment, visual development and function, and neuroimaging. We excluded 
studies of neonatal neurodevelopment in order to prevent confounding by NAS, and 
we excluded studies of alternative opioid substitutes in order to derive maximum 
inference about methadone, the single most commonly used pharmacological agent in 
the management of pregnant women with opioid use disorder.  
 
3.8 Study limitations 
Opioid dependent women prescribed methadone commonly use other drugs including 
alcohol(McGlone et al., 2012, McGlone et al., 2013b). Investigation and reporting of 
additional substance use in the studies reviewed was variable, and only one study had 
examined prenatal exposure in all infants in detail using extensive 
toxicology(McGlone et al., 2013a). Where additional drug use was investigated, the 
majority of infants were found to be polydrug exposed. Thus, a significant limitation 
of the meta-analysis is that its finding of poorer cognitive and motor indices at 2 years 
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of age cannot be attributed to methadone per se. However, the findings may be used 
for comparison with childhood outcome studies of alternative opioid substitutes in 
pregnancy.  
 
The review was also limited by intermediate to poor quality of included studies which 
introduces a risk of bias due to small study populations, high attrition, potential 
confounding by preterm birth, use of historical neurodevelopmental assessments, lack 
of assessor blinding and poor validity of comparison groups, with inadequate control 
for socioeconomic status, quality of care or environmental factors. However, meta-
analysis showed low statistical heterogeneity, although this could reflect restricted 
sample sizes. Attrition of methadone-exposed children at 2 years of age included in 
the meta-analysis was twice that of comparison children, increasing the chance of a 
type 2 error given that attrition is often explained by impairment in pediatric 
neurodevelopmental outcome studies. For the same reason, it is possible that the extent 
of neurodevelopmental and visual impairment associated with prenatal methadone 
exposure may be under-estimated.  
 
A further limitation is the historical nature of the majority of included studies, with 
only 15 of the 43 studies were published in the past decade. The original literature 
search included published literature from 1975 onwards, as this represents the time 
that methadone came into clinical use and it was important to capture all studies 
investigating potential effects of prenatal exposure, accepting that they may not 
represent our current population, in order to fully assimilate all the available evidence 
in this area. The eight studies assessing childhood development included in the meta-
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analysis were all of the original BSID era, which has now been superseded. Seven 
were published between 1979 and 1990 and one article contained combined data 
derived from several earlier studies (Hans and Jeremy, 2001) so although it was 
published in 2001 when Bayley-II was established, the article contained original data 
using BSID, therefore met inclusion criteria. 
 
The dated nature of the included literature might affect application of results to 
contemporary populations because patterns of drug misuse change over time and 
strategies for MAT of opioid use disorder in pregnancy have evolved. For example, 
the dose of methadone prescribed for MAT in current practice is typically higher than 
that reported in historical studies. A final limitation is that only nineteen of 43 studies 
provided information about maternal methadone dose, so it was not possible to explore 
dose response relationships.  
 
3.9 Clinical implications of this study 
Infants of methadone-maintained women with OUD are at increased risk for 
neurodevelopmental and visual impairment in early childhood, so may benefit from 
increased surveillance to aid early detection and timely intervention. This is 
particularly relevant for visual difficulties that are treatable, but which may be 
undiagnosed, or misdiagnosed as behavioural or learning difficulty. A history of opioid 
exposure during pregnancy should be sought if children present to services with 
disorders of visual function. The data indicate that follow-up to at least 2 years is 
required to detect neurodevelopmental difficulties, and carers should be made aware 




Improved understanding of the prenatal effects of OUD treatments, including the use 
of alternative substitutes, have been identified as research priorities(World Health 
Organisation, 2014). Buprenorphine is a partial mu-opioid agonist and kappa-
antagonist that binds to opioid receptors with higher affinity but lower activity than 
full agonists such as heroin and methadone(Walsh et al., 1995). Buprenorphine has a 
ceiling effect due to its partial antagonist activity, meaning that higher doses do not 
increase its effect due to opioid receptor saturation. This reduces the risk of overdose, 
but also means that buprenorphine can only be considered with daily doses of 
methadone of 30mg or less, as higher doses of methadone are unable to be matched by 
buprenorphine. 
 
Buprenorphine has been evaluated as an opioid substitute in pregnancy.  The 
MOTHER trial, one of the largest randomised controlled trials comparing 
buprenorphine to methadone in a total of 175 opioid dependent mothers, assessed short 
term infant outcomes relating to NAS and its treatment (Jones et al., 2010), appeared 
to produce encouraging results suggesting less severe NAS and shorter hospital stays 
with buprenorphine. These findings, along with improved growth and longer gestation 
have been replicated by other studies(Metz et al., 2011, Pritham et al., 2012, Lacroix 
et al., 2011). However, there was a large drop out in the MOTHER trial in the 
buprenorphine group (33% vs 18%) suggesting maternal dissatisfaction with the drug. 
If buprenorphine was rolled out as a replacement for methadone, this could result in a 
paradoxical increase in adverse fetal and/or neonatal outcomes if the mother then uses 




The concerns relating to buprenorphine replacing methadone have also been raised in 
a recent Cochrane review which concluded that there are insufficient data to establish 
whether buprenorphine is equivalent for all maternal outcomes, particularly adherence 
to treatment(Minozzi et al., 2013). Furthermore, confounding by indication could 
explain improved neonatal outcomes in buprenorphine groups(Brogly et al., 2014) due 
to the significant drop out in the buprenorphine groups secondary to maternal 
dissatisfaction with the treatment. It is therefore plausible that the improved outcomes 
reported in trials such as the MOTHER trial reflect intrinsically different populations 
of women with OUD, who are less severely affected and therefore able to tolerate the 
proportionally lower doses of opioid thus find buprenorphine an acceptable 
alternative. Therefore, although buprenorphine appears an attractive option when 
compared to methadone, the issues relating to confounding by indication result in 
clinical equipoise about the safest opioid substitute for mother and child. 
 
3.10 Future research  
Future research should aim to test methadone-exposed against buprenorphine-exposed 
infants and children, with well-matched un-exposed groups across a range of cognitive 
and behavioral domains with childhood follow-up extending beyond 2 years. 
Quantitative MRI is a powerful non-invasive technique that is sensitive to detecting 
alterations in neonatal brain structure and can predict functional impairment in 
childhood(Boardman et al., 2010, Ball et al., 2010) with relatively low sample 
size(Ball et al., 2013); its use could be informative in future research designed to 
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investigate the safety and harm of management strategies for opioid use disorder in 
pregnancy. 
 
This chapter of the thesis has explored the existing literature reporting childhood 
outcomes after prenatal methadone exposure. The data presented highlight that being 
born to an opioid-dependent mother who has been prescribed maintenance methadone 
in pregnancy is associated with adverse visual and neurodevelopmental outcomes in 
infancy and early childhood, but deficiencies in the existing literature limit causal 
inference about harm and factors other than methadone per se could account for these 
observations. The need for further contemporaneous research into optimal 
management of pregnant women with opioid use disorder is identified and future 
studies should be designed to evaluate neonatal brain development, as well as long 
term neurocognitive, visual and behavioural outcomes. The next chapter will describe 









CHAPTER 4: PRENATAL METHADONE EXPOSURE AND 
BRAIN DEVELOPMENT 
 
4.1 General introduction 
In Chapter One, the advantages of using MRI to understand disease in neonates was 
explored, in particular, the use of dMRI to investigate underlying brain microstructure, 
and advanced segmentation techniques to allow calculation of brain compartment 
volumes, all specific to the neonatal brain. The limited literature using MRI to 
investigate the effects of prenatal drug exposure was also reviewed in Chapter One. 
Comparisons were made with the adult literature on white matter changes associated 
with opioid use, which supports the hypothesis that opioid use contributes to a myelin-
related pathology resulting in disruption of the white matter microstructure. Chapter 
Three further explored the childhood neurodevelopmental and visual sequelae 
associated with prenatal methadone exposure. However, many of the studies in this 
area are unable to isolate the effects specifically of the prenatal drug exposure and are 
confounded by the potential influence of postnatal factors closely linked with parental 
substance misuse. 
 
In this chapter, the results of the MRI study undertaken in term born neonates exposed 
prenatally to methadone and those not exposed to any opioids during pregnancy will 
be presented. The recruitment of methadone-exposed study participants, obtaining 
informed consent from mothers prescribed methadone, preparation of the infant for 
MRI scan, transportation to MRI scanning area, supervising MR image acquisition, 
co-ordinating reporting of structural images, organising follow-up imaging in the 
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event of incidental findings and involvement in defining the TBSS covariates was 
performed by Victoria Monnelly. The final processing of the dMRI data and the TBSS 
analysis was performed by Dr Devasuda Anblagan. The control group of un-exposed 
infants were selected based on age matching from a previously described group of 
healthy term neonates recruited and scanned as part of a study of typical brain 
development. The use of previously acquired MRI data negated the need to recruit and 
scan healthy control term born babies as part of this study. 
 
The first part of this chapter is a formatted version of a first author paper published in 
Neuroimage Clinical (Monnelly et al., 2018) which tests the hypothesis that white 
matter development is altered in infants with prenatal methadone exposure, manifest 
by (1) reduced FA across the white matter skeleton (2) increased RD (3) increased MD 
across the white matter skeleton when compared with healthy neonates not exposed to 
opioids during pregnancy. The paper has been reformatted for the purpose of this 
thesis.  
 
The second part of this chapter assesses the brain volumes in a sub group of neonates 
with prenatal methadone exposure and compares them to unexposed control neonates 
to test the hypothesis that brain volumes will be smaller in prenatal methadone 
exposure compared with healthy neonates not exposed to opioids. The volumetric 
analysis included in this section of Chapter 4 was undertaken by Dr Ahmed Serag and 








Globally, in 2015 there were estimated to be 17.7million past-year users of heroin or 
opium, and increased heroin use is a major driver of the current opioid epidemic 
(United Nations Office on Drugs and Crime). Pregnant women with OUD due to 
heroin are recommended MAT with an alternative opioid, usually methadone or 
buprenorphine, because treatment is associated with improved use of antenatal 
services, reduced use of heroin during pregnancy and reduced preterm delivery. Fetal 
benefits of MAT include improved growth and lower risk of intrauterine death(Laslo 
et al., 2017).  
 
Methadone is a synthetic long acting mu-opioid agonist, which crosses the placenta 
freely, thereby exposing the developing fetus to exogenous opioid at a critical period 
of brain development. Pre-clinical studies suggest that prenatal methadone exposure 
may modify developing dopaminergic, cholinergic and serotonergic systems, and alter 
myelination. Antenatal exposure to the drug has behavioural consequences including 
depression, anxiety, and impaired learning, memory and social function(Wong et al., 
2014, Robinson et al., 1996, Vestal-Laborde et al., 2014, Chen et al., 2015). In humans, 
prenatal methadone exposure is associated with increased incidence and severity of 
NAS (Zelson et al., 1973, Wilson et al., 1981) compared with heroin exposure, and 
with altered visual maturation in childhood (McGlone et al., 2008, McGlone et al., 
2013a, Whitham et al., 2010). These observations raise the possibility that prenatal 
methadone exposure may modify early brain development; however, the possible role 
of confounding by postnatal events, including pharmacotherapy with opioid for NAS 
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and environmental factors, leaves uncertainty about the impact of prenatal methadone 
exposure on the developing brain. 
 
 
dMRI is an established technique for studying brain development in early life. It 
provides objective measures of white matter microstructure that are sensitive to 
atypical developmental and injurious processes in the perinatal period, and which 
correlate with neurodevelopmental outcome in childhood(Counsell et al., 2014). 
Specifically, FA is a voxel-wise measure of the directional dependence of water 
molecule diffusion in tissue which is influenced by fiber density, axonal diameter and 
myelination, thereby enabling inference about underlying tissue microstructure. TBSS 
enables unbiased group-wise analysis of FA volumes derived from dMRI data (Smith 
et al., 2006, Ball et al., 2010). It has been applied to neonatal dMRI to map 
microstructural change in white matter tracts of preterm infants at term equivalent age 
(Anjari et al., 2007), to identify clinical risk factors for altered brain development (Ball 
et al., 2010, Boardman et al., 2014, Anblagan et al., 2016), and to investigate 
neuroprotective treatment strategies in randomized clinical trials(Porter et al., 2010, 
O'Gorman et al., 2014, Azzopardi et al.) 
 
4.3 Hypothesis 
Based on the harmful effects of prenatal methadone exposure on neural systems and 
abnormal behavioural outcomes in pre-clinical models; and on human studies which 
suggest a modifying effect of prenatal methadone on postnatal behaviour and 
development, we hypothesized that white matter development of neonates would be 
altered in neonates exposed to methadone in utero. We used TBSS to examine risks 
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associated with prenatal methadone exposure, while minimizing the role of 
confounding by postnatal events and drug exposures. 
 
4.4 Methods and Materials 
4.4.1 Participants 
The study was conducted according to the principles of the Declaration of Helsinki 
and ethical approval was obtained from the UK National Ethics Service (South East 
Scotland Research Ethics Committee 02, 14/SS/1106). Written informed parental 
consent was obtained for all participants. The study group consisted of infants >37 
weeks’ postmenstrual age (PMA) whose mothers had been prescribed methadone 
during pregnancy for the treatment of OUD (cases) and a comparator group of healthy 
infants born at >37 weeks’ PMA whose mothers did not use opioids (controls).  
 
Mothers of cases were identified through a specialist antenatal clinic for pregnant 
women with substance misuse. All cases were born at the Royal Infirmary of 
Edinburgh between February 2015 and April 2017 and underwent MRI brain scanning 
at the Clinical Research Imaging Centre, University of Edinburgh. The controls were 
selected, based on age matching, from a previously described group of healthy term 
neonates recruited as part of a study of typical brain development (Blesa et al., 2016) 
(South East Scotland Research Ethics Committee 02, 13/SS/0143). For cases and 
controls, exclusion criteria were congenital infection or chromosomal abnormalities, 




Clinical and demographic information was extracted from the mother and infant 
clinical records. Birth weight and head circumference (HC) were described in terms 
of z-score for week of gestational age, calculated using INTERGROWTH-21st 
reference standards(Cheikh Ismail et al., 2013). The Scottish Index of Multiple 
Deprivation (SIMD) was used to characterize deprivation. The SIMD is the official 
Government tool used to identify areas of deprivation: it divides Scotland into around 
6,505 areas each containing around 350 households and assigns an index to each area 
based on multiple measures of deprivation. The data are ranked from most to least 
deprived and are presented as deciles.  
  
Details of methadone use, tobacco smoking, alcohol intake, and use of non-prescribed 
drugs were ascertained from medical records, including prescription charts, biological 
screening samples when these were performed as part of clinical care, and maternal 
interview at the time of delivery. 
 
The baby was prepared for MRI scan (VM) and this process involved checking with 
mother that consent for participating was still valid, ensuring the baby had been fed 
milk (as the MRI scan was performed as a ‘feed and swaddle’ scan), a full change of 
clothes to ensure the baby was free of any metal as most baby clothes contain metallic 
poppers which are not MRI compatible. Following this, the baby had acoustic 
protection applied as flexible earplugs and neonatal earmuffs (MiniMuffs, Nat's 
Medical Inc., CA), an open-topped hat applied to ensure the ear protection was secure 
but to avoid the head becoming too warm as MRI generates heat energy and were 
swaddled in a thin cotton swaddle blanket. The baby was then escorted in a pram (with 
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a full box of emergency drugs and equipment under the pram as a precaution) to the 
research MRI scanner, which was located approximately a ten minute walk from the 
maternity building. Often the baby was walked for longer than ten minutes in an 
endeavour to get them to sleep prior to arriving at the MRI scanner so he / she could 
be transferred during sleep into the scanner. With mother’s permission, a bottle of 
formula milk or maternal milk was also taken to MRI, along with a pacifier (dummy) 
if the baby had one to soothe the baby if they were unsettled at any point during the 
scan. This process took between 60 and 90 minutes for each baby. 
 
4.4.2 MRI acquisition 
MRI was performed on a Siemens Magnetom Verio 3T system (Siemens Healthcare 
Gmbh, Erlangen, Germany) using a 12-channel matrix phased array head coil. All 
infants were scanned axially to acquire: 3D T1-weighted MPRAGE volume (1 mm3 
resolution), T2-weighted STIR (0.9 mm3 resolution), T2-weighted FLAIR (1 mm3 
resolution), and dMRI (11 T2- and 64 diffusion encoding direction (b = 750 s/mm2) 
single-shot spin-echo echo planar imaging (EPI) volumes with 2 mm isotropic voxels, 
TE = 106 ms and TR =7300 ms. Images were reported by a pediatric radiologist with 
experience in neonatal MRI (AQ). 
 
MRI was performed in the neonatal period during natural sleep, without sedation. A 
neonatologist (VM) was present for the duration of each MRI scan, and the infant had 





DMRI data were preprocessed using FSL tools (FMRIB, Oxford, UK; 
http://www.ndcn.ox.ac.uk/divisions/fmrib). This included brain extraction, and 
removal of bulk infant motion and eddy current induced artefacts by registering the 
diffusion-weighted volumes to the first T2-weighted EPI volume for each subject. 
Using DTIFIT, FA volumes were generated for every subject. Diffusion volumes were 
assessed visually and were excluded if there was motion corruption. 
 
TBSS analysis was performed using a pipeline optimized for neonatal dMRI data (Ball 
et al., 2010). An average FA volume and mean FA skeleton (thresholded at FA > 0.15) 
were created from the aligned data. Statistical comparison between groups with and 
without exposure to methadone during pregnancy was performed with FSL’s 
Randomise using a general linear univariate model, with GA at image acquisition and 
HC z-score at image acquisition listed as covariates. All FA data were subject to 
family-wise error correction for multiple comparisons following threshold-free cluster 
enhancement (TFCE) and are shown at p < 0.05 (Smith and Nichols, 2009). 
 
4.4.3 Statistics 
Student’s t-test or the Mann-Whitney test was used to investigate differences in 
clinical and demographic variables between infants exposed to methadone (n = 20) 
and those not exposed (n = 20) and chi-squared or Fisher’s exact test was used to 






4.5.1 All participants 
Between February 2015 and March 2017, 55 women prescribed methadone received 
obstetric care at the Royal Infirmary of Edinburgh. A total of 25 methadone-exposed 
infants were recruited and underwent MRI scanning as part of the research study 
investigating brain development. See Figure 9 for participant flow.  
 
Conventional structural (sMRI) and dMRI data amenable to TBSS analysis were 
acquired from 40 neonates: 20 cases (10 female), who were exposed to prenatal 
methadone, and 20 unexposed controls (7 female). Tables 6 and 7 summarize maternal 











Table 6 :Maternal characteristics of participants with dMRI 
 
 
BMI, body mass index; SIMD, Scottish Index of Multiple Deprivation. 
 
 Methadone 
n = 20 
Control 
n = 20 
p value 





















Figure 10 : Euler diagram indicating prenatal drug exposures  
 
 




The mean methadone dose prescribed at pregnancy booking was 55 mg/day (range 0-
160) and the mean dose at delivery was 70 mg/day (range 8-160). Nineteen (95%) of 
the women prescribed methadone smoked tobacco, one reported drinking excessive 
alcohol (4 units/day at booking), and nineteen women had illicit or prescribed polydrug 
use (Fig 10). Additional prescribed medications included paroxetine (n=1), 








Table 7: Infant characteristics of participants with dMRI 
 Methadone 
n = 20 
Control 
n = 20 
p value 
Mean PMA at birth  
(range) / weeks 
38+5  
(37+1 – 41+0) 
39+1 
(37+2 – 41+3) 
0.32 
Gender (M:F) 10:10 13:7 0.52 
Mean birth weight  
(range) / g 
2721 
(2150 – 3440) 
3349 
(2346 – 4550) 
<0.01 
Mean birth weight 
z-score (sd) 
-1.062 (0.68) 0.443 (0.86) <0.01 
Median (range) 
postnatal age at 
scan / days 
3 (1 to 21) 13 (5 to 29) 0.005 
Mean PMA at scan 
(range) / weeks 
39+2 
(37+2 – 41+4) 
41+1 
 (39+0 – 42+2) 
0.004 
Mean HC at scan 
(range) / cm 
33.1 
(31.2 - 35.0) 
35.9 
(32.6 – 37.4) 
<0.01 
Mean HC z-score 
(sd) 
-0.523 (0.986) 1.146 (0.837) <0.01 






None of the cases had neonatal encephalopathy, seizures or hypoglycemia. The mean 
arterial cord pH of the group was 7.26 (range 7.16 – 7.36). There were three minor 
congenital anomalies (1 hypospadias, 1 cleft lip, 1 fixed bilateral talipes). One 
methadone exposed infant required admission to the Neonatal Unit for treatment of 
transient tachypnoea of the newborn. 
 
No infant had received pharmacological treatment for NAS at the time of image 
acquisition and none of the control group was exposed prenatally to opioid drugs. 
 
4.5.2 MRI features 
None of the cases or controls had features consistent with injury to white matter or 
grey matter on conventional structural T1- or T2-weighted structural MRI. Four cases 
had mild enlargement of the lateral ventricular system; 1 case had asymmetric 
myelination of the posterior limb of the internal capsule (but had developed symmetric 
myelination on repeat MRI four weeks later); and no case had abnormalities in 
brainstem, cerebellum, deep or cortical grey matter, or extracerebral space.  
 
4.5.3. Incidental MRI findings 
Two (10%) methadone exposed infants had developmental venous anomalies (DVA): 
one consisted of an area of low T2-weighted signal in the left peritrigonal white matter 
(most likely haemosiderin) with a curvilinear vessel extending peripherally and 
draining into the superior anastamotic vein of Trolland, which continues up to the 
superior sagittal sinus (see Figure 11).  The second DVA was characterized by an area 
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of low T2-weighted signal in the right peritrigonal white matter with a low T2-
weighted signal vessel that drains toward the choroid plexus. 
 
Figure 11 : Left developmental venous anomaly with associated 
cavernoma 
 
T1 weighted images in transverse (image on left and right) and coronal (middle image) 
planes. Red arrow depicts left sided developmental venous anomaly in the left 
peritrigonal white matter with a curvilinear vessel extending peripherally (image on 
left) up to the superior sagittal sinus. 
 
 
Another infant had asymmetrical myelination of the PLIC on their original research 
MRI. The left PLIC was starting to myelinate although there was no myelination of 
the right PLIC. There was normal myelination noted of the anterolateral thalami, 
brainstem and cerebellum and no cystic white matter change or evidence to suggest 
underlying volume loss in this case. The baby underwent a repeat MRI 4 weeks later 
which showed age and gestation appropriate symmetrical myelination in both PLICs. 





4.5.4 White matter correlates of prenatal methadone 
exposure 
Methadone-exposed neonates had decreased FA within the centrum semiovale, ILF, 
and the internal and external capsules after adjustment for PMA at MRI (p < 0.05, 
TCFE corrected) (Figure 12, panel A). Mean HC z-scores were lower in the methadone 
exposed group (-0.52 (0.99) vs 1.15 (0.84), p<0.001). After adjustment for HC z-
scores, differences in FA remained in the anterior and posterior limbs of the internal 
capsule and the ILF (Figure 12, panel B).   
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Panel A adjusted for PMA at scan and Panel B adjusted for PMA at scan and HC z-
score. Voxels with significantly lower FA in neonates with prenatal methadone 








RD was increased in internal capsule and ILF in neonates with prenatal methadone 
exposure (Figure 13). There were no differences in MD or AD between groups. 
 




Panel A adjusted for PMA at scan and panel B adjusted for PMA at scan and HC z-
score. Voxels with significantly higher RD in neonates with prenatal methadone 
exposure are shown in yellow-red colour scale.  
 
 
The median FA across the white matter skeleton was 12% lower among methadone-











Figure 14 : Mean FA across the white matter skeleton of neonates with 








4.6 Discussion  
 
These data show that prenatal exposure to methadone is associated with altered 
microstructure in major white matter tracts of the newborn brain, independent of head 
growth. Children whose mothers take methadone during pregnancy are at increased 
risk of neurodevelopmental impairment, behavioural difficulties, and visual problems, 
but study designs have left uncertainty about the role of confounding by prematurity, 
postnatal opioid exposure for treatment of NAS, and environmental factors, in 
mediating adverse outcomes(Rosen and Johnson, 1985, Wilson, 1989, van Baar, 1990, 
Hunt et al., 2008, McGlone and Mactier, 2015, Konijnenberg, 2015, Hans and Jeremy, 
2001). An association between prenatal methadone exposure and reduced somatic and 
head growth is documented(Mactier et al., 2014) but to our knowledge, this is first 
study to demonstrate brain tissue effects present around the time of birth after 
methadone exposure in utero. 
 
We used TBSS to investigate brain development because of its sensitivity to group-
wise differences in FA when used to survey the entire white matter skeleton (Ball et 
al., 2013). FA is a robust marker of tract microstructure that reflects fibre density, 
axonal diameter, wrapping by pre-myelinating oligodendrocytes and myelination. 
Therefore, these data suggest that neonates exposed to methadone in utero have less 
coherently organized and more immature fibre tracts compared to controls. 
Furthermore, correspondent increases in radial diffusivity without changes in axial 
diffusivity imply that abnormal myelination may contribute to altered FA among the 
cases. Since neonatal FA values in major white matter tracts correlate with later 
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neurodevelopment, the findings may explain the prevalence of neurobehavioral 
problems seen in children with prenatal methadone exposure.  
 
Quantitative MRI techniques have identified specific vulnerabilities of the developing 
brain to psychoactive drugs. Functional connectivity of the amygdala–frontal and 
thalamic networks is altered in neonates with prenatal cocaine exposure(Salzwedel et 
al., 2015) and in a preliminary study, Walhovd and colleagues reported higher mean 
diffusivity in the superior longitudinal fasciculus. However, this study was small, with 
13 methadone-exposed cases compared to 7 controls, infants were scanned at mean 
age of 3 weeks after birth and 85% of the cases had been treated with morphine for 
NAS, which limits inference about the effects of prenatal opioid exposure (Walhovd 
et al., 2012).  
 
Two (10%) cases had DVA, which was higher than expected based on estimated 
prevalence of 1.5% in neonates (Brinjikji et al., 2017). These did not occur in the cases 
exposed to cocaine, which is known to be associated with central nervous system 
vascular anomalies (Frank 1999); therefore, the possibility that prenatal methadone 
exposure is associated with CNS vascular malformation warrants further study.  
 
4.7 Study strengths 
The strengths of the study are that: dMRI acquisition took place soon after birth before 
exposure to postnatal opioids or other pharmacological treatment for NAS; preterm 
birth, which is an important source of confounding for neurodevelopmental outcome 
was excluded; detailed information about methadone dose and exposure to other drugs 
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was available; research resources were preserved as use of existing term MRI data 
negated the need to recruit a new cohort of term un-exposed infants . 
 
4.8 Study limitations 
A limitation of the study was the high rate of polydrug use, both illicit and prescribed, 
among the women prescribed methadone, and therefore evaluating causation was not 
possible. Polydrug use is consistently observed in other cohorts of methadone using 
pregnant women (McGlone et al., 2013b, van Baar, 1990, Rosen and Johnson, 1985). 
In our study population, heroin and oral benzodiazepines were used by 11 (55%) and 
12 (60%) of cases respectively, so it is possible that either drug could have confounded 
the observed association. No other drug class (anti-depressant, anti-epileptic, 
stimulant) was taken by more than 15% of the cases so it is unlikely that exposure to 
these classes of drug explained the findings.  
 
Furthermore, all of our cases had been exposed to once daily dosing with methadone, 
and we cannot exclude potential mediating or interacting factors such timing and dose 
effects of methadone. However, our data support pre-clinical studies, objective studies 
of visuo-cortical function in the newborn period and later infancy, and 
neurodevelopmental and behavioural studies, which strongly suggest an adverse effect 
of prenatal methadone upon the developing fetal brain and upon long-term childhood 
outcomes.  
 
Our study was also slightly limited by the use of historical term controls, as it was not 
possible to obtain detailed history of pregnancy exposures and there was a reliance on 
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maternal report for such exposures; however, none of the control participants were 
prescribed opioids during pregnancy, and the likelihood of undisclosed heroin use or 
non-prescription opioids was low.  
 
4.9 Clinical implications and future research 
Prenatal methadone exposure is associated with altered white matter microstructure 
that is apparent soon after birth. The data focus research attention on determining 
optimal management of pregnant women with OUD, including a pressing need to 
evaluate methadone dose regimens and alternative substitutes; future study designs 
should evaluate fetal or neonatal brain development and long-term neurocognitive 
outcome. 
 
The research implication of highly prevalent polydrug use in the target population is 
that future studies into optimal management of OUD in pregnancy are likely to require 
pragmatic designs that define case definition based on prescribed substitute, with post 
hoc adjustment for other drug exposures if they are shown to differ between groups. It 
is essential to obtain a clear prenatal exposure profile, and the gold standard should be 
to obtain meconium samples from all infants enrolled in studies investigating the 





4.10 Meconium analysis 
4.10.1 Background 
As discussed in Chapter One, substance misuse and alcohol misuse often co-exist, and 
in view of the well described neurological and developmental consequences of 
prenatal alcohol exposure, an attempt was made to ascertain prenatal alcohol exposure, 
to ensure results and interpretation of findings were not confounded by fetal alcohol 
spectrum disorder (FASD) by obtaining samples of meconium from the methadone-
exposed infants shortly after birth once informed consent for study participation had 
been obtained.  
 
As previously discussed in Chapter One, meconium is a stable matrix and is able to 
detect both drug and alcohol metabolites indicated prenatal exposure reflecting the 
midtrimester and last trimester of pregnancy. Free fatty acyl esters (FFAE and Ethyl 
Glucuronide (EtG) can be measured in meconium and concentrations of FFAE 
>600nanogram/gram indicate regular alcohol consumption during pregnancy (Chan et 
al., 2003), with a high sensitivity of 82% - 100% but variable specificity ranging from 
13 – 98% (McQuire et al., 2016). Thus a FFAE concentration >600ng/g translates into 
a positive predictive value of only 55% of excessive prenatal alcohol consumption 
(Abernethy et al., 2017). Concentrations of EtG >30nanogram/gram have a relatively 
high sensitivity and specificity for regular alcohol consumption during 
pregnancy(Himes et al., 2015). Measuring both FFAE and EtG results is more likely 





Where feasible, meconium samples from the methadone-exposed infant were obtained 
once informed consent had been gained. Since FAEEs are unstable at room 
temperature, samples were anonymized, frozen at −20°C and transported in batches 
on dry ice to the University of Firenze and Padova in Italy for analysis. A fully 
validated method was used for the detection of FAEEs and EtG by liquid 
chromatography-tandem mass spectrometry (Vaiano et al., 2016). As historical 
controls were used as part of the MRI study it was not possible to have a comparison 
group of meconium samples. 
 
4.10.3 Results 
Meconium samples were successfully obtained and analysed in 12 out 25 infants who 
took part in the study, see Table 8. Eleven of the infants participated in the TBSS study 
and 7 infants also had sMRI data amenable to brain volume analysis. There were 5 
cases of raised FFAE, but only one case with FFAE >600ng/g and EtG >30ng/g, 






Table 8 : Results of meconium samples 
Cases*  FFAE total 
ng/g 
EtG ng/g Indicative of 
excessive alcohol? 
1 204 ND No 
2 416 ND No 
3 441 ND No 
4 502 ND No 
5 533 ND No 
6 555 ND No 
7 575 ND No 
8 615 <10 No 
9 644 <10 No 
10 709 12 No 
11 791 21 No 
12 904 36 Yes 
 
*cases randomly assigned number  
 
Case 12* first sought antenatal care at approximately 29+5 weeks gestation, classifying 
her as a ‘late booker’. She was using heroin and codeine at booking and was 
commenced on a methadone programme during her pregnancy. Her reported weekly 
units of alcohol at her booking appointment was zero. Regarding the cases of raised 
FFAE with EtG below the threshold (cases 8 – 11), one mother was taking heroin and 
started methadone during pregnancy, two mothers successfully reduced their 
methadone dose during pregnancy, both of whom were also taking benzodiazepines, 
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and saliva testing in the remaining mother showed evidence of continued heroin and 
crack cocaine use during the pregnancy.  
 
4.10.4 Interpretation  
Based on interpreting both raised FFAE and EtG concentrations, there was only one 
case (8%) of prenatal excessive alcohol exposure in a high-risk population. Although 
fetal rates of alcohol exposure in a non-drug taking population in Canada have been 
estimated at 2.5%(Gareri et al., 2008),  population data from Scotland reports that with 
almost half infants with prenatal methadone exposure were also exposed to excess 
alcohol when their meconium was tested (McGlone et al., 2012). Therefore, this 
number is significantly lower than expected. If the cases with the raised FFAE were 
included, this figure rises to 5/12 (42%). However, the positive predictive value of a 
raised FFAE is only 55% (Abernethy et al., 2017) and so when the two biomarkers are 
interpreted together this results in increased accuracy relating to prenatal alcohol 
exposure (Bakdash et al., 2010). In addition, data from 235 babies selected at random 
every 8 days from a large maternity unit in the West of Scotland suggests that 
approximately 15% of pregnant women are consuming significant amounts of alcohol 
during the later stages of pregnancy(Abernethy et al., 2017). Further work funded by 
the Scottish Government is being undertaken to further our understanding of the scale 
of this problem, but results are not yet published.  
 
Importantly only 12 / 25 infants had meconium samples taken and analysed. It is likely 
that some or all of the mothers who did not provide a sample represent those who were 
using multiple drugs and / or alcohol, and so these results may under-represent the true 
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extent of prenatal alcohol exposure within a population of opioid dependent pregnant 
women prescribed methadone. The resultant sampling bias limits the interpretation of 
the meconium results in this study. 
 
 
4.11 Brain volume analysis 
4.11.1 Background 
As outlined in Chapter One, Section 1.4.5, HC is a surrogate for total brain volume. 
Reduced HC is well described in prenatal methadone exposure, even when 
confounders such as smoking and socioeconomic status are adjusted for(Mactier et al., 
2014). Brain volumes also correlate with neurodevelopmental outcomes in childhood, 
as explored in Chapter One. Two small studies investigating the effects of prenatal 
opioids on brain volumes have reported reduced regional volumes, particularly in the 
basal ganglia, but these studies used manual segmentation(Yuan et al., 2014, Walhovd 
et al., 2007). Another study reported brain volumes in later childhood when other 
postnatal environmental factors could confound the results(Sirnes et al., 2017). All 
three studies are limited by incomplete prenatal drug exposure profiling and small 
sample size. 
 
We aimed to explore whether total brain volumes and regional volumes are reduced in 






A sub-group of the originally recruited methadone-exposed infants with T2 weighted 
images amenable to volumetric analysis generating whole brain volumes were 
compared with a group of term born healthy unexposed control infants, matched as 
closely for GA at scan as feasible, who had been recruited for a previous 
study(Anblagan et al., 2016, Telford et al., 2017). There was a prioritization of MR 
sequence acquisition, which meant that not all infants had T2 weighted images that 
were suitable for volumetric analysis, resulting in a smaller subgroup analysis for the 
volume analysis. To estimate whole brain volumes, we used a method for brain 
extraction named ALFA (Accurate Learning with Few Atlases) which proved to 
provide robust and accurate volume measurements for neonatal brain MR images 
(Serag et al., 2016). The method uses a sparsity-based atlas selection strategy that 
requires a very limited number of atlases (here k=5) 'uniformly' distributed in the 
low-dimensional data space, combined with a machine learning based label fusion 
technique.  
 
A further subgroup of these infants (n= 8) had sMRI data amenable for full 
segmentation. To generate tissue segmentations, we used SEGMA(Serag et al., 2017) 
which is an automatic SEGMentation Approach for human brain MRI based on 
machine learning. SEGMA was proved to provide accurate segmentations across the 
life course (including the neonatal period) and was used to classify brain MRI scan 






Ten methadone-exposed infants and eleven un-exposed infants had sMRI data 
amenable to calculating whole brain volumes, see Tables 9 and 10 for maternal and 
infant characteristics respectively.  
 
4.11.3.1 Whole brain volume  
 
Table 9 : Maternal characteristics of participants with sMRI data used 
for whole brain volumes 
 
 Methadone 
n = 10 
Control 
n = 11 
p-value 
Mean age (range) / years 30.0 (22 – 35) 32.4 (27  -37) 0.27 
Mean BMI (range) 25  (20 – 33.3)* 23 (18.5 – 27.6) 0.34 
Median SIMD decile 
(Interquartile range) 
4.5 
(3 – 6) 
8.0 
(7 – 9) 
0.007** 
 







Figure 15 : Euler diagram illustrating the drug exposure profiles for the 





The mean daily methadone dose at booking was 61.5mg and this increased slightly to 
a mean dose at delivery of 63.2mg. All mothers were polydrug users, and one mother 
reported heavy alcohol use during parts of her pregnancy, see Figure 15. All 





Table 10 : Infant characteristics of participants with sMRI data used for 




Methadone-exposed infants have significantly lower intracranial volumes compared 
with unexposed infants, 408ml (sd 36ml) vs 511ml (sd 52ml), p<0.001, see Figure 16. 
Although GA at birth was similar, the mean gestational age at MRI scan differed by 
10 days, mediated by a significant difference in age at MRI scan (p = 0.001). 
 
 Methadone 
n = 10 
Control 
n = 11 
p value 
Mean PMA at birth  
(range) / weeks 
39+4  
(37+5 – 40+6) 
39+1 
(37+2 – 40+5) 
0.289 
Gender (M:F) 5 : 5 9 : 1 0.182 
Mean birth weight  
(range) / g 
3001 




Mean BW z-score (sd) -0.72 (0.94) 0.24 (1.09) 0.02 
Median (range) postnatal age 
at scan / days 
4  
(1 to 21) 
16  
(5 to 49) 
0.001 
Mean PMA at scan (range) / 
weeks 
40+2 
(38+5 – 41+4) 
41+5 
 (39+6 – 47+1) 
0.026 
Mean HC at scan (range) / cm 33.86 
(31.3 - 35.0) 
36.50 
(34.8 – 39.5) 
0.0002 
Mean HC z-score (sd) -0.23 ( 0.96) 1.40 ( 0.58) 0.0013 
Mean intracranial volume (sd) 
/ ml 
408 (36) 511 (52) <0.01 
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Figure 16 : Box plot showing median intracranial volumes in 












Figure 17 : Correlation between head circumference and total 
intracranial volume 
Green dots indicate prenatal methadone exposed infants, red dots indicate unexposed control infants 
 
 
There is a positive correlation between HC on the day on MRI acquisition and total 
intracranial volume, (R2 = 0.86), see Figure 17. These measurements do not account 
for gestational age at birth or at imaging as they are unadjusted. The outlier is a baby 






4.11.3.2 Intracranial segmentation volume analysis 
Of the 10 methadone-exposed, 8 were also suitable for segmentation analysis, and of 
the 11 control infants, 7 were amenable to segmentation, see Tables 11 and 12 for 
maternal and infant characteristics of the group amenable to full brain segmentation. 
 
Maternal age and BMI were similar, but methadone group were from more deprived 
parts of the city than the control mothers (p = 0.048).  
 
Table 11 : Maternal characteristics of participants with sMRI data 
amenable to full segmentation 
 
 Methadone 
n = 8 
Control 
n = 7 
p-value 
Mean age (range) / years 30.7 
(25 – 35) 
32.0 





(20 – 33.3) 
21.8 
(18.5 – 26) 
0.183 
Median SIMD decile 
(Interquartile range) 
4 
(2 – 6) 
7 








Figure 18 : Euler diagram illustrating the drug exposure profiles for the 




All mothers maintained on methadone were polydrug users. 7/8 were cigarette 















Table 12 : Infant characteristics of those with sMRI data amenable to 
full segmentation 
 
*n=6, not possible to calculate HC z-score from one patient with PMA 47+1 
 
 
Methadone-exposed infants were smaller, despite being older at birth, see Table 13. 
There was a significant difference in their HC, with methadone exposed having smaller 
HC (p = 0.001) and lower HC z-scores (p=0.008). The significant difference in HC 
and whole brain volume was accounted for by normalising the segmented brain 
volumes to the total intracranial volume, and the relative brain proportions of each 
group for the 6 segmented areas are presented in table 13.  
 
Methadone 
n = 8 
Control 
n = 7 
P value 
Mean PMA at birth  
(range) / weeks 
39+4  
(37+5 – 40+6) 
38+6 
(37+6 – 40+5) 
0.516 
Gender (M : F) 5 : 3 0 : 7 0.026 
Mean birth weight  
(range) / g 
2814 
( 2370 – 3252) 
3254 
(3070 – 3800) 
0.017* 
Mean BW z-score (sd) -1.06 (0.53) 0.06 ( 0.70) 0.006** 
Median (range) 
postnatal age at scan / 
days 
4 
(1  to  21) 
18  
(13 to 49) 
0.007** 
Mean PMA at scan 
(range) / weeks 
40+1 
(38+6 – 41+4) 
41+5 
 (40+4 – 47+1) 
0.023* 
Mean HC at scan 
(range) / cm 
33.75 
(31.3 - 35.0) 
36.85 
(35.9 – 39.5) 
0.001** 
Mean HC z-score (sd) -0.21 (1.09) 1.38* (0.44) 0.008** 
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Table 13 : Table showing relative brain proportions in the 15 infants 
with full intracranial segmentation 
 
 Relative brain proportions (%)  
p-value Methadone-
exposed 
n = 8 
Control 
n = 7 
White matter 27.5 29.9 0.049 
Deep gray matter 5.9 6.1 0.24 
Cortical gray matter 37.9 39.2 0.13 
Cerebellum 5.1 5.6 0.13 
Brainstem 1.2 1.2 0.81 




The relative volume of white matter was significantly lower in methadone-exposed 
infants than in unexposed control infants (p = 0.049). There was a concurrent increase 
in total cerebrospinal fluid in methadone exposed infants, which also reached 
statistical significance (p = 0.001). These results are illustrated in Figure 19.   
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Figure 19 : Box plot showing the relative volume of cerebral white 
matter and CSF in participants with full intracranial segmentation in  





These data showed reduced total brain volumes and a positive correlation between HC 
and intracranial volume in methadone-exposed neonates, consistent with previous 
research. In a smaller subgroup, segmentation analysis demonstrated reduced white 
matter volumes with presumed compensatory increased CSF volumes within the 
ventricles, normalized for HC. Although this differs from the limited published work 
describing lower basal ganglia volumes in association with prenatal opioid use, the 
potential biological mechanism relating to oligodendrocyte precursor vulnerability to 
exogenous opioids provides a plausible explanation for the observed results in this 
subgroup. It is also consistent with the novel finding described earlier in this Chapter 
that white matter microstructure is less coherently organised shortly after birth in 
prenatal methadone exposure before postnatal events confound interpretation. 
 
Diffuse white matter injury, resulting in reduced white matter volume is part of the 
observed preterm phenotype, and is associated with altered neurodevelopmental 
outcome(Boardman et al., 2010). Reduced white matter volume has also been shown 
to be predictive of delayed language in a cohort of infants with congenital heart 
disease(Rollins et al., 2017). Increased ventricular volumes are associated with worse 
neurodevelopmental outcome at 2 years, 3.5 years, and reduced processing speed at 
5.5 years in preterm infants(Keunen et al., 2016).  
 
A strength of the data is the use of contemporary automated validated technology to 
calculate the brain volumes and comparing to a group of healthy un-exposed neonates. 
Due to the prioritization of acquiring diffusion MR data many infants did not have T2 
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weighted images acquired or that were suitable for volumetric analysis, resulting in 
small numbers of participants for the volume analysis. Small sample size has been a 
challenge for other studies reporting brain volumes in the context of prenatal drug 
exposure, as has polydrug use. Benzodiazepine use was common in the mothers in this 
study, and midazolam exposure is known to result in alterations in hippocampal 
growth in preterm infants (Duerden et al., 2016), so it is possible that some of the 
differences demonstrated in this small group reflect other prenatal exposures, such as 
benzodiazepines, alcohol or other unknown substances. Although these findings are 
hypothesis generating and are pilot data, they warrant further investigation, as they are 





In this chapter of the thesis, age–optimized TBSS has been used to examine risks to 
the developing brain associated with prenatal methadone exposure, while minimizing 
the potential role of confounding by postnatal socioeconomic disadvantage, drugs used 
to treat NAS, and preterm birth. The association between prenatal methadone exposure 
and abnormal white matter development is described in term infants, compared with 
non-exposed controls, apparent at the time of birth. Pilot data from the volumetric 
analysis of a subgroup of participants showed reduced white matter with associated 
increased ventricular volume. Further research is still required to optimise 
management of OUD in pregnancy for the mother-infant dyad. The implications of 




CHAPTER 5: DISCUSSION 
This thesis has systematically reviewed the published literature and meta-analysed the 
results and investigated the possible effects of prenatal methadone exposure on early 
brain development using neonatal MRI. The key findings are summarised below and 
will be further explored in this chapter.  
 
5.1 Summary of key study findings 
• Systematic review of long term neurodevelopment, vision and neuroimaging 
in 1467 children with prenatal methadone exposure and 864 unexposed 
children shows that prenatal methadone exposed children are at increased risk 
of abnormal development (Chapter 3) 
• Meta-analysis reveals lower scores for both motor and cognitive outcomes at 
developmental testing age 6 months and 2 years in children with prenatal 
methadone exposure compared to non-exposed control children (Chapter 3) 
• Childhood behavioural problems are more likely in children with prenatal 
methadone-exposure (Chapter 3) 
• Visual development and function is adversely affected in children with prenatal 
methadone exposure, with strabismus and nystagmus being considerably 
higher than expected in children with prenatal methadone exposure (Chapter 
3) 
• Prenatal methadone exposure is associated with decreased FA within the 
centrum semiovale, ILF, and the internal and external capsules after adjustment 
for age at MRI (Chapter 4) 
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• Mean HC z-scores were lower in the methadone exposed group, but after 
adjustment for this, differences in FA persisted in the anterior and posterior 
limbs of the internal capsule and the ILF (Chapter 4) 
• Overall FA is 12% lower in prenatal methadone exposure than in un-exposed 
control infants (Chapter 4) 
• Head circumference positively correlates with overall brain volume, and so 
methadone-exposed infants have both smaller head circumferences and lower 
total brain volumes than non-exposed infants at similar gestations (Chapter 4) 
• When examining the relative brain proportions in a smaller subgroup, there is 
an increase in CSF, explained by a concurrent decrease in white matter volume 
in methadone-exposed infants (Chapter 4) 
• It was not possible to assess causation due to multiple confounders including 
polydrug use (Chapter 3, 4) 
• There was a higher than expected rate of incidental MRI findings of DVA, and 
the significance of this is unknown (Chapter 4) 
• There was a higher than expected rate of congenital anomalies, consistent with 
previous literature but in a small sample size the significance remains uncertain 
(Chapter 4) 
 
These data support pre-clinical studies, objective studies of visuo-cortical function in 
the newborn period and later infancy, and neurodevelopmental and behavioural 
studies, which strongly suggest an adverse effect of prenatal methadone upon the 
developing brain and upon long-term childhood outcomes, and importantly it shows 
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that prenatal methadone exposure is associated with atypical brain development which 
is apparent at birth. 
 
5.2 Challenges of research in OUD 
The challenges of undertaking research in OUD have been briefly discussed in Chapter 
One but will be further expanded upon in this chapter where relevant, based upon the 
experience from this study. 
 
5.2.1 Polydrug use  
The high rates of polydrug use observed during this study are consistent with the 
published literature(Lind et al., 2017).  
 
Higher rates of mental health disorders, particularly anxiety disorders treated with 
benzodiazepines, may in part account for the over-representation of benzodiazepine 
use in this population. There are adverse effects associated with postnatal midazolam 
exposure in preterm infants, including reduced hippocampal growth, which correlates 
to later adverse neurodevelopmental outcome(Duerden et al., 2016), and this may 
influence results from developmental outcome studies with high rates of polydrug use. 
The effects of other psychoactive substances on brain development have been 
discussed in Chapter Four. 
 
There were also high rates of cannabis use amongst pregnant women in this study. A 
systematic review of the MRI effects of cannabis use in adolescents reports abnormal 
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white matter microstructure in several major white matter tracts, and a dose-dependent 
relationship to these changes(Baker et al., 2013). Although this review included 
studies assessing alcohol as well as cannabis use, it again highlights the possibility that 
some of the observed changes of reduced FA and increased RD might be partly 
attributable to cannabis rather than methadone per se, a conclusion already drawn from 
this work. 
 
Pregnant women who only take opioids appear to be in a minority (McGlone et al., 
2013b) and this makes undertaking studies in a population of infants exposed to only 
one opioid extremely difficult. Although such studies would help to avoid the 
confounders of polydrug use and co-existent mental health disorders which currently 
limit the literature in this area, their usefulness on a pragmatic basis is questionable. 
Since polydrug use is an almost inevitable part of OUD, future studies in this field 
should have a pragmatic design to address this ongoing issue. 
 
5.2.2 Concomitant alcohol use 
Prenatal alcohol exposure results in a well described constellation of physical and 
behavioural problems, termed fetal alcohol spectrum disorder (FASD). Alcohol use is 
under-estimated in both pregnancy(Abernethy et al., 2017) and in some populations of 
opioid dependent women prescribed methadone (McGlone et al., 2012), and therefore 
is a potential confounder.  
 
Self-reported alcohol use within this study was low, with only one mother reporting 
alcohol use at booking. Of 12 samples obtained and analysed in the study, only one 
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sample (not the mother who admitted to alcohol use at booking) had both FFAE and 
EtG above the thresholds, indicating significant prenatal alcohol exposure. The details 
of this case have been discussed in Chapter Four (section 4.11.4).  
 
The low number of meconium samples obtained and amenable to analysis was 
disappointing. Possible reasons were multiple; Firstly, I could not obtain meconium 
until the mothers had signed consent. The majority of mothers were approached 
postnatally, and in order to allow enough time for them to consider participation, the 
consent process was at least one day after the initial approach, by which time most of 
the infants had already passed meconium. Secondly, I was reliant on the mothers to 
alert myself or midwifery staff once the baby had passed meconium to allow me to 
obtain and store the sample, and therefore those that did not want to provide a sample 
were able to discard the meconium. This is well described in a previous study relating 
to prenatal alcohol exposure (Abernethy et al., 2017). 
 
Finally, there was a considerable degree of apprehension from the mothers about the 
meconium sample and what information might be yielded from it and as a result less 
than half of the mothers (12/25) provided a meconium sample. It is interesting that of 
the 39 women initially approached, 31 gave informed consent for MRI scan (79%) 
although some were not eligible due to prematurity and some logistically could not be 
offered scans. This is a much higher uptake for MRI scans than the uptake for 
meconium sampling (79% vs 48%) and implies that MRI is an acceptable research 
modality for women with OUD. 
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Furthermore, despite reassurance that the samples were all anonymised, and the 
information was to quality assure the study to ensure that correct conclusions were 
drawn about methadone effects, many mothers remained sceptical and ultimately 
many did not provide samples. The majority of the mothers involved in the study had 
social services input as part of a comprehensive package of care, and in cases where 
the decision regarding discharge home or to foster care had not been finalised, the 
meconium sample seemed to place additional pressure on the mothers. It is possible 
that the mothers who did not provide a sample are more likely to be those who were 
polydrug using or using alcohol, and so these results may reflect an under-
representation of the true extent of prenatal alcohol exposure. This resultant sampling 
bias limits the interpretation of the meconium results in this study. 
 
5.2.3 Inherent population challenges 
I intended to first meet with potential participants when they attended antenatal 
appointments at the Royal Infirmary of Edinburgh Maternity department, before their 
baby was born to discuss the study and leave them with an information leaflet. It was 
standard practice for all women prescribed methadone to be regularly reviewed in a 
high risk obstetric clinic, by a consultant obstetrician with a specialist interest in 
maternal substance misuse. I would then aim to see them again as soon after delivery 
of their baby as was feasible to discuss study participation again, with the opportunity 
for questions. However, as mothers frequently did not attend their antenatal 
appointments, antenatal discussions about research participation were only possible in 




Full informed written consent was obtained prior to being enrolled. This involved at 
least two detailed conversations about what study enrolment meant for them and their 
baby. Particular details covered were (1) what the MRI scan would involve: feed and 
swaddle, no medication (2) timeline: up to an hour scan time (3) safety issues: mothers 
still hospital inpatients, therefore not able to go in the MRI scanner for safety reasons 
(4) possibility of incidental findings (5) meconium sample (6) voluntary nature of 
involvement, with emphasis on this point. 
 
Gaining the trust of the study participants was a challenge, requiring significantly more 
time than initially anticipated. One potential explanation for this is that rates of abuse, 
in particular early sexual abuse, amongst women with OUD, range between 30 and 
50% among women with OUD (Hans, 1999), and this may explain the apparent 
distrust of people in authority, or those with perceived ‘power’. 
 
There were four cases where maternal written consent was obtained, and this was 
withdrawn prior to the MRI scan. The most common reason for withdrawal was that 
the partner was not happy with research participation, even though the mothers were 
interested and had given consent. This illustrated the vulnerability of the women 
prescribed methadone; all the mothers who gave consent did so voluntarily. Although 
there is the possibility that they felt unable to say no to participating, they always had 
at least an overnight period to consider participating. Additionally, the overwhelming 
reaction of the mothers towards the study was positive, and many were grateful that a 
research study was interested in the outcomes of their children. Many also voiced 
concerns about previous children they had whilst also on methadone and were 
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extremely willing to participate. I was very careful to reiterate that participation was 
entirely voluntary, and care would be in no way compromised as I was not part of the 
primary care-giving team. Therefore, it seems more likely that their withdrawal of 
consent represented, at least in part, a dominance of their partner. 
 
A further challenge of performing research relating to prenatal drug exposure lay with 
the inherent socioeconomic risk factors such as mental health problems, domestic 
violence, poor physical health, low education, poverty, unemployment, crime and 
social isolation(Konijnenberg, 2015), all of which can also affect child development. 
These have been explored extensively in Chapter One, as have studies which have 
tried to disentangle the ‘nature vs nurture’ aspect. 
 
To the best of my knowledge this is the first study to demonstrate differences in the 
structure of the brain white matter within days of birth in infants prenatally exposed to 
methadone before postnatal factors can confound the results. This means that  the later 
outcomes of children with prenatal methadone exposure are not solely attributable to 
postnatal events.   
 
The significance of adequate levels of environmental stimulation for the maturation of 
central nervous system has been identified in a rat model, where exposure to an 
impoverished environment results in delayed maturation of the central nervous system, 
demonstrated by reduced amplitude VEP and delayed myelination (Narducci et al., 
2018). There is significant alteration of developmental trajectories under such 
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environmental conditions, and should the same be true in humans, any study which 
imaged children later in childhood would be potentially confounded by this.  
 
5.3 MRI to investigate potential effects of prenatal drug 
exposure 
Most of the existing literature using TBSS in neonates has been either in preterm 
infants or in term asphyxiated infants, and its use to investigate effects of prenatal drug 
exposure is relatively new.  
 
5.3.1 The advantages 
All of the aforementioned benefits of MRI are applicable to the infant prenatally 
exposed to drugs. MRI is safe, non-invasive, there is no ionising radiation, no need for 
sedation, and it allows detailed exploration of underlying brain microstructure. Water 
diffusion metrics such as FA map to later developmental outcomes, and other metrics 
such as RD give further information as to possible underlying pathophysiology 
underlying the findings. 
 
A particular advantage was the ability to perform an MRI very shortly after birth. It is 
common practice within the UK and throughout Europe and the US for infants with 
prenatal drug exposure to have an obligatory hospital stay after birth for a pre-defined 
period, usually 3-7 days. This is primarily to observe and score for NAS, and if 
appropriate, to commence pharmacological treatment. Thus, infants were already in 
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hospital and this facilitated the early acquisition of MRI data, before postnatal events 
could impact brain development and potentially confound results. 
 
Another major advantage was the small sample size of only 20 per group required to 
detect a difference between groups. Ball and colleagues have shown that TBSS is 
sensitive to detect change in groups of this size(Ball et al., 2013).They also noted that 
TBSS sensitivity is most stable in larger treatment groups or when a larger treatment 
effect is simulated. The effect observed within my study population was a 12% 
difference in FA, demonstrated amongst 20 methadone exposed and 20 unexposed 
infants, whilst the effect size Ball et al used to demonstrate a difference was 5% 
increase in FA. Smaller sample sizes have also been used; Porter and colleagues 
demonstrated significant and widespread changes in FA between asphyxiated and non-
asphyxiated term infants with only 10 infants per group(Porter et al., 2010), so the 
sample sized used, although seems small, is large enough using TBSS to detect 
significant differences using TBSS.  
 
Finally, the use of a standardised MRI protocol might enable the investigation of 
potential effects of prenatal drug exposures to be tested and potentially allow 
comparison of different drug effects. 
 
5.3.2 The challenges  
There were several challenges encountered during the organisation and running of the 
study, related to the MRI scan. Many mothers were surprised that the MRI scan would 
take so long, and some were put off by the length of time they would be away from 
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their baby for. For the mothers whose babies were going straight from hospital into 
foster care, their reluctance to participate was understandable, as their time with their 
baby was limited. Of the 25 methadone-exposed infants who participated, 11 went into 
foster care. 
 
Motion artefact was a problem, particularly with T2 weighted images. Of the 25 infants 
scanned, 20 had dMRI data amenable to analysis. Of note, a considerable amount of 
time was spent preparing the infants and optimising their comfort to try to obtain 
adequate conventional and diffusion imaging data. At times this involved long walks 
with the infant in the pram prior to the MRI scan, bottle feeding the infant prior to, or 
on occasion removing the infant from the MRI scanner and offering a further feed and 
then returning them into the scanner. All infants were swaddled to try to reduce their 
jitteriness, as they were all in varying stages of drug withdrawal. This required a 
significant amount of time and effort and flexibility from the whole research MRI 
team, including the radiographers. For a neonatal diffusion MRI study, a 20% rate of 
motion degraded images can be considered quite low when compared to other reported 
rates(O'Gorman et al., 2014) and is testament to the efforts made to try to obtain high 
quality imaging data. 
 
The occurrence of movement artefact was also likely influenced by the timing of the 
MRI scan relative to the infant’s clinical condition. The median day of scan was day 
2, with day 0 representing the day of birth. Thus, infants were usually between 24 and 
48 hours old at MRI, which correlated with the time that NAS starts to manifest. 
Although none of the babies were undergoing treatment for NAS at the time of MRI 
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scanning, this is not the same as reporting that none of the infants were starting to show 
features of NAS. One of the cardinal features of NAS is tremors and jitters. Whilst the 
swaddling contained some of their tremors, these fine tremors were still occurring in 
many of the babies, and this accounted for the distortion of images found in many 
subjects. dMRI is slightly less affected by movement artefact compared with 
conventional T1-weighted and T2-weighted images, which may be another reason 
why there were more subjects with diffusion than structural T2-weighted data. The 
movement degradation in one case was so bad that it was not possible even to provide 
a clinical interpretation of the conventional images and in this case the diffusion data 
was not usable either. 
 
 
Unfortunately, in spite of these measures, only 10 out of 25 subjects (40%) had T2 
weighted images that were amenable to calculating intracranial volumes, and only 8 
out of 25 (32%) had images where the intracranial segmentation could be performed. 
This likely reflects the sequence acquisition prioritisation, with the diffusion 
sequences being performed first, and repeated immediately if there appeared to be 




There were three cases of incidental findings (IF) out of 25 patients scanned, 
representing 12% of the study population; two cases had DVA and one case had 
asymmetrical myelination of the PLIC.  IF are defined as the finding of a brain lesion 
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on neuroimaging that clinicians would not have predicted, and as such are 
asymptomatic. The significance of most IF are unknown, and they can generate 
significant anxiety for parents(Gupta et al., 2016). IF were specifically discussed 
during the consenting process for the MRI study, and most mothers were accepting of 
the risk.  
 
The reported incidence of IF is variable, with little neonatal data. A meta-analysis in 
adults reports a prevalence of 0.7% (95% confidence intervals of 0.47% - 0.98%), with 
an increasing prevalence with increasing age(Morris et al., 2009). In a large paediatric 
population, there were IF in 25% children undergoing neuroimaging(Jansen et al., 
2017), however, this has selected out a population not entirely representative of normal 
healthy children and therefore could be an overestimate. Another paediatric study 
reported a 12.5% of children taking part in a research study had an IF discovered on 
neuroimaging (Kaiser et al., 2015). A study in very low birthweight infants estimated 
the incidence to be around 10% (Malova et al., 2017). The true incidence of IF in 
otherwise well babies is unknown and given the consistent reports of increasing 
prevalence with age, it is likely to be lower than the 10% or 25% quoted here. 
 
All three IF were managed as per the research protocol: parents were informed initially 
by telephone, repeat MRI scan was organised and referral was made to the appropriate 
healthcare team after the repeat MRI scan. For the two patients with DVA, the repeat 
MRI scans were discussed at a neuroradiology multidisciplinary meeting, and both are 
under follow up with a paediatric neurologist but being expectantly managed. The case 
with asymmetric myelination of the PLIC underwent a repeat MRI 4 weeks later, and 
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the asymmetry had resolved and the PLIC was fully myelinated. Mother was informed 
by telephone and there was no need for further follow up of the child.  
 
The importance of having the research MRI scans reported by a qualified radiologist 
was highlighted through these findings of IF. A considerable amount of time was spent 
by a consultant paediatric neuro-radiologist reporting the MRI scans, and for the 3 
cases of incidental findings, arranging repeat scans, and discussing the cases at 
relevant neuro-radiology multidisciplinary meetings to decide on appropriate follow 
up.  
 
An interesting observation was that many of the mothers felt a significant amount of 
guilt about the potential impact of their substance misuse on the health and wellbeing 
of their child, and this has been reported previously (Williams, 1985). It was important 
not to exacerbate this pre-existing guilt. Many mothers worried that the MRI scan 
would ‘find’ something relating to their methadone, or other drug / alcohol ingestion. 
Careful and simple explanation of the concept of groupwise MRI scan analysis (ie, not 
comparing individual scans, but comparing the group of babies exposed to methadone 
and babies not exposed) helped alleviate this.  
 
A final issue relating to the use of MRI to assess potential effects of prenatal drug 
exposure related to the inherent characteristics of the population, including their 





5.4 Prenatal methadone exposure and developmental venous 
anomalies 
There were 2 cases out of 25 of DVA, previously termed venous angioma. DVA are 
reported to be the most frequently occurring venous malformation, although as they 
are often identified as an incidental finding on MRI scans, the true incidence in 
neonates is unknown. Aetiologically DVA result from arrest in the parenchymal 
venous development. Although DVAs are usually are considered benign, they often 
co-exist with cavernous haemangioma(Aoki and Srivatanakul, 2016) and this can 
contribute to potential vascular morbidity and risk of spontaneous haemorrhage. 
 
The rate of 8% DVA in my study is higher than the previously reported 1.5%(Brinjikji 
et al., 2017). The prevalence appears to increase with age, with a reported prevalence 
in under 1 year olds of 1.5% compared with 7.6% in pre-school age children. A 
recently published large study in 3966 children reports that DVA is in the top 3 most 
common incidental brain findings on neuroimaging, with 63 DVA out of 940 children 
with IF (Jansen et al., 2017).  
 
DVA has previously been reported in association with prenatal methadone 
exposure(Brinjikji et al., 2017). Tinelli and colleagues published two case reports of 
children with prenatal methadone exposure and nystagmus (Tinelli et al., 2013), where 
one child had an MRI brain as part of their investigations, which showed an incidental 




DVA can also be accompanied by signal intense MRI lesions, which are felt to 
represent delayed myelination(Linscott et al., 2014). DVA has been reported in the 
context of acute demyelination in an adult (Jung et al., 1997), and recently in adults 
with multiple sclerosis there are case reports of DVA with demyelination occurring 
adjacent to the DVA(Ma et al., 2017, Rogers et al., 2018), suggesting that myelination 
or demyelination is linked to the aetiological process in some way.  
 
If DVA has an incidence of 1.5%, one would not expect to identify 2 cases in a cohort 
of 25 patients. This may be a chance observation, and its significance is unknown. It 
is nonetheless an interesting observation that warrants further consideration. 
 
5.5 VEP and MRI findings from this study 
In Chapter Three, the findings of abnormal or immature VEPs in infants and children 
with prenatal methadone exposure was discussed. Visual evoked potentials reflect the 
integrity and maturity of the cortico-visual system. More specifically, VEPs represent 
optic nerve myelination (Whitham et al., 2010); the more well myelinated the optic 
nerve, the faster the visual evoked potentials are conducted. Conversely, the less well 
myelinated, the more likely the VEP will have an increased latency or reduced 
amplitude or be absent altogether.  
 
We have demonstrated in our study that major white matter fibre tracts are less 
coherently organised in neonates with prenatal methadone exposure, reflected by 
lower FA values. This is likely to be mediated by impaired myelination, reflected by 
lower RD values. The reduced integrity of the white matter tracts offers a potential 
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pathophysiological explanation for the abnormal or absent VEPs demonstrated in 
several recent studies. The white matter abnormalities described in this study are 
evident in the same timeframe as a large VEP study of neonates demonstrated 
abnormal or atypical VEP (McGlone et al., 2013a). 
 
VEP findings correlate with dMRI measures in a mouse model of multiple sclerosis. 
FA decreased, and RD increased in the optic nerve, with decreases in VEP latency and 
reductions in amplitude(Nishioka et al., 2017). VEPs are also known to reflect the 
maturation pattern of the brain, with stepwise decreases in the VEP latency being 
demonstrated in preterm babies over time, reflecting a synchronized progress 
in myelination in several parts of the visual pathway(Tsuneishi and Casaer, 1997). In 
addition, using multiple sclerosis as a model of demyelination, there is human 
evidence of significant correlation between white matter microstructure alterations on 
dMRI and VEP latency using TBSS(Lobsien et al., 2014). 
 
 
5.6 Prenatal opioid exposure and congenital abnormalities  
There were 3 congenital abnormalities noted in the infants who had underwent TBSS 
analysis. These consisted of a cleft lip, a hypospadias and bilateral fixed talipes. There 
was also an addition case of an infant whose images were significantly degraded due 
to movement artefact and so was not included in the TBSS analysis, who had a 
hyposapadias and a facial nerve palsy. In total, there were 4 out of 25 infants with 
congenital anomalies. There were no congenital abnormalities in the control group. 
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Whilst the sample size is small, the number of congenital abnormalities appears to be 
over-represented in the methadone-exposed group.  
 
A recent systematic review assessing congenital malformations and opioid use in 
pregnancy reported the most common malformations as oral clefts in case-control 
studies and talipes in cohort studies(Lind et al., 2017). Our study finding, although in 
a small sample size, would be consistent with this finding. Another observational study 
reported the rate of congenital anomalies to be 8.3% in opioid-exposed compared to 
4.2% in unexposed infants(Norgaard et al., 2015), and a recent retrospective review 
reported a higher incidence of congenital abnormalities in methadone-exposed infants 
compared to unexposed infants, odds ratio 2.57 (95% confidence intervals 1.4 – 
4.7)(Kelty and Hulse, 2017). 
 
The occurrence of two cases of hypospadias in 25 methadone-exposed infants gives 
an incidence of 8%, which is also much higher than the reported 1 in 200 – 1 in 300 
usually reported(Cunha et al., 2015). The underlying mechanism for hypospadias is 
thought to be related to reduced exposure to testosterone during early fetal life, either 
via reduced levels or reduced sensitivity to testosterone(Baskin, 2000). Animal models 
of prenatal morphine exposure in males have shown opiate-induced suppression of 
testosterone in the fetal testes(Singh et al., 1980). A further study by Sandberg and 
colleagues postulated that if there was reduced fetal testosterone in prenatal opioid 
exposure, such children may show gender role differences in play and subsequently 
reported more feminised play behaviours in boys. Prenatal opioid exposure might 
result in sex hormone alterations in utero (Sandberg et al., 1990) and this mechanism 
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could underlie increased incidence of hypospadias, although the numbers in this study 
are very small. 
 
It remains unclear whether methadone exerts a directly teratogenic effect on the 
developing fetus. Most congenital anomalies occur at a rate of less than 1 per 1000 
births, and so although the small sample sizes of many of the included studies limit 
their ability to identify rare conditions, the fact that an association has been described 
between prenatal opioid exposure and congenital anomalies, suggests an increased 
incidence and warrants further study to prove this. 
 
5.7 Clinical implications of this study 
This study raises serious concerns about the effects of the most commonly used drug 
for OUD during pregnancy, methadone. It has also highlighted the increased risk of 
neurodevelopmental, behavioural and visual problems in children with prenatal 
methadone exposure, and this raises the question of how this information be taken 
forward into clinical practice. The thesis will now explore potential alternative options 
for the management of OUD in pregnancy, and the follow up options for at risk infants 
and children. 
 
5.7.1 Management of OUD in pregnancy 
Current management of OUD is pregnancy is opioid replacement therapy(2012). 
However, in light of the study findings of altered brain microstructure associated with 
prenatal methadone exposure, alterative treatment strategies for OUD in pregnancy 
should be considered. This is of such importance that the US congress have passed the 
 
162 
Protecting out Infants act 2015, which calls for a review of treatment options for 
prenatal opioid abuse(Laslo et al., 2017).   
 
5.7.1.1 Methadone dosing regimens  
Although the benefits of MAT with an opioid substitute during pregnancy are 
unequivocal(2012), there is no consensus regarding the optimal dosing regimen for 
methadone. A single daily dose of methadone is commonly prescribed, due to the long 
acting nature of methadone. Some authors suggest that accelerated metabolism of 
methadone during pregnancy might predispose women and fetuses to daily withdrawal 
stress and risk of relapse to illicit drugs(McCarthy et al., 2015, McCarthy et al., 2017, 
Bogen et al., 2013). Studies that support the use of divided dosing to minimize 
fluctuations in serum concentration report favourable effects on maternal symptoms 
of withdrawal, and on fetal neurobehaviour and reduced NAS prevalence (McCarthy, 
2015, Wittmann and Segal, 1991, Jansson et al., 2009), but no study has evaluated the 
impact of dosing regimen on brain development either fetal or neonatal, or long-term 
outcome. Monitoring of maternal plasma methadone concentration during the 
peripartum period with dose titration to keep levels within the maternal therapeutic 
range has been suggested, but this is not practiced widely(McCarthy et al., 2017). 
 
5.7.1.2 Alternative opioid substitutes: Buprenorphine 
Buprenorphine is a partial mu-opioid agonist and kappa-opioid antagonist. It appears 
to be an acceptable substitute to some pregnant women. As discussed in chapter One, 
there is less fetal neurobehavioural suppression with buprenorphine compared to 
methadone(Jansson et al., 2012). Buprenorphine is also associated with lower risk of 
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preterm birth, improved growth parameters at birth and less NAS, without apparent 
harm, when compared with methadone (Wurst et al., 2016, Jones et al., 2010). These 
neonatal outcomes suggest that buprenorphine may have a more favourable safety 
profile for the child in the short term although some more recent studies have shown a 
small and statistically non-significant difference in neonatal outcomes with 
buprenorphine compared with methadone(Nechanska et al., 2018). 
 
However, buprenorphine has also been shown to have an effect on 
oligodendrocytes(Eschenroeder et al., 2012), with subsequent effects on 
myelination(Sanchez et al., 2008). In addition, an increased rate of gastrointestinal 
birth defects with 3.2% occurring in buprenorphine compared to 0.6% in control 
groups has been reported(Kelty and Hulse, 2017). Studies of development and 
behaviour that include both buprenorphine-exposed and methadone-exposed infants 
to form an ‘opioid exposed’ group also report poorer outcomes in the opioid-exposed 
group(Norgaard et al., 2015, Konijnenberg and Melinder, 2015). However, ‘opioid-
exposure’ does not represent a homogenous group and should not therefore be 
interpreted as one. Furthermore, it is possible that more of the adversity is derived from 
the methadone-exposed group, as has been previously demonstrated(Whitham et al., 
2010, Konijnenberg and Melinder, 2015). It is imperative that more long-term data is 
acquired before another opiate substitute is widely adopted into practice without the 
evidence to support its use. 
 
5.7.1.3 Medically assisted opioid detoxification 
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One alternative treatment strategy for OUD in pregnancy increasingly being used is 
opioid detoxification, with parts of Europe and the US reporting its success. 
Detoxification has the benefit of avoiding the complications of addiction and limiting 
the prenatal exposure of the fetus to opioids.  
 
Current international guidance advises against detoxification during pregnancy, 
stating that there are increased fetal risks and a high rate of relapse(ACOG, 2012) . 
This is largely based around two case reports from the 1970s(Rementeria and Nunag, 
1973, Zuspan et al., 1975). As was the case with the introduction of methadone as a 
treatment for OUD in pregnancy, the clinical practice of avoiding opiate detoxification 
in pregnancy is also not supported by compelling evidence, rather by two case reports 
fifty years ago.  
 
There are several published studies attempting to provide evidence to support 
detoxification during pregnancy. However, the multitude of issues surrounding 
detoxification are complex. Firstly; Is it possible to detoxify during pregnancy? 
Secondly; is it safe for mother and fetus? Thirdly; does it matter how and when you 
detoxify? And finally; what are the long-term benefits of opioid detoxification during 
pregnancy?  
 
There are reports of over 600 patients in the literature who have been reported to 
detoxify from opiates during pregnancy with no apparent fetal harm(Bell et al., 2016, 
Jones et al., 2008, Luty et al., 2003), thus we could conclude that detoxification from 
opiates during pregnancy is possible. One study reporting successful detoxification in 
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21 women in Norway without adverse effects provides a very clear message that their 
results occurred in the context of a supervised and residential tapered detoxification 
programme, with full psychological support available and intensive fetal monitoring 
to guide the taper of opioid agonist therapy(Haabrekke et al., 2014). This may be 
integral to the success or failure of detoxification as a means of addressing perinatal 
opiate exposure. 
 
However, in many studies there is lack of denominator data about the proportion of 
mothers where detoxification was attempted but unsuccessful, ie relapse. Successful 
detoxification rates vary from 29% (17/58) (Maas et al., 1990), 41% (42/101) (Luty et 
al., 2003), 56% (53/95)(Stewart et al., 2013) and 58% (20/34) (Dashe et al., 1998). 
Thus, detoxification may not be a viable treatment option for some pregnant women.  
 
The issue of relapse following detoxification is an important consideration. Rates of 
relapse varied from 17% where intensive support was provided as part of a 
comprehensive detoxification programme to as high as 73% when detoxification was 
unsupported(Bell et al., 2016) suggesting that it can be modified and improved when 
delivered as part of a comprehensive care package. The variable but high risk of 
relapse and subsequent overdose poses a significant risk to both mother and fetus 
(Jones et al., 2017). A Norwegian study of non-pregnant addicts who underwent 
detoxification reported significant over-representation of recently detoxified patients 
in the deaths by overdose in the first four weeks following detoxification (Ravndal and 




In relation to the safety of detoxification during pregnancy, the main reported fetal 
outcomes are miscarriage or fetal demise, gestation at delivery and rate of preterm 
delivery, growth parameters and rates of NAS. All of the studies report longer 
gestation at delivery and less preterm birth, increased weight and head circumference 
and most report significantly lower rates of NAS, as would be expected.  
 
With regards to timing of detoxification, one study reported a single case of first 
trimester miscarriage out of five women who underwent detoxification in the first 
trimester of their pregnancy(Luty et al., 2003) and conclude that the trend to increased 
miscarriages observed supports the view that it is not safe in the first trimester. 
However, the baseline risk for miscarriage is significantly higher in the first trimester 
than later in pregnancy and this may account for the observed association. 
Furthermore, it is difficult to draw any firm conclusions from a study with a subgroup 
of 5 patients where one has an event. The largest study included 301 pregnant women 
of whom only 28 underwent detoxification during the first trimester, but this series 
reported no adverse fetal events or cases of miscarriage(Bell et al., 2016), suggesting 
that if Luty and colleagues 20% miscarriage rate had been true, there should have been 
8 cases of first trimester miscarriage, and there were none. 
 
The current studies are not powered to detect rare events such as stillbirth, SIDS and 
maternal overdose. These rare but important events may become more apparent if the 
practice of detoxification during pregnancy is widely adopted without further 
studies(Gleeson et al., 2017). In addition, at present there are no long-term studies 
assessing childhood outcome after opiate detoxification during pregnancy(Bell et al., 
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2016). The only study that attempted to address longer term outcomes was a small 
Norwegian study which compared 11 children aged 4.5 years prenatally exposed to 
opioids but whose mother underwent detoxification during pregnancy with 12 matched 
control children(Walhovd et al., 2015). There was no difference between HC at birth, 
intelligent quotient (IQ), neuroanatomical volumes quantified by MRI and there were 
no cases of NAS. However, there was a significant difference in vision between 
groups, with opiate-exposed children exhibiting reduced visual acuity compared to 
control children. As explored in detail in chapter Four, visual problems have been 
repeatedly associated with prenatal opioid exposure, and this study suggests that the 
onset of visual interference is early, asthese children had visual problems despite all 
mothers undergoing detoxified during pregnancy.  
 
Whilst there is inconclusive evidence at present to support widespread adoption of 
opiate detoxification during pregnancy, there continue to be ongoing and growing 
concerns surrounding the lasting adverse effects of prenatal methadone exposure on 
the developing brain, albeit the long-term effects remain unquantified. Current limited 
evidence suggests in the right population of pregnant women, and under the right 
circumstances, with appropriate fetal monitoring, that supervised residential 
detoxification, and intensive psychological support to prevent relapse may be the key 
to safe and successful opiate withdrawal in pregnancy and may be a viable option to 
optimise the outcomes for this vulnerable group of children. Further large studies, 
including assessment of timing of detoxification, and fetal, neonatal and childhood 




5.7.2 Neurodevelopmental follow up for all infants with 
prenatal methadone exposure 
Children with prenatal methadone exposure are an unequivocally vulnerable group of 
patients(Dryden et al., 2009). There is emerging evidence that these children have 
worse neurodevelopmental outcomes, more behavioural problems and more visual 
problems, and that early intervention would be beneficial (Moe, 2002). Yet despite 
this, there is no recommendation for increased surveillance to identify these problems 
at an early stage and support caregivers with early intervention strategies. This need 
has been previously identified to try to offset some of the risk conferred by prenatal 
drug exposure(Ornoy et al., 2010) but has not been widely implemented. 
 
Reduced FA correlates to worse neurodevelopmental outcome, as discussed in Chapter 
One. Should all infants with a history of prenatal methadone exposure, or indeed 
prenatal opioid exposure, be enrolled in a developmental follow up programme? A 
similar programme is well established for preterm infants, another vulnerable group of 
patients, and has been shown to improve outcome(Spittle et al., 2015).  
 
Instituting a follow up programme would have considerable impact on neonatal and 
paediatric services in terms of additional workload and is likely to face resistance in 
the short term at least, especially in the context of current NHS pressures. However, 
the additional work and cost are likely to be outweighed by the additional benefits 
gained by early identification of deficits, allowing early intervention- known to 
improve longer term outcomes(Brooks-Gunn et al., 1994), and may also result in 
improved school performance with longer benefits for health, education and society. 
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However, one must acknowledge the difficulties in engaging with families where there 
is substance misuse. Attrition rates in studies following up children at 2 years ranged 
from18%(Wilson, 1989) to 84%(Chasnoff et al.), and one study reported that over half 
the infants given appointments for outpatient clinic defaulted on two or more 
occasions(Dryden et al., 2009), reflecting the complex and chaotic lifestyles often 
associated with OUD. It is therefore very likely that should a developmental screening 
programme be instigated for these children, a significant proportion would not attend 
their appointments, resulting in a waste of valuable NHS resources, and a balance of 
benefit versus drain on resources would have to be judged. 
 
5.8 Study strengths 
Regarding the systematic review and meta-analysis (Chapter 3), a strength of this work 
is its pragmatic and systematic approach to summarizing childhood outcome following 
prenatal methadone exposure across three important domains chosen to reflect a broad 
perspective of the developing brain: neurodevelopment, visual development and 
function, and neuroimaging. Studies of neonatal neurodevelopment were excluded in 
order to prevent confounding by NAS. Studies often incorrectly consider ‘opioids’ as 
a homogenous group, and this limits causal inference about specific opioid 
medications. Therefore, studies reporting outcomes following exposure to alternative 
opioid substitutes were excluded, in order to derive maximum inference about a single 
pharmacological agent, methadone, commonly used in the management of pregnant 




Regarding the MRI study detailed in Chapter Four, the acquisition of dMRI took place 
soon after birth, before exposure to postnatal opioids or other pharmacological 
treatment for NAS could potentially confound the interpretation. Preterm birth, which 
is an important source of confounding for neurodevelopmental outcome, was 
excluded. The MRI analysis was quantitative, used well established processing 
pipelines specific for the neonatal brain and was adequately powered according to 
previous research in MRI studies (Ball et al., 2013). We adjusted for OFC and showed 
that the findings were robust to differences in global brain growth. Importantly, this is 
the first study that shows alterations in newborn brain structure associated with 
prenatal methadone exposure shortly after birth.  
 
5.9 Study limitations 
The major limitations relate to the interpretability of the systematic review and meta-
analysis and the limited inferences about harm. Firstly, estimates of impairment may be 
biased by intermediate to low quality evidence; most were intermediate, and some were 
low, with a mean modified GRADE score of 3.5/8. Secondly, comparison groups were 
often poorly described beyond the definition of ‘non-opioid exposed’, with inadequate 
control for socioeconomic status or environmental status or polydrug or alcohol use. 
Finally, many of the included studies were published prior to the millennium, making 
them now nearly 20 years out of date. This has potentially important implications, as 
patterns of substance misuse are changing. Where methadone dose was stated in the 
studies included in the meta-analysis, the mean dose was generally between 15mg and 
42mg per day which is much lower than the mean dose of methadone in this MRI 
study, 69mg per day. Therefore, research performed in the 1970s and 1980s may not 
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be representative or applicable to the current situation we are in. Although no study to 
date has demonstrated a dose-dependent relationship, mostly due to inability to derive 
such information due to methodological limitations, there is biological plausibility in 
a dose-dependent relationship existing and contributing to later adverse effects. The 
differences in doses then becomes more important, as the earlier studies may further 
under-represent any developmental under-performance that modern children exposed 
to higher doses of methadone may experience.  
 
Other sources of potential bias in the systematic review included high attrition, and 
likely confounding by preterm birth and postnatal opioid exposure. Attrition of 
methadone-exposed children at 2 years of age included in the meta-analysis was twice 
that of comparison children, increasing the chance of a type 2 error given that attrition 
is often explained by impairment in pediatric neurodevelopmental outcome studies. 
For the same reason, it is possible that the extent of neurodevelopmental and visual 
impairment associated with prenatal methadone exposure may be under-estimated.  
 
Polydrug use was seldom disclosed and infrequently reported in the included studies. 
Where additional drug use was investigated, the majority of infants were found to be 
polydrug exposed, consistent with previous observations that opioid dependent women 
prescribed methadone commonly use other drugs including alcohol (McGlone et al., 
2013b, McGlone et al., 2012) Investigation and reporting of additional substance use 
in the studies reviewed was variable, and only one study had examined prenatal 
exposure in all infants in detail using extensive toxicology (McGlone et al., 2013a).  
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These data highlight that being born to an opioid-dependent mother who has been 
prescribed methadone during pregnancy is associated with adverse visual and 
neurodevelopmental outcomes in infancy and early childhood, however, deficiencies 
in the existing literature limit causal inference about harm, and factors other than 
methadone per se could account for these observations. These findings may be used 
for comparison with childhood outcome studies of alternative opioid substitutes in 
pregnancy.  
 
Regarding the MRI study, polydrug use among cases was also a major limitation, as it 
prevented causal inference. Because evaluating causation was not possible, it was also 
not possible to exclude potential mediating or interacting factors such timing and dose 
effects of methadone or the role of other prenatal drug exposures. Whilst polydrug use 
is not a problem unique to our study, it continues to be a significant limitation within 
the field.  This study was also limited by reliance on maternal report for drug exposures 
among control women. However, none of the control participants were prescribed 
opioids during pregnancy, and the likelihood of undisclosed heroin use or non-
prescription opioids was low. 
 
Finally, the inability to obtain meconium samples for all participants involved, which 
precluded an accurate assessment of prenatal drug and alcohol exposure was a 
limitation. Studies assessing impact of prenatal drug exposure need sensitive and 
reliable measures of drug exposure, for both cases and control groups, and in order to 
achieve this a combination of maternal self-reporting and biological samples, such as 
meconium, should be used (Konijnenberg, 2015). 
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5.10 The future  
5.10.1 The impact of prescription opioids during pregnancy 
Opioid use during pregnancy is not solely seen in OUD secondary to illicit addiction. 
There has been a dramatic increase in prescription opioids over the last decade, 
contributing to the so called ‘opioid crisis’. Unlike previous opioid epidemics which 
predominantly affected poor urban minority populations, the current opioid crisis 
disproportionately affects white middle-class people covered by private health 
insurance(McCarthy 2016). This has been reflected in the subsequent increase in 
opioid-dependence related claims, which have risen by a staggering 3203% to 7 
million in 2014. Patients prescribed opioids for pain are at risk of opioid abuse and 
misuse, particularly if they have other co-morbid factors such as mental health issues 
or previous substance misuse disorders(Kaye et al., 2017).  Sadly, the surge in 
prescription opioid medications has been mirrored by a surge in fatalities related to 
overdoses, with 16,651 overdose deaths from prescription opioids versus only 3036 
heroin related deaths in 2010 (Volkow et al., 2014). 
 
The prescription opioid epidemic extends to pregnant women and their unborn 
children, who may be exposed to opioid during pregnancy, with one study estimating 
that 14.4% pregnant women had at least one opioid prescription dispensed during their 
pregnancy(Bateman et al., 2014). Although the majority of prescription opioids used 
during pregnancy in the US appear to be prescribed for acute pain(Yazdy et al., 2015), 
the increased use of prescribed opioids has been temporally associated with an increase 
in opioid use disorder among pregnant women in the US (Patrick et al., 2012), 
particularly in rural areas(Villapiano et al., 2017).  
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There are few studies reporting neonatal outcomes for prescription opioids(Lester and 
Lagasse, 2010) but their use is more commonly associated with neonatal complications 
(Patrick et al., 2015b), such as preterm birth, known to be associated with oxycodone 
(Kelly et al., 2011) and tramadol use (Kallen et al., 2013). NAS (Patrick et al., 2015b) 
is also more common, as prescription opioids also cross the placenta, exposing the 
developing fetus to exogenous opioid during pregnancy, which abruptly ceases after 
birth. However, as previously discussed in Chapter 1, NAS is a short-term description 
of behaviour and the long-term consequences of NAS per se remain unknown. 
Similarly, the long-term consequences of prenatal prescription opioid exposure rather 
than illicit opioid exposure remain unknown.  
 
There is the potential to study the effects of prenatal exposure to prescription opioids, 
as this population, especially if women are using a single opioid agent for analgesia as 
this minimises the effect of polydrug use, and this population may not have the same 
environmental and social confounders frequently encountered in those with OUD. 
Interestingly, a retrospective study investigating neonatal outcomes in two groups of 
methadone-exposed infants, those taking methadone for pain and those with OUD, 
found that outcomes (growth and NAS) were better in the pain group than the OUD 
group(Sharpe and Kuschel, 2004), although this could reflect confounding by 
indication. 
 
The American pain society suggest that counselling pregnant women about the risks 
versus the benefits of chronic opioid therapy and recommend no use or minimal 
use(Chou et al., 2009). However, it is extremely difficult to counsel women accurately 
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when there is very little data regarding prescription opioid use and neonatal outcomes, 
and no data on longer-term outcomes. In addition, prescription opioids encompass a 
variety of medications, and it cannot be assumed that the potential effects on the 
developing fetus will be the same for all medications within a class.  
 
The ideal solution is a primary prevention policy to curb inappropriate prescribing of 
opioids(Volkow et al., 2014) and doctors have been urged to limit opioid 
prescribing(McCarthy, 2016). However, the situation is more complex during 
pregnancy, and pain management in particular poses significant challenges, as many 
alternative analgesic medications are contraindicated. The reality is that numbers of 
pregnant women prescribed an opioid medication continue to rise, with nearly 27% of 
pregnant women having at least one prescription in a large data linkage study in the 
US(Patrick et al., 2015b), the vast majority being long term prescriptions. The 
assumption that opioids are ‘safer’ to use in pregnancy than other medications is 
unfounded, and possibly untrue. If there are no feasible alternatives, and opioid 
medications have to be prescribed during pregnancy for medical reasons, the 
prenatally exposed children could be entered into a longitudinal study to assess infant 
and childhood outcomes, to advance understanding of the consequences of 
prescription opioid use during pregnancy, accepting the potential limiting factor of 






5.10.2 Future directions 
Before concluding, this thesis will now highlight how this study should shape the 
direction of future studies. Firstly, there is an urgent need for studies which assess 
long-term childhood neurodevelopmental outcomes after prenatal opioid exposure. 
The research implication of highly prevalent polydrug use in the target population is 
that future studies into optimal management of OUD in pregnancy are likely to require 
pragmatic designs that define cases based on prescribed substitute, with post hoc 
adjustment for other drug exposures if they are shown to differ between groups. In 
order to do this, studies will need to quantify prenatal drug and alcohol exposure, using 
a validated biological sample analysis such as infant meconium. Many of the 
discussion points in Chapters Three, Four and Five would be addressed by a 
longitudinal pragmatic study design, which accurately profiles prenatal exposures 
using infant biological matrices such as meconium and is limited to one specific opioid 
substitute. Grouping together several opioids as a combined ‘opioid exposure’ is not 
useful, as it is not a homogenous exposure, and different opioids are likely to have 
different effects on the fetus. Additionally, future studies should follow children into 
adolescence as the emergence of subtle developmental sequelae, such as problems 
with executive dysfunction often become more apparent in later childhood.  
 
Furthermore, future studies should use emerging technologies including advanced 
imaging techniques, faster acquisition times, motion correction, and further evaluate 
early infant brain development before postnatal environmental factors influence brain 
development and neurodevelopment. There remains a pressing need to evaluate 
alternative opioid substitutes, to allow comparison of outcomes, and improve 
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understanding about the optimal management of OUD in pregnancy. As part of this, 
alternative strategies for managing OUD in pregnancy should also be explored. The 
ultimate goal would be for pregnant women to not expose their unborn child to any 
opioid, or to as little as possible to minimise adverse effects. The potential harm 
associated with detoxification during pregnancy has not been adequately 
demonstrated, and future research in this area is vital, and again, it is vital that study 
designs include long term childhood outcomes. Medically assisted detoxification 




This thesis has furthered the understanding of the detrimental effects of prenatal 
methadone exposure, firstly through systematic review and meta-analysis of existing 
published literature describing adverse neurodevelopmental and visual outcomes and 
secondly, using advanced MRI to study a challenging population and demonstrate 
altered white matter microstructure which is apparent soon after birth. This new 
information about timing of brain changes is critical, as it indicates that prenatal 
methadone exposure has early demonstrable effects on brain connectivity, which may 
in turn account for differences observed in the developmental trajectories of such 
exposed infants. In the context of an opioid epidemic this data strongly supports the 
pressing need to evaluate methadone dose regimens in pregnancy, alternative opioid 
substitutes and alternative treatment strategies for OUD. Future study designs should 
evaluate fetal and neonatal brain development and long-term neurocognitive outcome, 
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ND 0 0 0 1 0 0 0 0 1 
Strauss 
1976  * 
ND 0 1 ½ 1 0 0 0 1 3 ½ 
Kaltenbach 
1979  ‡ 
ND 0 1 0 1 1 ½ 0 1 4 ½ 
Strauss 
1979  
ND 0 1 ½ 1 1 0 0 1 4 ½ 
Wilson 
1981  
ND 0 1 ½ 1 1 ½ 1 1 6 
Marcus 
1982  
ND 0 1 0 1 1 ½ 0 1 4 ½ 
Chasnoff 
1984 *‡ 
ND 0 1 ½ 1 0 ½ 0 1 4 
Suffet 
1984  
ND 0 0 ½ 1 0 ½ 0 0 2 ½ 
Lifschitz 
1985  
ND 0 1 ½ 1 0 0 0 1 3 ½ 


























Rosen   
1985  * 
ND 0 1 ½ 1 0 ½ 0 1 4 
Kaltenbach 
1986 
ND 0 0 0 1 0 0 0 1 2 
Kaltenbach 
1987 
ND 0 1 1 1 0 ½ 0 1 4 ½ 
Davis   
1988 
ND 0 1 0 1 0 0 0 1 3 
Doberczak 
1988 
ND 0 0 0 1 0 0 0 1 2 
Kaltenbach 
1989  *‡ 
ND 0 1 0 1 0 ½ 1 1 4 ½ 
Wilson 
1989 ‡ 
ND 0 1 0 1 0 ½ 0 1 3 ½ 
Sandberg 
1990 
ND 0 1 ½ 1 0 0 0 1 3 ½ 
Van Baar 
1990  *‡ 
ND 0 1 ½ 1 0 ½ 0 1 4 
De Cubas 
1993 
ND 0 1 ½ 1 0 0 0 1 3 ½ 
Van Baar 
1994 
ND 0 1 ½ 1 0 0 0 1 3 ½ 
Schneider 
1996 
ND 0 1 ½ 1 1 1 0 1 5 ½ 
Bunikowski 
1998 
ND 0 1 0 1 0 1 0 0 3 

























2001    ‡ 
ND 0 1 ½ 1 1 ½ 0 1 5 
Hunt       
2008 
ND 0 1 ½ 1 0 ½ 0 1 4 
Paul       
2013 
ND 0 0 0 1 0 0 0 1 2 
Konijnenberg 
2015 
ND 0 0 ½ 1 0 1 0 1 3 ½ 
Bier        
2015 
ND 0 1 ½ 1 0 0 0 1 3 ½ 
McGlone 
2015 
ND 0 0 1 1 0 1 1 1 5 
Nelson    
1987 
V 0 0 0 1 0 0 0 0 1 
Gaillard 
2002 
V 0 0 0 1 0 0 0 0 1 
McGlone 
2008 
V 0 1 1 1 1 0 0 1 5 
Hamilton 
2010 
V 0 0 0 1 0 0 0 ½ 1.5 
Whitham 
2010 
V 0 1 ½ 1 1 ½ 0 1 5 
Gupta     
2012 
V 0 0 ½ 1 0 0 0 1 2 ½ 
McGlone 
2013 
V 0 1 1 1 1 1 0 1 6 

























Notes relating to Table 14. 
 
a ND = neurodevelopmental, NI = neuroimaging, V = visual; b Randomised controlled trial = 1, observational study = 0; c Comparison unexposed group (not exposed 
to opioids) = 1, no comparison unexposed group = 0; d ≥36 w GA = ½, <36w GA = 0; e Sample size ≥20 = ½, sample size <20 = ½; f Objective assessment tool used = 
1, no objective tool = 0; g Blinded = 1, not blinded = 0; h Confounder identified = ½, confounder adjusted for = ½, confounder not identified or not adjusted for = 0 
(potential confounders included socio-economic status and/or polydrug use); i Attrition ≤20% of original cohort = 1, >20% of original cohort = 0, if not applicable due 
to study design, score 0; j Clear finding with statistical analysis = 1, findings not clear and no statistical analysis = 0; k Total scores 0–3 = poor, 3½ –6 = intermediate, 






















Tinelli    
2013 
V 0 0 0 1 0 0 0 0 1 
McGlone 
2014 
V 0 1 1 1 1 1 1 1 7 
Konijnenberg 
2015 
V 0 1 ½ 1 0 0 0 1 3 ½ 
Whitham 
2015 
V 0 1 0 1 0 ½ 0 1 3 ½ 
Yoo         
2017 
V 0 0 0 1 0 0 0 1 2 
Pasto        
1985 
NI 0 1 ½ 1 0 ½ 0 1 4 
Walhovd 
2012 








































2-3 m  
4-6 m  
7-9 m  
10-15 m  






in 6 urine) 
BSID (MDI, 
PDI) at all ages 
 
 
2-3 m: MDI 117.3 (16.56); PDI 
136.4 (18.67) 
4-6 m: MDI 116.43 (17.91), PDI 
116.29 (19.2) 
7-9 m: MDI 110.4 (31.41), PDI 
110.4 (30.26) 
10-15 m: MDI 113.57 (13.25), 
PDI 105.71 (14.65) 
16 -24m: MDI 99.25 (16.76), 
PDI 107.25 (18.7) 
Original cohort 35 methadone-
exposed infants (26 females, 9 
males), no unexposed group. 
One early neonatal death from 
meconium aspiration. Mean GA 
at birth not stated; one infant was 
36 weeks, the remainder were 
>36 weeks GA. Pharmacological 
treatment for NAS in 14; 
Diazepam first line, paregoric 
(morphine) used as second agent 
in 2 cases, phenobarbital used for 
some cases of NAS. 10 infants 
received ‘medication for comfort’ 
and 4 ‘required regular sedative 
medications’. Medications used: 


























Results appear as methadone 










3 m  











PDI) at all ages 
 
3 m: MDI 101 (no sd); PDI 112 
(no sd), no statistics reported 
6 m: MDI 103 (no sd); PDI 107 
(no sd), no statistics reported 
Original cohort 42 methadone 
exposed infants, no unexposed 
group.  
10 infants were preterm.  














3 m  
6 m * 






PDI) at all ages 
 
 
3 m: MDI 112.5 (11.5) vs 
115.3 (13.5); PDI 119.4 (9.1) 
vs 117.1 (14.5)  
6 m*: MDI 115.7 (16.8) vs 
114.3 (20.9); PDI 109.4 (12.2) 
vs 111.7 (14.5)  
1 yr: MDI 113.4 (10.2) vs 
114.8 (11.3); PDI 102.8 (11.0) 
vs 110.4 (9.8).  
Decline in PDI between 3m 
and 12m in methadone exposed 
infants compared with 
unexposed: 16.6 points vs 6.7 
points (p<0.01) 
Original cohort 60 methadone-
exposed infants and 53 
unexposed infants; all infants 
were African-American. 
Data reported only for infants 
who underwent BSID at all 3 
ages. One case of sudden infant 
death in the methadone-exposed 
group. Matching of unexposed 
group not stated. GA at birth not 
stated. Assessor blinding not 
stated. No information about 


















Results appear as methadone 
vs unexposed Commentsd 
Kaltenbach 









1 yr  
2 yr ‡ 
Mean dose 
for 1 yr 
cohort: 30; 
Mean dose 







BSID (MDI) at 
all ages 
 
1 yr:   MDI 103.4 (9.26) vs 
109.4 (9.35), p<0.05 
2 yr ‡:   MDI 90.88 (8.26) vs 
94.62 (11.93), ns  
 
 
Original cohort 43 methadone vs 
51 un-exposed (matched for 
maternal SES, ethnicity and 
medical conditions). 
Assessors blinded to group. 1 
year cohort had a mean GA of 40 
weeks vs 39 weeks for 
unexposed infants. No range 
stated. 62% treated for NAS. 
2 year cohort mean GA of 39 
weeks vs 39 weeks, no range 
stated. 67% 2 year old cohort 
had been treated for NAS in the 
neonatal period. No 
pharmacological agent stated. 
Unclear whether overlap of 
participants assessed at 1 year 














(15 of 27 scales) 
 
GCI 86.8 (13.3) vs 86.2 (16.2), 
ns. Modified IBR: Gross bodily 
movement: 5.5 (1.4) vs 4.7 
(1.4), p<0.05. Levels of 
energy: 3.4 (0.9) vs 2.8 (1.1), 
p<0.05. Fine motor co-
ordination: 3.0 (0.8) vs 2.5 
(1.0), ns. Irrelevant motor 
movement: 5.3 (1.7) vs 4.1 
(1.7), p<0.01. Immaturity in 
interaction: 33% vs 7%, p<0.05 
Original cohort 60 methadone-vs 
53 un-exposed infants (matching 
not stated).Same cohort as 
Strauss et al 1976. 1 case of 
SIDS in the methadone-exposed 
group. All infants African 
American. Mean GA at birth not 
stated, range GA not stated. 
Assessor blinding not consistent. 





















Results appear as methadone 

























MDI 99.3 (15.5) vs 105.5 
(15.6) ns; PDI 89.9 (12.6) vs 
99.0 (14.5), p<0.01 
 
IBR:    
Poor fine motor co-ordination: 
27/33 vs 27/55 unexposed (c2 
=8.80, p<0.01)  
Less attentive: 8/33 vs 4/55 (c2 
=4.88, p<0.05) 
Original cohort 39 methadone-
exposed and 59 unexposed, one 
SIDS death in methadone-
exposed group before 
assessment at 12 months. 
Unexposed matched for maternal 
age, SES, marital status and 
ethnicity. 
Mean GA not stated; 7/39 (18%) 
methadone-exposed group were 
preterm, compared with 6/57 
(10%) of unexposed group. 
Assessor blinded to group. 34/39 











IBR sum score: 22.2 (2.57) vs 
18.13 (2.72), p<0.001 
Tension: 5.33 (0.9) vs 4.61 
(1.47), ns. Activity: 4.93 (1.49) 
vs 3.87 (1.18), p<0.05 
Interest in body motion: 5.4 
(1.24) vs 3.96 (0.98), p<0.001 
Co-ordination (gross motor): 
3.13 (0.64) vs 2.68 (0.57), 
p<0.05. Co-ordination (fine 
motor): 3.4 (0.63) vs 2.96 
(0.56), p<0.001 
No information about original 
cohort of infants. 
All African-American infants. 
One case in methadone-group of 
SIDS and one stroke. Unexposed 
infants matched for maternal age 
and SES. 
Mean GA not stated, range GA 
not stated. Assessors blinded to 
group. No methadone-exposed 































Results appear as methadone 
vs unexposed Commentsd 
Chasnoff et 















3 m  
6 m * 
1 yr  
2 yr ‡ 
Mean dose 











PDI) at all ages 
 
3 m: MDI 105.0 (12.5) vs 99.2 
(9.0); PDI 105.0 (18.6) vs 
102.8 (7.0) 
6 m*: MDI 105.9 (12.4) vs 
111.0 (12.3); PDI 103.9 (9.0) 
vs 107.6 (15.1) 
1 yr: MDI 104.2 (7.1) vs 105.8 
(8.1); PDI 106.0 (14.4) vs 
103.8 (12.5) 
2 yr ‡: MDI 97.5 (16.1) vs 96.2 
(15.9); PDI 99.3 (16.9) vs 98.2 
(8.9)  
No p values stated 
Original cohort 39 methadone 
exposed and 34 unexposed. 
Unexposed group matched for 
maternal age, education, 
gravidity and smoking. 
All infants were term (Ballard 
criteria), no range stated. 
Assessor blinding not stated. No 



















Results appear as methadone 













3 m  
6 m  
1 yr  



















PDI) at all ages 
 
 
3 m: MDI 106.3 (13.5)    PDI 
112.1 (15.5). 6 m: MDI 108.1 
(19.4) PDI 105.0 (14.5). 1 yr: 
MDI 97.7 (17.3)PDI 101.3 
(16.1). 2 yr: MDI 89.3 (17.0) 
PDI 106.5 (19.1) 
Compared by gender at all 
ages, girls vs boys: 1 yr: MDI 
108.8 (11.2) vs 102.7 (12.8), 
p<0.05; PDI 102.3 (14.2) vs 
95.7 (14.5), p<0.05. At 2 yr:    
MDI 99.2 (14.8) vs 82.0 (14.9), 
p<0.01  
Significant associations 
between both BW and gender 
and MDI and PDI: 
A. Positive correlation 
between birthweight and 
MDI at 6 months 
(p<0.001) PDI and 6 
months (p<0.01), which is 
still present at 24 months: 
MDI p<0.01, PDI p<0.05). 
B. Male vs female. 1 year:  
MDI 108.8 (11.2) vs 102.7 
(12.8), p<0.05,  
PDI 102.3 (14.2) vs 95.7 
(14.5), p<0.05 
Original cohort 220 infants, all 
methadone exposed; 3.2% 
congenital anomalies; 5 deaths, 3 
neonatal and 2 sudden infant 
deaths. 
20% original cohort were <37 
weeks GA at birth. 
18.2% original cohort treated for 




















Results appear as methadone 






study   
B 26 41 Mean 3 yr 
5 m  
(range 3 
yr – 5 yr 
11 m) 
No dosing or 
screening 
information;   







GCI: 90.4 (13) vs 89.4 (10.8), 
ns 
 
9 children (35%) in 
methadone-exposed group 
scored >1 sd below mean 
compared to 56% heroin 
exposed children and 22% 
unexposed children, p<0.01. 
Original cohort 33 methadone-
exposed and 57 unexposed 
infants (matched for maternal 
age, parity, SES and marital 
status). 
Mean GA 38.8 weeks vs 39.2 
weeks in unexposed group, range 
GA not stated. Assessors blinded 
to group. 88% methadone-
exposed were treated for NAS, 
pharmacological agent not 
stated. 
Rosen et al 

















6 m * 
1 yr  
18 m  
2 yr ‡ 
3 yr  
42 (mean of 
original 
cohort) 
MUS;   

















M-P at 3yr 
6 m *: MDI 95 (2.5) vs 100.7 
(4.2), ns; PDI 101 (2.8) vs 
105.1 (2.9), ns 
1 yr: MDI 98.4 (2.7) vs 107 
(2.8) p=0.05; PDI 94.9 (2.5) vs 
102.8 (2.3) p=0.05 
18 m: MDI 96 (2.3) vs 106.4 
(3.6), p =0.05; PDI 92.6 (2.4) 
vs 105.3 (2.2) p=0.05 
2 yr ‡:  MDI 90.4 (2.6) vs 96.9 
(3.1) ns; PDI 99.1 (2.7) vs 108 
(2.7), p=0.05 
3 yr: M-P 44.6 (2.1) vs 46.3 
(2.3) ns. 
All scores are mean (SE) 
Original cohort 61 methadone-
exposed infants and 32 
unexposed infants (matched for 
maternal ethnicity, SES, infant 
gender, BW and GA). 
15.4% preterm vs 11%, no range 
GA stated. 
Assessor blinding not stated. 
75% methadone-exposed had 
NAS; number treated 


















Results appear as methadone 
vs unexposed Commentsd 
Kaltenbach 













6 months           
Group 1        
Group 2 






MDI at 6 months reported by 
groups depending on the 
treatment for NAS:  
Group 1: paregoric (morphine) 
MDI 103 (no sd stated) 
Group 2: phenobarbital                
MDI 104 (no sd stated) 
Group 3: >1 agent                          
MDI 103 (no sd stated) 
Group 4: no treatment                  
MDI 101 (no sd stated) 
No difference between the 4 
groups, p>0.1 
All infants were term. No mean 
GA stated. 
69/85 treated for NAS with 
either paregoric (morphine), 

















6 m: MDI 103.53 vs 104.39 
(no sd stated) t=0.45, ns 
 
Original cohort was 141 
methadone exposed at birth. 
Unexposed group matched for 
maternal ethnicity, SES and 
medical background. 
All infants >36 weeks GA, 
mean GA at birth 38.7 vs 39.4 
weeks, no GA range stated. 
Blinding of assessors not stated. 
70% methadone-exposed were 





















Results appear as methadone 







C 12 28 Mean  
8.5yr vs 
11.2 yr  
(range 6 – 
15 yr)  
No 
information 
WISC-R  Results stated are methadone 
subgroup vs unexposed at mean 
age of 8.5 yr vs 11.2 yr 
Verbal IQ: 89 (11.33) vs 94.29 
(9.13) no p-value 
Performance IQ: 92.75 (10.16) 
vs 100.0 (9.82) no p-value  
Full scale IQ: 89.58 (10.32) vs 
96.32 (8.72) no p-value  
 
Original cohort 28 opiate-
exposed, of which there was a 
subgroup of 12 methadone-
exposed and 9 heroin exposed 
and 28 unexposed (no prenatal 
exposure to methadone but living 
in a ‘narcotic environment’ with 
an addicted parent/partner). 
Mean GA not stated, range GA 
not stated. 
Assessor not blinded. No 
information about NAS or 
treatment 
Doberczak 










5 – 7 m  
8 – 16 m  
Mean dose 





MUS, IUS;  
Both groups 











Results stated are seizures vs 
no seizures 
5 - 7 m: MDI 103.1 (19.9) vs 
111.5 (19.6), ns; PDI 114.7 
(14.9) vs 103.4 (16.6), ns 
8 - 16 m: MDI 114.0 (8.2) vs 
109.7 (10.9), ns; PDI 109.7 
(10.9) vs 99.5 (13.5), ns 
Original cohort was 14 infants 
with methadone-related NAS-
associated seizures and a 
comparison group of methadone-
exposed infants with no seizures. 
No unexposed comparison 
group. 
Mean GA of seizure group 39 
weeks (range 33 – 43 weeks).  
Mean GA of no seizure group 39 
weeks (range 33 – 42 weeks). 
Assessor blinded to infant 
history. Treatment for NAS with 



















Results appear as methadone 
vs unexposed Commentsd 
Kaltenbach 













6 m * 
1 yr  
2 yr ‡ 









BSID (MDI) at 
6m, 1 yr and 2 
yr. 
MSCA (GCI) at 
3.5-4.5 yr 
6 m*: MDI 107.9 (12.23) vs 
105.6 (7.31) no p value 
1 yr: MDI 102.5 (11.38) vs 106 
.53 (6.41), no p value  
2 yr ‡: MDI 100.9 (18.04) vs 
103.9 (11.49) no p value  
3.5 - 4.5 yr: GCI 106.5 (12.96) 
vs 106.05 (13.10), t=0.11 
Limited information about 
original cohort. Unexposed 
group were matched for maternal 
ethnicity and SES. GA infants 
not stated, no GA range stated. 
Blinding of assessors not stated. 
92% were treated for NAS, 


















9 m  
18 m  
2 yr ‡ 
3 – 5 yr  










BSID (MDI) at 
9m, 18m, 2yr. 




11 yr (survey, 
school reports 
and IQ testing) 
9 m: published in Wilson et al 
12 1981 
18 m: MDI   92 (14.5) vs 97.4 
(14.4) ns 
2 yr ‡: MDI 88.8 (15.5) vs 90.2 
(14.6) ns 
3 – 5 yr: GCI 90.4 (13.0) vs 
89.4 (10.8) ns 
6 – 11 yrs:  IQ 1- 2 sd below 
norm 8% vs 5%; Language 
disability 8% vs 5%; Special 
education needs 16% vs 19%; 
Behavioural problems 75% vs 
48%; Psychiatric referral 16% 
vs 5%. 
Original cohort 39 methadone-
exposed, 57 unexposed infants 
(matched for maternal age, 
ethnicity, SES and marital 
status). 
Mean GA not stated for either 
group, range GA not stated. 
Assessor blinding not stated.87% 
original cohort treated for NAS, 
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showed more feminine game 
play than unexposed boys 
(p<0.04). No significant 
differences in girls. Overall 
CBAQ scores were not 
significantly different between 
methadone-exposed and 
unexposed boys. Group split by 
gender and by PD use creating: 
boys methadone only (n=5) and 
boys methadone + PD (n=9) 
In the methadone only boys 
group (n=5), ANCOVA with 
age as covariate of individual 
elements of the feminine 
behaviour sub-scale showed 
higher (more feminine 
behaviour) scores for 2 items: 
“he is good at imitating 
females”, p<0.001, “he dresses 
in female clothing”, p<0.05 
In the PD boys group (n=9) 
there were higher feminine 
scores on “he is good at 
imitating females”, p<0.05, and 
“he does things with female 
relatives’, p<0.05  
Original cohort 61 methadone-
exposed infants and 32 
unexposed infants (matched for 
maternal ethnicity, SES, infant 
gender, BW (±250g), GA (±2w) 
and APGAR score).  
2 methadone-exposed infants 
from original cohort died of 
sudden infant death. 
GA at birth and range GA not 
stated. NAS treatment not stated. 
Mother or primary care-giver 
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6 m * 
1 yr  
18 m  
2 yr ‡ 
2.5 yr  





cohort; 6 IV 






PDI, NDI) at all 
ages  
 
WWPAf at  
18 m (n=14),  
2 yr (n=16) and 
2.5 yr (n=15) 
 
 
*6 m MDI 103 (12) vs 107 
(13); PDI 116 (18) vs 114 (21); 
NDI 105 (13) vs 109 (14). At 1 
yr: MDI 108(13) vs 114 (17); 
PDI 112 (21) vs 119 (20); NDI 
109 (12) vs 112 (18). At 18 m: 
MDI  94 (14) vs 99 (19); PDI 
108 (20) vs 112 (19); NDI 97 
(15) vs 99 (17). At 2 yr ‡: MDI 
86 (15) vs 98 (16) p<0.05; PDI 
102 (16) vs 100 (18) ns; NDI 
93 (16) vs 102 (22). At 2.5 yr: 
MDI 87 (15) vs 101 (20) 
p<0.05; PDI 96 (19) vs 101(24) 
ns; NDI 100 (19) vs 108 (19) 
ns. WWPAd, medians (range) 
18m: 1.78 (1.40 – 2.62) vs 1.73 
(1.23 – 2.52) ns  
2y: 1.66 (1.33 – 2.660 vs 1.76 
(1.19 – 2.52) ns. At 2.5 yr: 1.62 
(1.03 – 2.66) vs 1.64 (1.28 – 
2.52) ns; Methadone had lower 
MDI at 2 and 2 ½ years due to 
delayed early language. No 
differences in motor t, non-
verbal or hyperactivity scores. 
Original cohort 35 methadone-
exposed and 37 unexposed 
infants (not matched). 
In methadone-exposed group 
9/35 were preterm but results 
presented are subgroup of term 
only methadone-exposed infants. 
Assessor blinding not stated. 
28/35 (80%) were treated for 
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B 20 20 Mean age 










SBIS:  97.6 vs 98.1 ns.  
Within methadone-exposed 
group: NAS (n=5) vs No NAS 
(n=15) 89.9 vs 100.2, t =3.65, 
p<0.002 
KABC-A: 98.8 vs 102.4, no p 
value; Faces and places subtest 
95 vs 103, p<0.02; 
RATC: Methadone-exposed 
scored higher on anxiety, 
aggression, rejection and 
maladaptive outcome, p<0.01 
for all; 
CBCL: More behaviour 




internalising and externalising 
behaviour] reported by parents 
in methadone group, p<0.05 all 
categories. 
Unexposed group matched for 
demographics (not stated) 
age/grade level, sex, ethnicity, 




Mean GA not stated; In 
methadone-exposed one child 
was preterm; In the unexposed 
group 10/20 had “perinatal 
complications such as 
prematurity or SGA”. 
Assessor blinding not stated. 
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3.5 yr  
4 yr  
4.5 yr 












SON IQ at 3.5 
yr;  
RC and RE at 4 
yr;   
RAKIT at 4.5 
and 5.5 yr; IBR 
at  
3.5 yr (n=22),  
4.5 yr (n=23)   
5.5 yr (n=22)  
 
 
SON IQ 99 (9) vs 109 (11), 
p<0.01. RC 46 (6) vs 52 (6), 
p<0.01. RE 46 (9) vs 50 (6), 
p<0.05. RAKIT 4.5 yr: 85 (11) 
vs 103 (15), p<0.01; 14 / 23 
methadone-exposed children 
had developmental delay 
(defined as scores >1 sd), 
p<0.01. RAKIT 5.5yr: 90 (12) 
vs 102 (17), p<0.05 
IBR: Results median(range) 
3.5 yr:  Free of fear: 9 (4-9) vs 
6.5 (2-9), p<0.05; Activity 
level: 6 (3-9) vs 5 (2-9), 
p<0.05; Attention: 5 (1-7) vs 
5.5 (1-9) p<0.05; Fine motor: 3 
(1-5) vs 3 (1-5), p<0.05  
4.5 yr:  Co-operation: 6 (2-9) 
vs 7 (3-9), p<0.01; Endurance: 
4 (2-9) vs 6 (1-9), p<0.01; 
Attention: 8 (2-9) vs 5 (2-8), ns 
5.5 yr: Co-operation: 6 (1-9) vs 
8 (4-9), p<0.01; Free of fear: 8 
(2-9) vs 9 (5-9), ns; Attention: 
5 (2-8) vs 5 (3-9), ns. 
Original cohort 35 methadone-
exposed vs 35 unexposed 
(unmatched). 
Mean GA for original cohort 38 
weeks vs 39.7 weeks, no range 
stated; 7/23 methadone exposed 
infants were preterm, range of 
GA not stated. 
Blinding of assessors not stated. 
28/35 were treated for NAS, all 
treated with phenobarbital. 
 
After correcting for behaviour 
that differed between groups, 
significant differences between 
methadone-exposed and 
unexposed children still existed 
at 3.5 years for SON IQ, p<0.05, 
and at 4.5 years for RAKIT, 
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B 30 44 2 yr  Mean <20 









Focus Ratio  Focus ratio at 2 yr:  0.35 (0.15) 
vs 0.31 (0.13) ns 
 
ANCOVA to unexposed for 
cannabis (F(1,69 = 0.16), 
nicotine (F(1,69) = 0.16) and 
alcohol (F(1,69 = 0.04) ns 
Unexposed comparable for low 
income. 2 methadone-exposed 
were preterm (30w and 33w). 
Attrition: 4 children died before 
2 years of age in the methadone-
exposed group, and one had 
massive cerebral haemorrhage. 1 
in unexposed group withdrew 
following diagnosis of cerebral 
palsy. Assessors scoring video-
taped encounter were blinded to 
group. No methadone-exposed 
child was treated for NAS. 
Bunikowski 










Methadone sub group data 
extracted: 
Hearing and speech: 99.7 (8.1) 
vs 98.8 (9.1) 
Intellectual performance at 1 
yr: 104.3 (11.6) vs 108.5 (11.1) 
No p values as these results 
taken out of text as subgroup 
analysis 
Original cohort 46 opiate 
exposed versus 47 unexposed 
infants (matched for maternal 
smoking). 27 opiate exposed 
underwent Griffiths assessment 
at 1 year; opiate group split into 
methadone (n=18) and heroin 
(n=9), sub-group analysis 
reported. Mean GA not stated; 
13/34 opiate exposed were 
preterm, range not stated 
Assessor blinding not stated. 
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4 m  
8 m  
1 yr  
18 m 
2 yr ‡ 
Mean <20 
















PDI) at all ages 
 
 
4 m: MDI 111 (12.3) vs 114 
(15.1); PDI 116 (12.5) vs 121 
(12.3) 
8 m: MDI 116 (19.5) vs 120 
(20.2); PDI 111 (12.4) vs 111 
(12.4) 
1 yr: MDI 107 (14.3) vs 109 
(13.7); PDI 106 (18) vs 110 
(17.7) 
18 m: MDI 95 (16.3) vs 103 
(13.1); PDI 105 (14.2) vs 109 
(14.9) 
2 yr ‡: MDI 92 (12.7) vs 96 
(12.3); PDI 100 (14.2) vs 108 
(14.9) 
Mean across all ages:   
MDI 104 (7.8) vs 108 (8.3), 
p<0.05; PDI 108 (9.2) vs 112 
(10.4), ns 
Original cohort 47 methadone-
exposed infants and 45 
unexposed infants (matched for 
maternal age, SES and IQ).  
4 SIDS in the methadone-
exposed group. All infants 
included were African-
American. 3 subjects not tested 
at 2 years, not stated which 
group these subjects were in. 
Scores were estimated, based on 
their median 18 month scores 
and the average scores for the 
entire sample. Mean GA not 
stated, no GA range stated. 
Assessors blinded to group. No 
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BSID III (MDI, 
PDI) at 18 m;  
VL at 18m and 
3 yr;  
SBIS and 
MSCA (GCI) at 
3 yr;  
RC and RE at 3 
yr 
18 m: MDI 88.2 (16.4) vs 
105.02 (23), p <0.001;   PDI 
107.5 (16.8) vs 110.13 (14.7) 
SBIS: 99.9 (15.1) vs 107.5 
(13.4), p<0.01 
GCI: 49.5 (8.7) vs 53.9 (8.3), 
p<0.05 
VL 18 m: 113.2 (15.6) vs 
119.15 (17.5), p<0.05 
VL 3 yr: 38.4 (8.1) vs 46.1 
(7.7), p<0.05 
RC 42.4 (11.6) vs 49.2 (11.4), 
p<0.05; RE 35.5 (7.9) vs 42.8 
(12.8), p<0.05   
 
Original cohort 133 methadone 
exposed and 103 unexposed 
infants (matched for maternal 
age, height and ethnicity).  
In families lost to follow up, 
10/133 methadone taking 
mothers had died before their 
child was 3 years old. 
Original cohort mean GA at 
birth 37.7 vs 40.2 weeks, 32/133 
were preterm, all singleton 
pregnancies.  
Assessor blinding not stated. 
74 /133 infants were treated for 
NAS with morphine. No NAS 
related seizures. 












4-15 d  
16 – 32 d  












P2 amplitude greater in 16 – 32 
d and 22 – 120 d in the frontal 
region, p<0.001 both  
Latency to oddball stimulus 
longer only in in 4 – 15 day 
group, p 0.04, but not in the  
Mismatch negativity amplitude 
became less negative as P2 
amplitude to oddball stimulus 
increased at Fz, r2 0.38, 
p<0.001 
Three separate cohorts of 
infants, no unexposed group. 
Mean GA at birth for all groups 
was 38 weeks, no range stated. 
All infants in the 4 – 15 day 
group were receiving 
pharmacological treatment for 
NAS at the time of ERP testing. 
Pharmacological agent used for 
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in 40% and  
25% alcohol 
CBCLf Methadone-exposed children 
aged 4 scored >55 on 
aggressive behaviour and 
withdrawn behaviour.  
 
 
Part of a larger cohort study 
comparing buprenorphine with 
methadone.  
No unexposed group. Mean GA 
at birth 38.7 weeks. Inclusion of 
preterm infants not stated. No 
assessor blinding. 
13/24 treated for NAS, 
pharmacological agent not 
stated 












4 m  
 
Mean dose 














Subgroup methadone data 
extracted from paper. Scores 
presented are low dose vs high 
dose. MDI 96.6 (7) vs 94.3 
(9), ns. AIMS percentile (sd): 
44.8 (24) vs 38.1 (24) ns  
High dose methadone 
associated with decreased HC 
z-score compared with low 
dose methadone, p<0.025. 
No statistics reported on BSID 
or AIMS scores comparing 
low vs high, as subgroup data 
extracted from paper 
Regression analysis confirmed 
an association between high 
dose methadone and lower HC 
z-score, p <0.025 
Part of a study comparing low 
doses of methadone, high doses 
of methadone and 
buprenorphine. No unexposed 
comparator group.  
Subgroup results presented. 
Mean GA low group 37 weeks, 
18/84 preterm. 
Mean GA high group 38 weeks, 
13/81 preterm. 
Assessor blinded to infant 
background 
NAS treated in 72/84 in low 
group and 73/81 in the high 
group, treated with morphine 
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All data median (IQR) and 
adjusted p values (correcting 
for maternal smoking and 
alcohol) GQ: 97 (93 -100)  vs 
105 (101-108)  p<0.001;  
Locomotor: 102 (97 – 107) vs 
111 (101-111) p=0.006; 
Personal-social: 94 (88-96) vs 
99 (94 – 103) p=0.001; 
Language – hearing: 105 (105 
– 109) vs 109 (105 – 109) 
p=0.007; Eye – Hand: 94 (86 – 
99) vs 104 (99 – 104) p=0.001; 
Performance: 96 (86-100) vs 
101 (101 – 111) p=0.002. 
8/81 methadone-exposed had 
GQ <85. All infants in 
unexposed group scored ³95.  
Infants treated for NAS vs 
those not treated for NAS had 
different scores: Median GQ 
95 vs 99, (p=0.008). Infants 
exposed to multiple drugs had 
lower scores for locomotor and 
hand-eye skills (p=0.002) 
Original cohort 100 methadone-
exposed infants and 50 
unexposed infants 
(matched for gestation, 
birthweight and maternal 
postcode). 
Infants excluded if GA <36 
weeks. Single assessor, not 
blinded to allocation. 
39 infants treated for NAS with 
morphine, 15/39 treated with 
morphine and phenobarbital. 
 
Adjusted p values correct for 




independently associated with 
adverse neurodevelopmental 
















Notes relating to Table 15. 
 
*indicates studies included in meta-analysis at 6 months, ‡ indicates studies included in meta-analysis at 2 years.  
 
a QR = quality rating: A = good, B = intermediate, C = poor, based on modified GRADE criteria; b Age expressed in days (d), months (m) or years (yr);  
c Drug information includes mean daily methadone dose (in milligrams), maternal urine screening (MUS) and/or infant urine screening (IUS) for drug exposure and 
information on maternal polydrug (PD) use, where these are reported. Unless otherwise stated, all information in this column refers to methadone-exposed group only; 
d Scores are presented as mean values (standard deviation) unless otherwise stated; e Comments include information on attrition, matching, gestation, blinding, 
proportion of infants treated for NAS and pharmacological treatment for NAS, where this is provided in the original publication; f Questionnaire completed by parent 
or care-giver; g Mean methadone dose excludes outlier daily dose of 660mg methadone 
 
AIMS = Alberta Infant Motor Scales, ANCOVA = analysis of co-variance, BDZ = benzodiazepine, BSID = Bayley Scales of Infant Development, 1969, BSID III = 
Bayley Scales of Infant Development, 3rd edition, BW = birth weight, CBAQ = Child Behaviour Attitude Questionnaire CBCL = Child Behaviour Checklist, GCI = 
Cognitive General Index (used in the MSCA), CGPQ = Child Game Participation Questionnaire, ERP = event-related-potentials, Focus ratio = focussed attention : 
total play time (as observed by an assessor during 3 minutes of free play), GA = gestational age, GQ = Griffiths Quotient, KABC-A = Kaufman Assessment Battery for 
Children, achievement component (tests the acquired knowledge of fact), NAS = neonatal abstinence syndrome, NDI = Non-verbal Developmental Index, PD = 
polydrug (defined as methadone plus any other drug use during pregnancy, excluding tobacco), RATC = Robert’s Apperception Test for Children (tests the child’s 
perception of common interpersonal situations), RAKIT = Revision of the Amsterdam Children’s Intelligence Test, RC = Reynell Developmental Language Scales, 
comprehension, RE = Reynell Developmental Language Scales, expression, SBIS = Stanford-Binet Intellectual Scale, sd = standard deviation, SES = socio-economic 
status, SIDS = sudden infant death syndrome, SGA = small for gestational age, SON-IQ = Snijders-Oomen Nonverbal Intelligence Test, Vineland SM = Vineland 






The original format of the following first author paper is shown in this appendix. 
Monnelly et al (2018) is reproduced from John Willey and Sons with permission: 
 
Monnelly VJ, Hamilton R, Chappell FM, Mactier H, Boardman JP: Childhood 
neurodevelopment after prescription of maintenance methadone for opioid-
dependency in pregnancy: a systematic review and meta-analysis.  

















































































































The original format of the following first author paper is shown in this appendix. 
Monnelly et al (2018) is reproduced from Elsevier with permission: 
 
Monnelly VJ, Anblagan D, Quigley A, Cabez MB, Cooper ES, Mactier H, Semple 
SI, Bastin ME, Boardman JP: Prenatal methadone exposure is associated with altered 
neonatal brain development. Neuroimage Clin 2018;18:9-14. 
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